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Drugs and harm
Although drugs can cure, they can also cause harm (1-3). The World Health Organization 
defines an adverse drug reaction (ADR) as “a response to a drug which is noxious and 
unintended, and which occurs at doses normally used in man for the prophylaxis, 
diagnosis, or therapy of disease, or for the modification of physiological function” (4). It 
is classified as serious when it is fatal, life-threatening, disabling, incapacitating, or when 
it results in or prolongs hospitalization (5). An ADR can be caused by drug related factors 
(drug effects, drug use, synergistic effects between a drug and a disease or between two 
drugs) and also non-drug related factors (abnormal pharmacokinetics due to genetic 
factors, age or disease states).
An adverse drug event may result from either appropriate care (non-preventable ADE) 
or from suboptimal care (preventable ADE). Among all medical adverse events that 
cause harm, adverse drug events are the most frequent type in patients (6). Medication 
errors can occur at any stage of the hospital medication process (reconciling, prescribing, 
transcribing, dispensing, administering and monitoring), but especially inappropriate 
prescribing is a frequent cause of ADEs (7). Prescribing errors can have serious 
consequences and can lead to potentially preventable death, disability, increased length 
of hospital stay and readmission (3, 8). The drug classes most commonly associated with 
potentially preventable ADEs are pain medication (non-steroidal anti-inflammatory 
drugs (NSAIDs) and opioids), (combination of ) antitrombotics, certain antibacterial drugs, 
diuretics, angiotensin-converting enzyme inhibitors, antiepileptic drugs and drugs that 
are renally excreted (1, 9-14).
Many studies have addressed the nature, occurrence and consequences of medication-
related adverse events in the hospital, showing that up to 20-50% of admitted patients 
experience one or more adverse drug events during their hospital stay. Approximately 
50% of ADEs are potentially preventable (1, 9, 11, 15, 16). A high variability in outcome 
among studies can be explained by the different methods used for measurement, 
definition and assessment of ADEs (3, 17-22). To measure actual patient harm in terms 
of death, disability, increased length of hospital stay or readmission, studies with large 
patient populations are needed. Analysis of these data through assessment by experts is 
very intensive. Alternative measures, such as quality indicators as process measures, are 
more efficient in assessing the quality of care, but these measures will only provide an 
indication of real patient harm.
Patients at risk of adverse drug events
In the last years, a patient population, that is older and more vulnerable, has been 
growing. These vulnerable patients are often admitted to a hospital because of transient 
disease, and they frequently need surgical procedures. Surgical patients admitted to the 
hospital have comorbidities, like heart failure, diabetes or kidney dysfunction, are often 
treated with multiple high risk drugs and suffer from cognitive and social problems. In 
case of a surgical procedure, patients are treated with analgesics (NSAIDs and opioids) and 
frequently antibiotics are given because of the procedure or complications. In addition 
anticoagulant therapy must be temporarily changed because of the surgical procedure. 
Diuretics and cardiovascular drugs must be adapted on a day to day basis because 
of rapid alterations of hydration status due to gastro-intestinal disturbances (bowel 
obstruction, vomiting, diarrhoea), fever, sweating and lack of intake of fluid and food. Also, 
these patients are often given radiocontrast for diagnostic procedures.
It is known that the complexity of care for these patients contributes to the problem of 
potentially preventable adverse drug reactions in the hospital. 
Several studies tried to identify (surgical) patients at risk for adverse drug events and 
hospital prescribing errors, and different potential risk factors to select high-risk patients 
have been described (22-26). Organizational factors, such as ward of admission, pharmacy 
services or staffing, patient related factors such as comorbidity, age, or length of stay and 
drug related factors have been related to medication errors and adverse drug events. 
However, results are still inconclusive and it seems even more difficult to translate these 
findings to a risk prediction model for adverse drug events, that can be automated and 
made applicable in clinical practice (27-30). Such a model could help to focus safety 
interventions on high risk patients.
Improvement by education
Pharmacotherapy in high-risk patients in the hospital is very complicated. Prescribing 
errors defined as ‘irrational, inappropriate and ineffective prescribing, underprescribing 
and overprescribing’ caused by a lack of clinical pharmacological knowledge might 
particularly be amenable to a clinical pharmacological educational intervention.
It is well known that, in the hospital, the majority of drugs are prescribed by junior medical 
residents, who are relatively inexperienced and do not feel adequately prepared to do 
so (31-33). Especially at surgical wards, these junior doctors are supervised by surgeons 
who often have no specific expertise with respect to complicated pharmacotherapy. The 
logical strategy to reduce prescribing errors in hospitals by educating the prescriber has 
been shown to reduce prescribing errors, but this effect is not sustained over time (34). 
Moreover, it is unclear if education programmes actually reduce patient harm.
The development of a more targeted educational programme that covers 
pharmacotherapy associated with adverse drug events caused by prescribing errors 
and addresses national and local pharmacotherapeutic guidelines seems useful. This 
programme should be followed by continuous audit and feedback of the prescriber to 
boost the effect of education and assures sustainability of knowledge and prescribing 
behaviour over time.
Support by information technology
Computerized physician order entry (CPOE) with an integrated clinical decision support 
system (CDSS) supports both the physician and the hospital pharmacist in clinical decision 
making. It has been shown to reduce medication errors and even ADEs (35).
The CPOE-CDSS system currently used in Dutch hospitals, connects to a national database 
known as ‘G-standard’ and generates a vast amount of alerts of drug-drug interactions, 
duplicate medication and dosing advices. The most prevalent alerts generated in 
hospitals concern combinations of NSAIDs, cardiovascular medication and anticoagulants. 
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10 However, these alerts are only relevant in a minority of cases and often the physician is 
unnecessarily warned (36). The aspecificity of the vast amount of alerts generated by the 
electronic ordering system has led to the situation that some of the more relevant alerts 
are neglected. 
Van der Sijs et al. showed that if the burden of alerts is too high, alert fatigue may cause 
overriding both important and unimportant alerts, in a manner that compromises the 
desired safety effect of integrating decision support into computerized physician order 
entry systems (37, 38). 
More advanced clinical decision support systems find their way into daily practice 
of hospitals. Most Dutch hospitals have implemented ´clinical rules´ to improve the 
specificity of the alerts. These clinical rules (advanced CDSS) combine clinical data of 
the patient (like laboratory results) with the medication to assess whether for instance 
dose adjustments should be made in case of renal insufficiency (39, 40). The efficiency 
of alerts has been reported to increase when augmented with an advanced CDSS (41, 
42). However, specificity of these clinical rules is still limited and not suitable yet to be 
integrated into the prescribing workflow of the physician, because not all data needed are 
digitalised and available and pharmacotherapy is often too complicated to be covered by 
a set of clinical rules (43). 
Medication review in high risk patients
Medication review by clinical pharmacists or clinical pharmacologists is deployed to 
improve prescribing quality in hospital patients. Hereby a systematic assessment of the 
medication of the patient is performed in combination with assessment of the clinical 
data of the patient with feedback to their physician or to the patient. It capitalizes on the 
model of structured interdisciplinary teamwork in a well organised clinical environment in 
the hospital. 
Different methods, such as the Screening Tool of Older Persons’ Prescriptions (STOPP), 
Screening Tool to Alert doctors to Right Treatment (START) (44, 45) and The Updated 
Beers Criteria for Potentially Inappropriate Medication Use in older adults (46), although 
not specifically developed for use in the hospital, can be used by the physician and 
the hospital pharmacist to perform medication reviews and to design interventions to 
prevent adverse drug events in hospitalized patients (47). 
It is clear from literature that when pharmacists play a proactive role in performing 
medication reviews, pharmacotherapy for older patients improves (48-50). However, 
the evidence of the impact of this approach on clinical outcomes such as lowering the 
incidence rates of adverse drug events or cost effectiveness of care is scarce (51-53). 
Moreover, performing medication reviews is time consuming. There is a need for trials 
in hospitals, to determine the effectiveness and possibilities of medication review in 
the optimization of pharmacotherapy in hospital patients, in combination with other 
interventions as education of the prescriber and further development of more advanced 
clinical decision support systems (54, 55).
Implementation of guidelines
Clinical practice guidelines with evidence-based recommendations for physicians have 
been developed to assist doctors and to improve clinician prescribing in hospitalized 
patients. In routine daily practice however, it appears to be difficult to implement key 
recommendations and guidelines seem to have a limited ability to change physician 
prescribing behaviour. The adherence to guidelines by prescribers is inconsistent, despite 
their potential to improve the quality of health care and patient outcomes (56). Different 
determinants have been described that prevent or enable guideline adherence (57, 58). 
When individual health professional factors, such as knowledge, skills and awareness, 
guideline factors, such as the quality of evidence, local consensus and accessibility of the 
guideline and other possible barriers are taken into account when developing strategies 
to improve guideline adherence, the quality of the treatment of hospitalized patients 
improves (59, 60).
Organization of care
In recent years, hospital care is characterized by increasing demands for efficiency 
in health care. The publication of the report “To err is human” in 1999 showed that 
medication errors account for an increase in hospital costs of about $2 billion and over 
7000 deaths annually in the United States at that time (61). In the Netherlands adverse 
drug events in hospitalized patients result in an excess length of stay of about 6 days 
and additional costs of more than 2500 Euro per event (1). On the basis of the available 
literature, an estimate of the proportion of clinically relevant, potentially preventable, 
drug-related problems due to prescribing errors among patients in the hospital is 0.7%. 
Taking into account that in Dutch hospitals per year 688000 patients are admitted on 
a ward for either surgery (437000 per year) or orthopaedic surgery (251000 per year), 
this could implicate an incidence of potentially preventable adverse drug events in only 
surgical patients of 4800 per year. Implementation of strategies to prevent adverse drug 
events, that lead to death, disability, increased length of hospital stay or readmission is 
therefore worth the effort of clinical pharmacists and prescribing physicians.
It is important that interventions, that are designed to prevent prescribing errors are 
cost-effective. Time spent by the hospital pharmacist and the physician on education, 
implementation of guidelines, optimal use of CPOE-CDSS or performing medication 
reviews will also incur costs. Through a change of focus to high-risk patients and less 
focus on low risk patients, these interventions could be more efficient. Less intensive 
pharmacovigilance in low risk patients can be made possible by optimal use of CPOE/
CDSS and for instance automatically settle alerts and clinical rules which are known to 
be without harm for low risk patients, without intervention by the physician or hospital 
pharmacist.
Because of a growing need for cost-effective care and a local shortage of medical 
doctors, as well as concerns about the continuity and safety of clinical processes, another 
development is that medical ward care is increasingly reallocated to physician assistants 
(62-64). A physician assistant is a non-physician health care professional licenced to 
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(65). Since January 2013, PAs are authorized to indicate and perform predefined medical 
procedures and prescribe medication without supervision. Often, PAs who are employed 
for medical ward care work in a system of collaborative care that contains PAs, medical 
doctors (MDs) and hospitalists, comprising a patient medical care team. Although some 
studies suggest that this reallocation of tasks provides quality and efficiency similar to that 
of traditional house staff services (66-69), studies on the quality of prescribing, occurrence 
of prescribing errors or guideline adherence are lacking.
Outline and objective of this thesis
In the Canisius-Wilhelmina hospital we started a multifaceted approach, combining 
different safety interventions, to address the problem of prescribing errors leading 
to adverse drug events. An educational programme covering pain management, 
antithrombotics, fluid and electrolyte management, prescribing in the case of renal 
insufficiency, application of radiocontrast agents and surgical antibiotic prophylaxis 
was developed. National and local hospital guidelines related to these subjects were 
included. Nowadays, this programme is mandatory for all new prescribers in the 
Canisius-Wilhelmina hospital. In addition, medication reviews are performed by hospital 
pharmacists and clinical pharmacologists in high-risk patients, that are identified 
by a computerized screening method. This screening method is based on literature 
on prescribing errors and targets patients at risk for potentially preventable, drug-
related problems. The reviews are performed weekly and discussed with the prescriber 
(medical doctor or physician assistant) on the ward in so called medication safety 
consultations (MSC). We assumed that these MSCs would sustain the effect of education 
on pharmacotherapeutic topics, would promote the accessibility and adherence to 
guidelines, and could lead to reduction of adverse drug events, less death, disability and 
readmission, and reduced length of hospital stay. Introducing clinical rules and achieving 
local agreement on how to assess alerts in CPOE/CDSS in “low risk patients” allows us 
to focus more on patients at risk for potentially preventable drug related events in our 
hospital.
Hospital pharmacists and physicians from the surgical wards of the Isala Hospital and 
the Meander Medical Centre were willing to adopt this multifaceted approach and to 
cooperate in the P-REVIEW study (Pharmacist-led Risk patients medication Evaluation to 
Initiate Event reduction on surgical Wards).
The main objective of this thesis is to assess the effect of education and support of 
prescribing physicians at surgical wards on clinically relevant drug-related complications 
in hospitalised surgical patients, on guideline adherence and costs.
This thesis contains eight chapters. In Chapter 1 the general introduction, the main 
objective and the outline of this thesis are described.
In Chapter 2 we present an overview of research on the education of prescribers, that 
reports outcomes on (potential) patient harm.
We designed the P-REVIEW study to determine whether a multifaceted intervention of 
educating the prescriber combined with medication review of high-risk patients and 
pharmaceutical visits to the ward by the hospital pharmacist could lead to a reduction in 
clinically relevant drug-related complications among surgical patients. We used a CDSS-
based screening method to target patients at risk for potentially preventable, drug-related 
problems. We also studied the costs that were associated with time spent on study-related 
activities in Chapter 3.
In Chapter 4 we determined if the approach of the P-REVIEW study combining education 
of the prescriber with audit and feedback by the hospital pharmacist reduces the non-
adherence of prescribers to pharmacotherapeutic guidelines.
In Chapter 5 we used the results of the P-REVIEW study to develop an automated risk 
prediction model in order to be able to predict which patients are at risk to experience 
adverse drug events at surgical wards in the hospital.
Chapter 6 describes the effects of substitution of hospital ward care from medical doctors 
to physician assistants on quality of prescribing of medication.
In the summarizing discussion, Chapter 7, the main results are summarized and discussed 
in a broader context. Implications for clinical practice and recommendations for future 
research are provided.
In Chapter 8 the English and Dutch summary are provided.
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Abstract
Aims
Educating prescribers is a strategy to reduce prescription errors in hospitals. The present 
systematic review gives an overview of original research papers on the education of 
prescribers and reporting outcomes on (potential) patient harm.
Methods
A search of the databases Embase and Medline, using the Ovid interface, was performed. 
Research on the effect of physician education in order to prevent medication-related 
problems in inpatients, and on reporting original data and outcomes on prescribing errors 
and/or (potential) patient harm, was included. The assessment of methodological quality 
and risk of bias was performed using the Methodological Index for Non-Randomized 
studies (MINORS) checklist and the suggested risk of bias criteria for Effective Practice and 
Organization of Care (EPOC) reviews.
Results
Eight studies investigated an intervention on education alone and in seven studies 
education was the main part of a multifaceted intervention. All studies were small 
and had short follow up periods. The educational programmes varied and were given 
to physicians of different specialties and levels of experience. Most studies reported 
intermediate process parameters as the outcome. The risk of performance and reporting 
bias were high.
Conclusion
All included studies suffered from poor methodology. The majority, especially studies 
in which education was part of a multifaceted intervention, reported effectiveness on 
intermediate outcome markers as prescription errors and potential adverse drug events. 
However, we found no firm evidence that educating prescribers in the hospital leads to 
a decrease of patient harm. Further work is needed to develop educational programmes, 
accompanied by more high-quality research with outcomes on the improvement of 
patient care.
 
Introduction
Although drugs can cure, they can also cause harm. This holds especially true inside 
the hospital. Vulnerable patients are often admitted because of a transient disease, and 
this category of patients that frequently needs surgical procedures. In these patients, 
prescribing errors can easily have serious consequences. Several papers have addressed 
adverse drug reactions in the hospital, showing that up to 20% of admitted patients 
experience adverse drug reactions during hospital stay (1). 
Risk factors for preventable adverse drug events (ADEs; defined as an injury resulting 
from the administration of a drug with a causal link to a drug effect (2)) are patient age, 
time since starting new drug, total number of prescription drugs and type of hospital 
ward. The drug classes most commonly associated with potentially preventable ADEs are 
antiplatelet drugs, anticoagulants, diuretics (loop and thiazide diuretics), angiotensin-
converting enzyme inhibitors, opioids, antibiotics and antiepileptic drugs (3,4). Many 
potentially preventable drug reactions are a consequence of inappropriate prescribing by 
hospital physicians (5). 
Many barriers limit the prescribing process, such as information and communications 
technology (ICT) shortcomings, high workload, increasingly complex polypharmacy and 
patient factors, lack of standardization and frequent rotations of inexperienced physicians 
on the ward(6). It is necessary to understand the causes that contribute to prescribing 
errors, in order to be able to address these factors.
Various strategies, such as the introduction of computerized physician order entry 
(CPOE), pharmacist involvement, the introduction of protocols, guidelines, education 
programmes and support systems for clinical decision making (SSCD) have been studied 
to improve clinician prescribing in hospitalized patients (7-9). 
Errors - for example, due to incomplete prescriptions or prescriptions that do not 
satisfy medication order checklists - can probably best be solved by CPOE with decision 
support or other strategies, although a combination with a form of education may be 
useful. Prescribing errors defined as ‘irrational, inappropriate and ineffective prescribing, 
underprescribing and overprescribing’ caused by a lack of clinical pharmacological 
knowledge might particularly be amenable to a clinical pharmacological educational 
intervention.
Therefore, a logical strategy to reduce prescribing errors in hospitals is to educate 
prescribers. It is well known that, in the hospital, the majority of drugs are prescribed by 
junior doctors, who do not feel adequately prepared to do so (10). However, it is unclear 
if education programmes actually reduce patient harm. Various education programmes, 
with different scopes, have been described. Scientific evaluation of these programs is 
challenging due to difficulties in blinding and definition of outcome.
Earlier reviews published in this area describe education as one of several possible 
interventions to improve prescribing quality, examples of others including introduction 
of CPOE and pharmacist involvement in prescribing. In addition, many of the education 
programmes in the hospital target nurses, or even the patient, rather than the prescribing 
physician (7-9). 
Other reviews that have reported more specifically on educational interventions have 
targeted medical students or general practitioners (GPs). Almost every included study has 
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reported on intermediate endpoints, such as an increase in knowledge or measures of 
self-assessment instead of improvement of patient care (11-13). Increase in knowledge in 
these studies has mainly been measured by written examinations. Practical assessments 
have been based primarily on written patient scenarios, with a limited number of disease 
topics (11). Although simulation-based education has been shown to improve learning 
outcomes, the contribution to clinical outcomes remains unclear (14). Moreover, a recent 
study showed that self-assesment of prescribing skills is poorly correlated with assessed 
competence (15).
In the present review, we focus on the existing literature on the education of prescribers 
in hospitals reporting outcomes of (potential) patient harm. We address the scope and 
form of the education programmes described in the literature and give an appraisal of the 
scientific merits of the individual studies.
Methods
Search strategy and study selection
A computer-assisted search of the medical databases Embase and Medline using the Ovid 
interface (from 1990 to May 2016) was performed with the aid of a clinical librarian.
A combined search term was constructed as outlined below. The search aimed at finding 
articles that reported original research data on the prevention of (potential) patient 
harm due to an intervention involving the pharmacotherapy education of prescribers 
in a hospital. The search was constructed combining searches according to the PICO 
(Population: inpatients, Intervention: hospital prescriber education, Comparison: usual 
care, Outcome: patient harm) model.
The search was performed using MeSH subject headings, combined with keywords to 
search in the title/abstract and in keyword heading words. Language was restricted to 
English, Dutch and German. 
To retrieve studies on hospitalized patients, the MeSH terms ‘Inpatients’, ‘Adolescent, 
hospitalized’, ‘Child, hospitalized’, ‘Critical care’, ‘Emergency service, hospital’, ‘critical care’, 
‘hospitalization’, and ‘trauma centers’ were used. Keywords to search in the title/abstract 
and keyword heading words were ‘inpatient*’, ‘hospital*’, ‘emergenc*’, ‘intensive care’, and 
‘critical care’.
The MeSH terms ‘physicians’, ‘hospitalists’, ‘surgeons’, ‘physicians/ed’, ‘hospitalists/ed’, 
‘surgeons/ed’ ‘education, professional’ or ‘education, medical’, ‘education, medical, 
continuing’, ‘education, medical, graduate’, ‘internship and residency’ and ‘drug therapy’ 
were used to retrieve articles that studied the pharmacotherapy education of doctors. 
Keywords to search in the title/abstract and keyword heading words were ‘educat*’, ‘drug 
therap*’, ‘medicat*’ and ‘polypharmac*’.
To retrieve articles that reported on patient harm caused by prescribing errors the MeSH 
terms ‘Drug-Related Side Effects and Adverse Reactions’ and ‘Medication Errors’ were used. 
Keywords to search in the title/abstract and keyword heading words were ‘adverse drug 
event’, ‘adverse drug reaction’, ‘medication error’, ‘medication related problem/event/error’ 
and ‘prescribing error’.
Appendix 1 shows the search strategy performed in Ovid.
Two independent reviewers (J.B., C.K.) selected the articles that were retrieved from 
the search. This selection was performed based on titles and abstracts. In the case 
of disagreement, the full text of the article was retrieved. Research on the effect of 
pharmacotherapy education on doctors in hospitals in order to prevent medication-
related problems in inpatients, and on reporting original data and outcomes on 
prescribing errors and/or (potential) patient harm was included. The full text of these 
studies was retrieved. Each of these selected articles was read fully by two authors (J.B., 
C.K.), who independently assessed whether the articles met the inclusion criteria. In the 
case of disagreement, consensus was achieved in a consensus meeting. In addition, the 
reference lists of the selected articles were checked for potentially relevant literature. 
Research was excluded if the education of doctors in hospitals was only a small part of the 
intervention. 
Assessment of methodological quality and risk of bias
The Methodological Index for Non-Randomized studies (MINORS) checklist, developed 
by Slim et al. (16) was used for quality assessment of the included studies. This checklist 
was developed to determine the methodological quality of nonrandomized studies, and 
consists of 12 methodological items. Eight items are scored for noncomparative studies 
and four additional items for comparative studies. The items are scored on a three-point 
scale; 0 (not reported), 1 (reported, but not adequate) or 2 (reported and adequate) (16). 
To assess the risk of bias, the suggested risk of bias criteria for Effective Practice and 
Organization of Care (EPOC) reviews were used. These consist of different items regarding 
risk of bias for interrupted time series (ITS) studies, controlled before-after studies (CBA) 
and randomized controlled trials (RCTs) (17).
The assessment of methodological quality and risk of bias was performed by two 
reviewers (J.B., C.K.). In the case of disagreement, consensus was achieved in a consensus 
meeting.
Because of the high heterogeneity between studies in terms of study designs and 
outcome measures reported, a meta-analysis was not deemed feasible. We therefore 
provide a descriptive summary of the available evidence.
 
Results
Search results
The initial literature search strategy yielded 899 articles. A total of 846 articles were 
excluded after selection, based on title and abstracts and the full text of the remaining 
53 articles were retrieved. Based on the full text, 15 articles fulfilled inclusion criteria. 
The reasons for exclusion of the other articles by the reviewers were that the education 
was not aimed at prescribers in the hospital (nine articles), no outcome was reported on 
prescribing errors or (potential) patient harm (20 articles) and no original research was 
reported (nine reviews and commentaries).
The study characteristics of the selected articles are listed in Table 1. Eight studies 
investigated an intervention on education of the prescriber alone, and in seven studies 
the education of the prescriber was the main part of a multifaceted intervention. 
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Descriptive summary
Study design
All included studies were relatively small. Sample sizes varied from 112 evaluated patients 
by Rajamani et al. (18) to 685 patients by Gazarian et al (19). Several studies reported the 
total number of prescriptions (20-27) or the number of pharmacy interventions (28) as 
the sample size. Only two studies made a prospective calculation of the study size using 
prescription error rates in literature or the results from a pilot study (25,29).
Most studies had a prospective before-after intervention design; two studies had a 
prospective ITS design (16,23), two studies had a CBA design (20,24) and one study was 
randomized for the intervention (30). In only one study, a blinded assessment of the 
outcome parameter was performed (24).
The follow-up of the studies was relatively short, varying from two weeks to a few months. 
Consequently, the sustainability of the effect of the intervention was poorly investigated. 
Only the studies by Peeters et al. (26) and Gazarian et al. (19) looked at sustainability after 
seven months and four years, respectively. 
Scope and form of the educational intervention
In seven studies, the intervention was aimed solely at education of the prescriber in the 
hospital (20, 24, 26, 28-31), and in eight studies the educational intervention was the main 
part of a multifaceted strategy. In these studies, education was combined with updates 
and implementation of guidelines and protocols, the introduction of medication order 
checklists or the performance of audits on the prescribing process (18, 19, 21-23, 25, 27, 
32).
Most of the educational programmes that were studied aimed to improve prescribing 
skills. The definition of these skills varied from prescribing correctly (prevention of 
incomplete prescriptions) to safer prescribing behaviour and prevention of ADEs. In 
only a few studies, the educational programme aimed primarily to increase the specific 
pharmacotherapeutic knowledge of the physicians (29, 30). 
The method of educating the prescriber also varied between the studies. For example, 
Thomas et al. (27) compared online education with high-intensity education sessions. 
Educational programs were offered to different physicians in different settings. Seven 
studies describe education to pediatricians (19, 21, 22, 24, 25, 28, 32). Three studies were 
performed on general intensive care units (18, 27, 31); the others were performed on 
surgical, internal or geriatric wards (20, 23, 26, 29, 30). Garbutt et al. (23) focused their 
intervention on surgical house staff and medical house staff. Finally, Thomas et al. (27) 
looked at education of trainees. 
Outcome
Outcomes on potential patient harm were most frequently investigated on intermediate 
process parameters, with prescribing errors as the main outcome. One study reported 
the number of pharmacy-interventions (28). A few studies report potential ADEs as an 
outcome measure (19, 21, 28). Only the study of Trivalle et al. (30) reported ADEs as the 
main outcome.
Definitions of prescribing errors and (potential) ADEs differed between studies (2). 
A potential ADE is the result of a prescription error that could possibly have resulted 
in patient injury if it had reached the patient. However, damage was not assessed as 
an outcome measure. This might have been one of the reasons why there was a wide 
variability in reported percentages of prescribing errors and (potential) ADEs (Table 1). 
Nine studies reported a significant decrease in prescribing error rates after an education 
intervention (18, 19, 21, 22, 25-27, 29, 32). In seven of these, the intervention was part of a 
multifaceted approach and in two the intervention was education alone.
Three studies reported no change in overall rates of prescribing errors (20, 24, 31). Kozer et 
al. (24) and Thomas et al. (27) showed no change in the first month after the intervention, 
Ajemegbitse et al. (20) measured the rate of prescribing errors during a six-month period 
after their intervention; in all of these studies, the intervention was education alone. 
Foster et al. (education alone) reported a significant decrease in specific pharmacy 
interventions (28). Garbutt et al. (multifaceted approach) found a decrease in prescribing 
errors by surgical staff, but an increase by medical house staff (23). The study of Trivalle et 
al. is the only study that reports an effect on actual patient harm (30); a decrease in ADEs 
was shown in the intervention group (from 36% to 22% P=0.004).
Three studies (Gazarian et al. (19), Burmester et al. (21), Foster et al. (28)) reported on 
potential ADEs as secondary endpoint. Two (Burmester et al. (21), Foster et al. (28)) found 
no substantial effect, Gazarian et al. (19) reported a decrease in potential ADEs from12.3 to 
4.6 per 100 patients (P<0.05).
Peeters et al. reported a return to baseline 7 months postintervention (26). Gazarian et 
al. showed a sustained long-term improvement in reducing medication errors after four 
years (19).
 
Methodological quality and risk of bias
The results of the assessment of methodological quality and risk of bias for EPOC are 
presented in Figure 1.
The most important methodological limitations of the studies included in the present 
review were short the follow-ups (less than three months), lack of appropriate (equivalent, 
contemporary) control groups and absence of blinded evaluation of the outcome.
It was generally unclear if the educational intervention was independent of other 
changes over time and whether the rate of prescription errors was influenced by other 
confounders during the study period. All together, this resulted in the included studies 
having a high risk of performance bias. In addition, the risk of reporting bias through 
selective outcome reporting scored high. 
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Figure 1. Assessment of methodological quality and risk of bias
Discussion
The present review showed that only a relatively small number of studies have evaluated 
the effects of educational programs for hospital physicians, and of reporting outcomes on 
(potential) patient harm. 
Most studies suffer from poor methodology; the majority of studies were small and the 
follow-up of the studies was relatively short. The risk of performance bias and reporting 
bias were high in all of the selected studies.
In half of the studies, education was the main part of a multifaceted intervention and 
all of these studies showed efficacy on intermediate outcome markers as prescription 
errors and potential ADEs; this was the case in only four out of seven studies in which the 
intervention was education alone. The content of the educational programmes and the 
way of providing the education varied considerably. Different definitions of prescribing 
errors and ADEs were used, contributing to a large variation in the percentages found. 
This large variation can also be explained by the difference in the study settings and in the 
prescribers targeted in the intervention.
The restriction of the present review to studies of inpatients, in combination with the 
restriction to outcome measures on prescribing errors and/or patient harm, resulted in the 
selection of a limited number of studies. We chose to focus on education in the hospital, 
especially because of the complex patient categories and the specific care environment. 
We consider that the effect of education in other settings - for example, nursing homes 
or GP practice - will be diverse, and measures to improve medication safety, including 
education, probably need a different approach.
There might have been publication bias on this subject, although we did not find the 
number of negative studies targeting education alone (20, 24, 27) to be larger than 
that of positive studies (26, 28-30). However, it is possible that some initiatives on 
education in hospital practice do not reach the literature, owing to negative outcomes or 
methodological challenges. 
It has been suggested that prevention of patient harm is likely to require complex, 
multi-faceted intervention strategies (4). This implies that education alone is not likely to 
have a large (if any) effect, and that education should be embedded in a broader array 
of measures aimed at appropriate prescribing. All of the studies in which education was 
a part of a multifaceted approach reported a positive outcome, whereas only four out of 
seven studies in which the intervention was education alone were positive. This suggests 
that future research should be targeted at the most optimal combination of measures - for 
instance, combining education with implementation of clinical rules (33) and medication 
reconciliation.
We found considerable methodological limitations in all of the studies, but it should be 
noted that evaluating education or a multifaceted strategy including education cannot 
easily be performed in RCTs. Instead, a CBA/ITS design or a cluster RCT must be used, all of 
which have their inherent methodological limitations and challenges. However, blinded 
evaluation of clinical relevant outcomes is important, given the subjectivity of definition 
of ADEs. In addition, sustainability is an important aspect that should be addressed. In the 
case of a CBA design or an ITS, a control group without intervention should be included. 
The outcome of any research regarding this subject should be improvement of patient 
care, preferably using clinically relevant endpoints.
Although it is plausible that patients will benefit from educating hospital prescribers in 
pharmacotherapy, the present review showed that further work is needed to develop 
effective educational interventions and to perform robust evaluations. 
The knowledge of how to teach effectively should be combined with optimizing 
the content of education. At present, there are no data supporting a specific form of 
education. A recent article of Franchi et al. (34) showed that an e-learning educational 
program alone failed to improve clinician drug prescription for hospitalized older patients. 
One of the authors’ suggested explanations for failure was the low level of interactivity 
of the program. In addition, they suggested that educational programs need a follow 
up, to enhance learning retention. The authors also indicated that education should 
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be combined with different strategies in a multifaceted intervention to obtain a real 
improvement in prescription quality (34).
The qualifications or training of teachers that deliver the educational interventions was 
rarely addressed in the included studies. This could also have influenced the quality of the 
intervention and the outcomes. 
The present review suggested that educational sessions should be combined with other 
measures to improve medication safety. In regard to the form of education, there are 
indications that workplace-based pharmacotherapy education, using complementary 
knowledge in interdisciplinary settings is most effective (35). With continuous audit and 
feedback on the main pharmacological issues and prevailing guidelines in the workplace 
of healthcare professionals, there will be a higher likelihood of a sustained effect. 
Moreover, in our opinion, this educational approach should start early in the programmes 
of undergraduates. Clinical pharmacological teaching involving students in prescribing 
in ‘real context’ training programmes, in addition to more classical teaching, has been 
described to be of great educational value (36). Furthermore, in our view, the content of 
pharmacology education should be related to known risk factors for medication errors in 
hospital patients and should focus on the use of high-risk drugs in high-risk patients or 
high-risk situations. In addition, education should also cover correct use of the electronic 
prescribing system and a clinical decision support system.
Conclusion
Taken together, there is currently no firm evidence that educating prescribers in the 
hospital leads to a decrease in patient harm. However, there is also no sound research 
showing that education has no effect, and many studies, especially those with the 
multifaceted interventions, have shown benefit on intermediate outcome parameters. 
Future research should be targeted at development and implementation of educational 
programmes, with outcomes on improvement of patient care, which should be 
evaluated by high-quality research. In our view, these programmes should be a part of a 
multifaceted approach in which education is supported by other measures. It is hoped 
that this will result in evidence for measures which can be taken to improve medication 
safety in the hospital.
Appendix 1.
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid 
MEDLINE(R) <1946 to Present>
Search Strategy:
1.  adolescent, hospitalized/ or child, hospitalized/ or inpatients/ or inpatient?.tw. or inpatient?.kf. or 
hospital*.tw. or hospital*.kf. or exp critical care/ or hospitalization/ or emergency service, hospital/ 
or trauma centers/ or emergenc*.tw. or emergenc*.kf. or ((intensive or critical) adj3 care).tw. or 
((intensive or critical) adj3 care).kf. (1320173)
2.  physicians/ or hospitalists/ or surgeons/ or physicians/ed or hospitalists/ed or surgeons/ed or 
education, professional/ or education, medical/ or education, medical, continuing/ or education, 
medical, graduate/ or “internship and residency”/ or ed.fs. or educat*.tw. (706878)
3.  exp Drug Therapy/ or ((drug adj3 therap*) or medicat* or polypharmac*).tw. or ((drug adj3 therap*) or 
medicat* or polypharmac*).kf. (1373658)
4. 1 and 2 and 3 (7555)
5. dt.fs. (1855920)
6.  3 or 5 (2637038)
7.  1 and 2 and 6 (9757)
8.  “Drug-Related Side Effects and Adverse Reactions”/ or Medication Errors/ or (adverse adj3 drug adj3 
(event? or reaction?)).tw. or ((medicat* adj3 error?) or (medicat* related adj3 (problem? or event? 
or error?))).tw. or (prescribing adj3 error?).tw. or (adverse adj3 drug adj3 (event? or reaction?)).kf. or 
((medicat* adj3 error?) or (medicat* related adj3 (problem? or event? or error?))).kf. or (prescribing 
adj3 error?).kf. (49627)
9. 7 and 8 (977)
10.  (dutch or english or german).la. (22079904)
11. 9 and 10 (928)
12. limit 11 to yr=”1990 -Current” (899) 
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Abstract
Aim
The P-REVIEW study was a prospective, multicenter, open intervention study, designed 
to determine whether a multifaceted intervention of educating the prescriber combined 
with medication review and pharmaceutical visits to the ward by the hospital pharmacist 
could lead to a reduction of drug-related complications among surgical patients.
Methods
A total of 6780 admissions of 5940 patients to surgical, urological and orthopaedic 
wards during the usual care period and 6484 admissions of 5711 patients during the 
intervention period were included. 
An educational programme covering pain management, antithrombotics, fluid and 
electrolyte management, prescription in case of renal insufficiency and antibiotics was 
developed. National and local hospital guidelines were included. Hospital pharmacists 
performed medication safety consultations, combining medication review of high-risk 
patients and a visit to the physician on the ward.
Results
A significantly lower proportion of admissions with one or more clinically relevant, 
potentially preventable, drug-related problems (including death, temporary or sustained 
disability, increased length of hospital stay or readmission within 30 days ) occurred in the 
intervention period (1.1% (73/6484) compared to the usual care period (1.6% (106/6780)) 
(P=0.029). The relative risk (RR) was 0.72 (95% CI 0.53-0.97). Several types of drug-related 
problems occurred less frequently. Costs incurred as result of time spent on study-related 
activities were not different before and after the intervention.
Conclusions
The P-REVIEW study shows that education and support of the prescribing physician 
with respect to high-risk patients in surgical departments leads to a significant, clinically 
relevant benefit for patients without generating additional costs.
Introduction
Problems due to errors in pharmacotherapy are common among hospitalized patients 
(1-4). Many of these derive from prescribing errors that lead to potentially preventable 
morbidity, mortality and costs. The majority are caused by pain medication (non-steroidal 
anti-inflammatory drugs (NSAIDs) and opioids), (combination of ) antithrombotics, 
antibacterial drugs, cardiovascular drugs, and drugs that are renally excreted (1-3, 5, 6). 
Especially patients on surgical wards are at risk, due to the need for pain medication and 
antibiotics, frequent adjustments of antithrombotic regimens and blood and fluid loss(7). 
In the case of elderly surgical patients, multiple co-morbidities requiring multiple drugs 
add even more to the potential drug-related problems (8). The care for these patients is 
often provided by junior physicians. These junior doctors do not consider themselves 
sufficiently trained to prescribe (9-11) and they are often supervised by surgeons who 
have no specific expertise with respect to complex pharmacotherapy. 
Guidelines have been developed to assist doctors and improve care, but implementation 
of these guidelines is challenging and adherence is limited, possibly because of frequent 
rotations of inexperienced physicians on these wards (12, 13).
Several approaches may be considered to minimize prescription errors. It was shown that 
implementation of a comprehensive checklist, including medication-related items, can 
reduce surgical complications and mortality (14). In addition, computerised physician 
order entry (CPOE) in combination with a clinical decision support system can support 
both the physician and the hospital pharmacist. However, some prescription errors may 
still be missed (15, 16), while at the same time alert fatigue may arise as the result of 
irrelevant alerts, increasing the likelihood that important alerts go unnoticed (17, 18). The 
inexperienced physician on the ward lacks adequate knowledge to interpret the alerts. 
In most hospitals, overridden alerts are checked by hospital pharmacists. However, for a 
comprehensive judgement of the medication of the patient by the hospital pharmacist, 
detailed knowledge about the clinical situation is needed.
This has led to more active involvement of hospital pharmacists on clinical wards. This 
approach, however, is time consuming. Despite research, that demonstrates the benefits 
of different clinical pharmacy services (19-21), there is only scarce evidence of benefit on 
clinically relevant outcome measures for patients on general (non-ICU) wards (22-24). 
Another strategy to reduce prescribing errors aims at educating the prescriber. Although 
this has been shown to reduce prescribing errors, the effect is not sustained over time 
(25). An educational programme could be made more sustainable by combining it with 
pharmaceutical care visits by the hospital pharmacist to the ward. The educational 
programme teaches the pharmacological aspects of using high-risk drugs in high-
risk patients. The goal of the visits by the hospital pharmacist is to boost the effects of 
education and to suggest interventions based on a medication review of the patient. 
By discussing prescribing errors these medication reviews will also have an educational 
effect. To reduce the workload of the hospital pharmacist and to improve feasibility of the 
intervention, patients at risk of drug-related problems, are selected based on medication 
use and clinical features. Guidelines (e.g. on peri-operative anticoagulation policy) are an 
important part of the educational programme. The visiting hospital pharmacist actively 
checks and teaches on guideline adherence. 
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The P-REVIEW study (Pharmacist-lead Risk patients medication EValuation to Initiate Event 
reduction on surgical Wards) was designed to investigate whether such an approach 
could lead to a reduction of drug-related complications among high-risk surgical patients.
 
Methods
Study design and setting
The P-REVIEW study was an open intervention study with a before-after design performed 
in two large general teaching hospitals in the Netherlands (the Isala Hospital in Zwolle, 
779 beds and the Meander Medical Centre in Amersfoort, 600 beds). In total, 12 hospital 
pharmacists participated in the study.
The institutional review boards of the Isala Hospital and the Meander Medical Centre 
stated that the study was exempt from ethical approval. Patient data were collected and 
stored in accordance with prevailing privacy regulations.
Study population
All patients who were admitted to the surgical, urological and orthopaedic wards of 
the two hospitals during a usual care period (1 June 2011-1 December 2011) and an 
intervention period (1 March 2012 - 1 September 2012) were included in the study. 
Both periods were of six months duration, with a three-month period in between, during 
which the intervention was introduced. Patients were followed up until discharge. 
Patients could be included more than once, in case of readmission. Day care patients were 
excluded. 
Usual care period
During the usual care period, the normal procedures of medication surveillance and 
communication between hospital pharmacists and physicians were maintained.
A computerized physician order entry (CPOE) system with clinical decision support (CDS) 
was applied in both hospitals. There was no orthogeriatric service at the time of the study.
Briefly, hospital pharmacists checked medication of all patients on a daily basis with 
the aid of computer-generated alerts based on a national database (‘G-standard’ ; 
www.z-index.nl). Hospital pharmacists could warn the physician by telephone or send 
a fact-sheet to the ward. In both hospitals, pharmacists were supported by a set of 
computerized ‘clinical rules’ to screen for specific prescription errors. These clinical rules 
combine clinical patient data (like renal function and electrolyte abnormalities) with the 
medication to judge, for example, whether dose adjustments should be made in case of 
renal insufficiency or if gastric protection should be added to an NSAID (26). 
Intervention period
During the intervention, a combination of an educational programme and medication 
counselling for prescribers dealing with high-risk patients on the wards took place, in 
addition to the procedures described above. 
An educational programme covering pain management, antithrombotics, fluid and 
electrolyte management, prescription in the case of renal insufficiency, application 
of radiographic contrast agents and surgical antibiotic prophylaxis was developed. 
National and local hospital guidelines relating to these subjects were also included. The 
programme consisted of two parts of approximately 2 hours each. All prescribers on the 
participating wards attended the course.
Hospital pharmacists were trained to perform medication safety consultations (MSC), 
combining a medication review and a visit to the ward. A computerised screening method 
identified high-risk patients. The screening method was based on recent literature on 
prescription errors and targeted patients at risk for potentially preventable, drug-related 
problems (1, 27) (Appendix 1). Hospital pharmacists performed the medication review by 
using a checklist, in order to establish uniformity (Appendix 2). The review was performed 
weekly and discussed with the prescriber on the ward. 
Study endpoints
The primary outcome of this study was the proportion of patients with one or more 
potentially preventable, clinically relevant, drug-related problems. Clinically relevant 
problems included death, temporary or sustained disability, increased length of hospital 
stay or readmission within 30 days. Secondary endpoints were characterization of drug-
related problems and costs that were incurred by the hospital as a result of running the 
programme.
Data collection
Collected data included patient characteristics, laboratory and medication data, as well as 
admission mutations, medical correspondence and medical interventions. Data regarding 
radiology, microbiology, blood transfusion and information about medical incidents were 
also collected. 
A semi-automatic trigger instrument using electronic patient records was used to identify 
possible drug-related problems based on these data (Appendix 3). It consisted of a 
comprehensive set of phenomena such as (change in) laboratory results, medication use, 
clinical interventions (e.g. gastroscopy), radiology examinations, consultations of other 
specialists, transfer to the intensive care unit, readmission within 30 days and death (1, 28-
31). Assessment of triggers and filling out of the case report was performed at least two 
weeks after discharge or death of the patient to avoid influencing daily practice. The major 
part of the data collection and the identification of possible cases with a clinically relevant, 
drug-related problem based on the trigger list was performed automatically, using a 
validated multisource Microsoft Access database (Microsoft version 2003). In addition, 
some of the data were collected manually and edited by a trained research assistant in the 
hospital using a predefined protocol (Appendix 3). 
Recommendations on pharmacotherapy, based on the MSC, performed by the hospital 
pharmacist during the invention period, were documented in the database. 
On the fifth month of both periods, pharmacy assistants and hospital pharmacists 
registered the time they spent on activities such as checking prescribed medication 
and interventions performed. In the intervention period they also registered time spent 
on activities such as medication review of high-risk patients and medication safety 
consultation on the ward. They also made an estimate of the time spent by the prescribing 
physician to follow up the advice. Time spent on the educational programme by hospital 
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pharmacists and prescribing physicians of the participating wards during the intervention 
was also registered. 
Costs were calculated by multiplying the time spent on the study-related activities 
by salary expenditures of health-care providers, obtained from the collective labour 
agreement of Dutch hospitals (www.nvz-ziekenhuizen.nl). 
All case record forms (CRF) of the patients with one or more triggers were assessed by 
three teams of two experts. Every team consisted of a hospital pharmacist and a hospital-
based physician. These teams had no relation to the hospitals where the study was 
performed. 
The experts independently assessed if there was a clinically relevant, drug-related 
problem that had led to death, temporary or permanent disability, increased length of 
hospital stay or readmission within 30 days. Prescription errors, leading to drug-related 
problems, were identified in a broad perspective, including identification and prevention 
of possible adverse drug reactions, drug interactions, protocol adherence and omission of 
medication. To classify seriousness the National Coordinating Council for Medication Error 
Reporting and Prevention (NCC MERP) index was used. Categories E to I of this index were 
considered to be clinically relevant (32). The causality between prescription error and the 
drug related problem was assessed using the algorithm by Kramer et al. (33). The potential 
preventability was assessed using the algorithm according to Schumock et al., modified 
by Lau et al. (34, 35). The experts were blinded to the period (usual care or intervention) 
during which the problem occurred.
If there was no agreement between the experts of a team about the occurrence of a drug-
related problem or about the clinical relevance, the causality or the preventability of the 
problem, consensus was achieved in consensus meetings with the expert teams. 
Sample size and data analysis
On the basis of the available literature, we estimated that the proportion of clinically 
relevant, potentially preventable, drug-related problems among surgical patients would 
be 0.7% (36).
Our study was powered to detect a reduction of this proportion by at least 50%. A two-
group, Chi square test with a 0.05 one-sided significance level will have 80% power to 
detect such difference when the sample size per group is 5300.
Baseline characteristics were presented as means and standard deviation or percentages 
for continuous or dichotomous outcomes, respectively. 
Differences between groups were tested on statistically significant difference with either 
an independent t-test or a chi-square test depending on type of data. 
The difference in proportion of clinically relevant drug-related complications was 
expressed in relative risk with 95% confidence interval. In addition, the average number 
of high-risk patients needed to review in order to prevent one clinically relevant drug-
related complication was calculated (1/ARR). As a secondary analysis, the relative risk (RR) 
of clinically relevant drug-related complications between the two periods was corrected 
for confounders using binominal logistic regression. Age, gender, department where the 
admission took place and whether or not the admission was planned were considered as 
confounders and included in the regression analysis as fixed factors. Costs were compared 
between the two periods with a student’s t-test. Statistical analyses were performed using 
SPSS Statistics version 21. 
 
Results
In the usual care period of the study, 6780 admissions (5940 patients) and in the 
intervention period 6484 admissions (5711 patients) were included. Table 1 details the 
characteristics of these admissions. 
A significantly lower proportion of admissions with one or more clinically relevant, 
potentially preventable, drug-related problems occurred in the intervention period (1.1% 
(73/6484) compared to the usual care period of the study (1.6% (106/6780)) (P=0.029). The 
relative risk (RR) was 0.72 (95% CI: 0.53-0.97).
After correction for potential confounders (age, gender, department, planned admission) 
the adjusted RR was 0.74 (95% CI: 0.54-1.00) (Table 1).
When the included patients were divided into to the predefined risk classes the primary 
end point changed from 3.7% (89/2392) to 2.8% (61/2126) in high risk patients; RR 0.77 
(0.55-1.06); and from 0.4% (17/4388) to 0.3 % (12/4358) in low risk patients; RR 0.71 (0.34-
1.49). The average number of high-risk patients that needed to be reviewed in order to 
prevent one clinically relevant drug-related problem was 111 (100/0.9).
Table 2 shows a comparison of intervention-related characteristics. There was no 
difference in the number of medications the first day after admission. However, there 
was a (small) decrease in the percentage of admitted patients using specific medication 
groups. In some groups (heparin/LMWH, diuretics, beta blockers, opioids) this reduction 
was statistically significant.
In addition, length of hospital stay and the number of patients with renal insufficiency was 
decreased after the intervention. 
Table 3 describes the characteristics of the patients with an event. The patients who 
had an event were older and used more drugs at the first day after admission. The mean 
length of hospital stay of these patients was slightly shorter after the intervention than in 
the usual care period, but significantly longer than the mean length of hospital stay of the 
total of patients. The mean time until the occurrence of the event showed no difference 
between the two periods.
Table 4 describes the types of events in patients with a drug-related problem. Several 
types of events occurred less frequently during the intervention period, especially 
haemorrhage, thrombosis and central nervous systems events (mainly delirium).
Table 5 shows the costs of study-related activities during the usual care period and the 
intervention period of the study. During the intervention, the costs per admission were 
higher for hospital pharmacists because they performed MSC and ward visits. The costs 
of pharmacy assistants, however, were lower. Costs of the training of pharmacists and 
prescribers were assessed and expressed as extra costs per admission. Taken together, 
mean total costs were €6.04 (95% CI: 5.82-6.26) per admission in the usual care period. 
These were not statistically significant different from €6.18 (95% CI: 6.06-6.30) per 
admission in the intervention period.
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Table 1. Characteristics of admissions
Usual care period Intervention period P-value
No. of admissions 6780 6484
No. of patients 5940 5711
Mean age of patients in years ± SD 63.3 ± 17.6 62.2 ± 17.6 <0.001
Gender of patients, n (%) female 3380 (49.9 %) 3238 (49.9%) 0.71
Department of admission <0.001
- General surgery, n (%) 3947 (58.2%) 3727 (57.5%)
- Orthopaedic surgery, n (%) 1595 (23.5%) 1455 (22.4%)
- Urology, n (%) 1238 (18.3%) 1302 (20.1%)
Planned admission, n (%) 2306 (35.2%) 2217 (34.2%) 0.18
Table 2. Comparison of intervention-related characteristics
Usual care period
(n = 6780)
Intervention period
(n = 6484)
P-value
Mean no. of medications the first day 
after admission, ± SD
6.65 ± 5.54 6.57 ± 5.65 0.397
Medication the first day after 
admission, n (%)
- Hypoglycemics 846 (12.5%) 717 (11.1%) 0.011
- Vitamin K antagonists 598 (8.8%) 531 (8.2%) 0.193
- Heparin/LMWH 4298 (63.4%) 3893 (60.0%) <0.001
-  Thrombocyte aggregation 
inhibitors
1245 (18.4%) 1223 (18.9%) 0.460
- Diuretics 1578 (23.3%) 1342 (20.7%) <0.001
- Beta blockers 1632 (24.1%) 1372 (21.2%) <0.001
- Calcium channel blockers 641 (9.5%) 687 (10.6%) 0.029
- RAS inhibitors 1654 (24.4%) 1453 (22.4%) 0.007
- NSAIDs 2381 (35.1%) 2201 (33.9%) 0.156
- Opioids 2733 (40.3%) 2398 (37.0%) <0.001
- Antipsychotics 419 (6.2%) 346 (5.3%) 0.037
Mean length of stay, days ± SD
- General surgery 6.9 ± 8.7 5.7 ± 6.7 <0.001
- Orthopaedic surgery 6.7 ± 7.2 6.0 ± 5.6 0.005
- Urology 4.1 ± 4.3 3.7 ± 3.4 0.027
MDRD eGFR of patients  
(ml/min/1,73 m2), n (%)
(n = 4637a) (n = 4258a) 0.006
- <10 34 (0.7%) 30 (0.7%)
- 10-30 146 (3.1%) 150 (3.5%)
- 30-60 972 (21.0%) 835 (19.6%)
- >60 3485 (75.2%) 3243 (76.2%)
a  Number of admissions during which a MDRD of the patient was measured
LMWH = low molecular weight heparin; NSAIDs = non-steroidal anti-inflammatory drugs; RAS = renin angiotensin 
system
Table 3. Characteristics of patients with an event
Usual care period Intervention period
Mean age of patients in years ± SD 78.6 ± 8.7 74.8 ± 13.9
Female patients, n (%) 51 (48.1%) 34 (46.6%)
Department
- General surgery, n (%) 74 (69.8%) 43 (58.9%)
- Orthopaedic surgery, n (%) 28 (26.4%) 22 (30.1%)
- Urology, n (%) 4 (3.8%) 8 (11.0%)
Mean no. of medications the first day after 
admission, ± SD
11.1 ± 4.9 12.4 ± 5.1
Mean length of stay, days ± SD 14.2 ± 10.4 13.1 ± 9.7
Mean duration until occurrence of event 
(including events, leading to readmission), 
days ± SEM
6.7 ± 0.7 6.8 ± 0.8
Table 4. Clinically relevant, potentially preventable, drug-related problems due to prescription errors: 
type of events
Usual care period
106a (1.6%)
Intervention period
73a (1.1%)
Haemorrhage (NSAID, antithrombotic 
therapy) 
19 15
Arterial or venous thrombosis (antithrombotic 
therapy)
7 3
Renal insufficiency, hydration or electrolyte 
related event (diuretics, NSAID, RAAS inhibitors)
13 14
Drug intoxication in renal insufficiency 
(unadjusted therapy)
4 1
Central nervous systems events mainly delirium 
(tramadol, anticholinergic therapy)
48 20
Faecal impaction (opiates) 11 9
Hypoventilation (opiates) 0 2
Unclassifiableb 4 9
a  These drug-related problems occurred in 102 patients in the control period and 69 patients in the intervention 
period.
b  Variable drug-related problems, for instance Addison crisis because of omission of corticosteroids; prescribing 
salbutamol to a patient, with a known allergy to salbutamol; lithium intoxication because of drug-drug 
interaction; pulmonary edema, provoked by naproxen.
3
47
3
46
A multifaceted intervention to reduce drug-related complications in surgical patients
Table 5. Mean costs of usual care and of intervention (pharmaceutical care and training of prescribers) per 
admission
Mean costs per admission (€)
Usual care period Intervention period
Pharmaceutical care by:
- Pharmacy assistants
- Hospital pharmacists
- Prescribers
€ 4.86
€ 1.08
€ 0.10
€ 2.16
€ 1.90
€ 0.15
Training of prescribers - € 1.97
Total (P=0.272) € 6.04 (95% CI: 5.82-6.26) € 6.18 (95% CI: 6.06-6.30)
Discussion
The P-REVIEW study shows that a teaching programme for prescribers, combined 
with performing medication reviews in patients, at risk for drug-related problems, and 
weekly visits of a hospital pharmacist to the ward significantly reduces clinically relevant, 
potentially preventable, drug-related problems in patients admitted to surgical wards. 
The results reveal a significantly lower proportion of admissions with one or more of these 
problems in the intervention period. Costs incurred by the hospitals did not increase 
during the intervention period as the result of time spent on education, medication 
review and ward visits by hospital pharmacists.
P-REVIEW is a study with clinically relevant outcome measures in a very large patient 
cohort. Different interventions to minimize medication errors such as medication review, 
medication reconciliation, computerised physician order entry system with clinical 
decision support, educational programmes and multifaceted approaches have been 
studied before. These studies were generally insufficiently powered and focused on 
surrogate endpoints such as prescription errors, medication discrepancies or prevention 
of potential harm. The studies showed substantial heterogeneity in these outcomes. 
Some studies indicate that these interventions improve patient management or clinically 
relevant outcomes (19). However, most studies were methodologically weak, as they used 
non-blinded designs and lacked robust data collection methods (15, 37-46).
In two smaller studies it was shown that educational programmes reduced prescription 
errors in the ICU and among hospitalized elderly, although they failed to show an 
effect on clinically relevant outcomes (45, 47). When education was incorporated in a 
multifaceted approach, hospital anticoagulation management improved, which led to 
reduction of venous thromboembolism (VTE) and costs (48). Reduction of VTE was also 
found after implementation of a computerized clinical decision support system (49). 
Decision support plus validation by a pharmacist led to more efficient pharmaceutical 
care on the ICU and reduction of potential prescribing errors on clinical wards in a tertiary 
referral hospital, but did not show improvement on clinically relevant patient outcomes 
(50, 51). The SUREPILL study, which evaluated a protocolled, ward-based pharmacy 
method compared with standard pharmaceutical care in surgical patients, showed no 
reduction in medication-related harm or changes in clinical outcomes (24).
The P-REVIEW study has several strengths. The intervention combines two strategies 
which have been employed separately in the past: structured medication reviews 
followed by visits to the ward by the hospital pharmacist and education of prescribers. 
Both interventions have been found to be effective in reducing drug-related problems, 
but the effect on clinically relevant endpoints was still unknown. Education of prescribers 
has been found to have only a transient effect on the frequency of prescription errors (25). 
In our study we aimed to boost this effect by the weekly visits of the hospital pharmacist 
as a form of workplace-based pharmacotherapy education. 
Furthermore we used risk stratification to make the efforts of the hospital pharmacist 
more efficient. As one of the purposes of the weekly medication review and the visits 
to the ward was education of prescribers, we reasoned that we did not need to address 
all possible prescription errors. We showed that low-risk patients (without medication 
reviews) may also benefit from the effect of the intervention. 
As the primary outcome we studied clinically relevant patient outcome measures (death, 
temporary or permanent disability, increased hospital stay or readmission) in a very 
large patient cohort. Prescription errors, leading to these clinically relevant drug-related 
problems, were identified in a broad perspective, including possible adverse drug 
reactions, drug interactions, guideline non-adherence and omission of medication.
The intervention was performed by healthcare providers already active in the hospital, 
so implementation was relatively straightforward. The study was performed in two large 
teaching hospitals that are representative for the majority of hospitals in the Netherlands.
Besides these strengths, the study also has a number of limitations. The study had 
a before-after design. Therefore, it is impossible to ascertain whether differences in 
characteristics, such as the use of certain drugs, are caused by the intervention or should 
be ascribed to differences between the groups. We considered a randomised controlled 
design impossible, since both the educational programme and the visit by the pharmacist 
will contaminate usual care as residents and other healthcare providers learn from this 
intervention. By blinding all case record forms with respect to the study period before 
assessment by the experts and by correcting for confounders, the probability of bias was 
minimized.
Next, the study was performed in two hospitals in the Netherlands possibly limiting the 
external validity of the study. The role of the hospital pharmacist on the ward can be 
different in other countries. 
This study used a trigger instrument to identify clinically relevant, medication-related 
events, based on different trigger instruments described in the literature. However, this 
has not been formally validated and therefore some events might have been missed. 
Nevertheless, as events will have been missed both before and after, this may only limit 
the power of the study, without biasing the outcome.
The cost analysis shows that this intervention does not lead to extra costs. However, in the 
analysis only time spent by healthcare workers was taken into account. Possible effects on 
medication use and laboratory tests were not included, but the costs of the drug-related 
complications were not calculated either.
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This study shows that introducing a teaching programme for prescribers, combined 
with performing medication reviews in high-risk patients and weekly visits of a hospital 
pharmacist to the surgical ward, contributes to patient safety and should be implemented 
in all hospitals. The implementation of these activities is relatively easy and can be 
performed by healthcare providers already active in the hospital. The time and effort 
needed from the hospital pharmacist to perform MSC and ward visits and to train 
prescribers are compensated by less time consumed by pharmacy assistants probably due 
to less need for interventional activities. 
Although on first sight reducing clinical relevant drug related errors from 1.6 to 
1.1 % seems not especially impressive, one has to take into account that each year in 
the Netherlands 4 million hospital admissions take place. This means that thousands of 
patients would benefit from nationwide implementation of this intervention.
Further investigation should address improvement of the identification of high-risk 
patients. We intend to perform a post-hoc analysis of the P-REVIEW database to identify 
more specific predictive factors for patients at risk for clinically relevant preventable 
medication related adverse events. Being able to more accurately predict which patients 
are at risk for a drug-related complication during hospital admission would improve the 
efficiency of interventions. The method used for risk identification could be different 
between hospital wards of different medical specialties.
In addition, we intend to investigate whether the implementation of education of 
prescribers and performing medication reviews also has an effect on relevant patient 
outcomes in non-surgical medical specialties as internal medicine, neurology or 
psychiatry.
In summary, this large study shows that education and support of the prescribing 
physician by the hospital pharmacist with respect to high-risk patients in surgical 
departments leads to a significant clinically relevant benefit for patients. This study 
also shows this helps reduce clinically relevant medication-related problems without 
generating additional costs. 
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Appendix 1. Screening method to identify high-risk patients on surgical 
wards
All patients with renal insufficiency (MDRD < 60ml/min/1.73m2)
or use of high-risk medication or medication combinations: 
-  Renin angiotensin aldosterone system (RAAS) inhibitor and loop diuretic
-  RAAS inhibitor and loop diuretic and non-steroidal anti-inflammatory drug (NSAID)
-  (Coumarin or heparin or high-dose low molecular weight heparin (LMWH)) and Adenosine 
diphosphate (ADP) receptor antagonists (e.g. clopidogrel)
-  (Coumarin or heparin or high-dose LMWH) and acetylsalicylic acid
-  (Coumarin or heparin or high-dose LMWH) and NSAID
-  ADP receptor antagonists and acetylsalicylic acid
-  NSAID and (coumarin or serotonin-specific reuptake inhibitor (SSRI) or prednisone or acetylsalicylic 
acid)
-  Use of digoxin, sotalol, lithium, aminoglycosides or methotrexate
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Appendix 2. Checklist for performing medication review on surgical wards
The checklist below is not meant to be complete, but is meant to support the hospital 
pharmacist in performing medication review and to establish uniformity.
Clinical consideration Relevant conditions Drugs concerned
Renal function
- What is the MDRD?
- Muscle mass abnormal? e.g. wheel chair, neuromuscular 
disease, amputation, >2 weeks 
bedridden 
prednisone
-  Dose adjustments necessary 
for medication with narrow 
therapeutic indexes that are 
processed by the kidneys or 
contraindication?
NSAID, digoxin, sotalol, lithium, 
metformin, therapeutic dose 
LMWH, nitrofurantoin, aciclovir, 
aminoglycoside, atenolol,  
SU derivate etc.
Electrolyte disturbances
-  Hyponatraemia < 135 mmol/l? (Combination of two of the three of ) 
SSRI, thiazide, carbamazepine?
-  Hypokalaemia (< 3.5 mmol/l)? (Combination of ) thiazide and loop 
diuretic?
-  Hyperkalaemia (> 5.3 mmol/l)? (Combination of two) potassium-
saving diuretics, spironolactone, 
eplerenone, ACE inhibitor, ARB, 
trimethoprim, NSAID?
NSAID/renal function
-  (This dose) NSAID necessary? heart failure, impaired renal 
function, liver cirrhosis, 
hypovolaemia
Combination with ACE inhibitor 
and/or diuretic
NSAID/risk of bleeding
-  (This dose) NSAID necessary? 
Add PPI?
>70 years old, ulcer in history,  
heart failure, diabetes mellitus, 
severe rheumatism 
Combination with coumarin, high 
therapeutic dose LMWH, SSRI, ASA, 
spironolactone, prednisone
NSAID otherwise contraindicated? ulcerative colitis or Crohn’s 
disease, liver cirrhosis, intercurrent 
infections, SLE, AP, psoriasis, etc.
Anticoagulation/antithrombotics
-  Indication vitamin K antagonists? 
Associated target value?
-  Pharmacodynamic interaction 
coumarin. INR values? Bleeding? 
Hb values?
Cotrimoxazole or other antibiotics, 
enzyme inhibitors (triazoles 
omeprazole), enzyme inductors 
(rifampicine, carbamazepine, 
phenytoin)
-  Pharmacokinetic interaction 
coumarin? 
NSAID, SSRI, prednisone, ASA, ADP 
receptor antagonists, heparin, 
antibiotics
-  Perioperative antithrombotics 
correct and according to 
guidelines? 
-  Indication LMWH? Dose correct? LMWH prophylactic or therapeutic 
dose
-  Indication ASA or ADP receptor 
antagonists?
Combination of ASA + ADP 
antagonist or with oral 
anticoagulants?
Clinical consideration Relevant conditions Drugs concerned
Pain
-  Use of opioids? 
Laxative added? Stoma, diarrhoea
Short-term use of opioids?
-  Use of opioids? Consider (risk for) delirium, has an 
antipsychotic been started?
opiates, especially tramadol 
relatively contraindicated
-  Use of opioids? Consider respiratory depression benzodiazepine?
Infection
-  Dosing of antibiotics in impaired 
renal function?
-  Serum concentrations monitoring 
necessary?
gentamicin, tobramycin, 
vancomycin
-  Duration of antibiotic therapy? 
Intravenous therapy indicated?
Antibiotics
-  Allergies?
-  Perioperative antibiotic 
prophylaxis indicated?
-  Endocarditis prophylaxis 
indicated?
Imaging diagnostics
-  Radiocontrast used? Combination with diuretics, NSAID, 
metformin?
-  Hydration indicated? Renal impairment? Multiple 
myeloma? Waldenstrom’s disease? 
Peripheral vascular disease, heart 
failure, anaemia, age > 75 years, etc.
Glucocorticoids
-  Osteoporosis prophylaxis 
indicated?
Biphosphonates, vitamin D, 
calcium?
-  PPI indicated? PPI
Osteoporosis
-  Osteoporosis prophylaxis 
indicated?
Any corticosteroids, anti-androgens, 
antiepileptics
-  Vitamin D indicated
-  Falling incident? antihypertensive agents, diuretics, 
alpha blockers, or other orthostatic 
drugs; sedatives (promethazine, 
codeine, benzodiazepines, 
barbiturates)
Drug-drug interactions
-  Important CYP interactions? Check on CYP inhibitors, inducers 
and substrates
-  Risk for QT-prolongation? Check potassium and magnesium 
levels
Check on QT prolonging medication
Digoxin
-  Indication? In case of AF, antithrombotics 
needed?
-  Dose adjustment for renal function 
and age?
-  Potassium levels?
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Clinical consideration Relevant conditions Drugs concerned
Other
-  Check statins in case of any form of 
arterial vascular disease
Statin
-  Use of methotrexate? Supplementation of folic acid?
-  Has an antipsychotic been started? Check on delirium provoking 
medication (anticholinergics, 
tramadol, etc.)
ACE inhibitor, angiotensin-converting enzyme inhibitor; ADP receptor antagonist, adenosine diphosphate 
receptor antagonist; AF, atrial fibrillation; ARB, angiotensin-receptor blocker; ASA, acetylsalicylic acid; INR, 
international normalised ratio; LMWH, low molecular weight heparin; MDRD, modification of diet in renal disease; 
NSAID, non-steroidal anti-Inflammatory drug; PPI, proton pump inhibitor; SSRI, selective serotonin reuptake 
inhibitor; SU derivate, sulfonylurea derivate
Appendix 3. Trigger tool used to select patients for potential drug-related 
events 
No. Trigger Automatic trigger instrument Modification by research 
assistant according to protocol
1 Readmission within 30 days Admission in the hospital within 
30 days after discharge
Exclusion of planned 
readmission
2 Unplanned transfer to ICU/CCU/
MCU
Admission to ICU/CCU/MCU Exclusion of planned admission 
to ICU/CCU/MCU
3 Death Death -
4 Interdisciplinary consultation Interdisciplinary consultation -
5 Report of a problem Report of an incident during 
admission
Inclusion of medication-related 
incidents/ complications
Report of a complication during 
admission
6 Bleeding Use of eptacog alfa Inclusion of possible medication-
related bleeding according 
protocol
Inclusion in case of gastroscopy 
or colonoscopy
Use of high-dose intravenous 
proton pump inhibitor
Use of prothrombin complex
Decrease in haemoglobin of  
≥ 3 mmol/l
Diagnosis code: bleeding
Blood transfusion
7 Probable bleeding Use of desmopressin in 
combination with decrease in  
Hb ≥ 1.5 mmol/l
Inclusion of possible medication-
related bleeding according 
protocol
Inclusion in case of gastroscopy 
or colonoscopy
Use of tranexaminic acid in 
combination with decrease in  
Hb ≥ 1.5 mmol/l
Use of vitamin K in combination 
with decrease in Hb ≥ 1.5 mmol/l
INR ≥ 6 in combination with 
decrease in Hb ≥ 1.5 mmol/l
Thrombocytopenia while using 
methotrexate or co-trimoxazole 
in combination with decrease in 
Hb ≥ 1.5 mmol/l
-
8 Possible heparin-induced 
thrombocytopenia (HIT)
Use of argatroban, danaparoid -
9 Thrombo-embolic complication Diagnosis code: pulmonary 
embolism or deep venous 
thrombosis
-
10 Cerebrovascular accident/TIA Diagnosis code: cerebrovascular 
accident/TIA
Inclusion of CVA/TIA
Inclusion of possible medication-
related bleeding according to 
protocol
11 Myocardial ischemia Diagnosis code: myocardial 
ischemia
-
12 Hyperkalaemia Use of polystyrene sulphonate -
K ≥ 5 mmol/L Inclusion of possible medication-
related hyperkalaemia according 
to protocol
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No. Trigger Automatic trigger instrument Modification by research 
assistant according to protocol
13 Acidosis pH < 7.3 Inclusion if bicarbonate  
≤ 22 mmol/L or PCO2≥6 in 
combination with use of opioids 
or benzodiazepines
14 Hypokalaemia K ≤ 2.5 mmol/L Inclusion of possible medication-
related hypokalaemia according 
to protocol
15 Nephrotoxicity Creatinine rise ≥ 50% Inclusion of possible medication-
related nephrotoxicity according 
to protocol
Diagnosis code: nephrotoxicity
16 Hypoxemia pO2 ≤ 8 kPa (60 mm Hg) Inclusion of pCO2 ≥ 6 in 
combination with use of opioids 
or benzodiazepines
Inclusion in case of chest X-ray
Inclusion in case of use of 
diuretic or RAS inhibitor
Inclusion of infusion or blood 
transfusion prior to hypoxaemia
Oxygen saturation ≤ 90%
Diagnosis code: dyspnoea
17 Dehydration Diagnosis code: dehydration Inclusion of use of diuretics prior 
to dehydration
18 Heart failure Diagnosis code: heart failure -
19 Opioid intoxication Use of naloxone
pCO2 ≥ 7 in combination with 
use of opioid
20 Faecal impaction while using 
opioid
Laxative or enema in 
combination with use of opioid
Inclusion of opioid use without 
laxative
21 Hypoglycaemia Glucose ≤ 3 mmol/L Inclusion of use of insulin or 
antidiabetic medication
22 Hyperglycaemia Glucose ≥ 30 mmol/L
23 Infection Positive blood culture during 
admission
-
Diagnosis code: sepsis -
24 Antibiotics level if deviant from 
reference
Gentamicin concentration if 
deviant from reference
-
Amikacin concentration if 
deviant from reference
-
Vancomycin concentration if 
deviant from reference
-
Tobramycin concentration if 
deviant from reference
-
25 Leucopenia while using 
methotrexate or co-trimoxazole
Leucocytes ≤ 3 x 109/L while 
using methotrexate or  
co-trimoxazole
-
26 Benzodiazepine intoxication Use of flumazenil -
27 Lithium intoxication Lithium concentration  
≥ 2 mmol/L
-
28 Digoxin intoxication Digoxin concentration ≥ 2.5 µg/L -
29 Seizure Use of intravenous or rectal 
diazepam 
-
30 Concentration of antiepileptic 
drug deviant from reference
Carbamazepine concentration 
≤2 mg/L or ≥ 12 mg/L
-
Valproic acid concentration  
≤ 20 mg/L or ≥120 mg/L
-
No. Trigger Automatic trigger instrument Modification by research 
assistant according to protocol
31 Allergic reaction/anaphylactic 
shock
Use of clemastine -
32 Delirium Use of haloperidol Inclusion of possible medication-
related delirium according to 
protocol
CCU, cardiac care unit; CVA, cerebral vascular accident; ICU, intensive care unit; MCU, medium care unit; 
TIA, transient ischemic attack
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Abstract
Background
Despite the potential of clinical practice guidelines to improve patient outcomes, 
adherence to guidelines by prescribers is inconsistent. 
Objective
To determine whether an approach of introducing an educational programme for 
prescribers in the hospital combined with audit and feedback by the hospital pharmacist 
reduces non-adherence of prescribing physicians to key pharmacotherapeutic guidelines.
Setting
This prospective intervention study with a before-after design evaluated patients at 
surgical, urological and orthopaedic wards.
Method
An educational program covering pain management, antithrombotics, fluid and 
electrolyte management, prescribing in case of renal insufficiency, application of 
radiographic contrast agents and surgical antibiotic prophylaxis was presented to 
prescribers on the participating wards. Hospital pharmacists performed medication safety 
consultations, combining medication review of patients who are at risk for drug related 
problems with visits to ward physicians.
Main outcome measure
The outcome measure was the proportion of the admissions of patients in which the 
physician did not adhere to one or more of the included guidelines. Difference was 
expressed in odds ratios with 95% confidence intervals. Multivariable logistic regression 
analysis was performed.
Results
1435 Admissions of 1378 patients during the usual care period and 1195 admissions of 
1090 patients during the intervention period were included. 
Non-adherence was observed significantly less often during the intervention period 
(21.8% (193/886)) as compared to the usual care period (30.5% (332/1089)). The adjusted 
odds ratio (OR) was 0.61 (95% CI 0.49-0.76). 
Conclusion
This study shows that education and support of the prescribing physician can reduce 
guideline non-adherence at surgical wards. 
Introduction
Preventable, clinically relevant problems due to complex pharmacotherapy are common 
among hospitalised patients (1-4). Examples are haemorrhage, arterial or venous 
thrombosis, drug intoxication in renal insufficiency, delirium and faecal impaction. Many 
of these problems derive from prescribing errors that lead to potentially preventable 
morbidity, mortality and costs (5). The majority of these are caused by pain medication, 
antithrombotics, antibacterial drugs, cardiovascular drugs, and drugs that are renally 
excreted (1-3, 6-9).
Different strategies, including introduction of computerized physician order entry (CPOE), 
pharmacist involvement on the ward, educational programs and support systems for 
clinical decision making (CDS) have been studied to address this problem and to improve 
clinician prescribing in hospitalized patients (10-12).
Clinical practice guidelines with evidence-based recommendations for physicians 
have been developed to assist doctors and to improve patient outcomes. In routine 
daily practice however, it appears to be difficult to implement key recommendations 
and guidelines seem to have limited impact on physician prescribing behaviour. Most 
clinicians can barely keep pace with the rapid advances in pharmacotherapy. And even 
if doctors are aware of the guidelines and are willing to change, to alter well established 
patterns of prescribing is difficult (13). Earlier research showed that non-compliance to 
several guidelines by prescribers varies between 33 % and 70% (14-16).
Several determinants of practice that prevent or enable guideline adherence, have been 
described. Guideline factors, such as quality of evidence and accessibility of the guideline, 
organizational factors and resources, such as the information system, frequent rotations of 
physicians on the ward and workload, patient factors such as increasingly complex multi-
morbidity and also individual health professional factors, such as knowledge and skills, 
awareness and professional behaviour play a role (17, 18). When these factors are taken 
into account in the development of strategies to improve guideline adherence, the quality 
of the treatment of hospitalised patients improves(19, 20).
Education is one of the possible strategies to tackle several of these determinants for 
non-adherence. Education of prescribers is most effective when it is interactive and 
continuous, includes discussion of evidence and local consensus and when it is followed 
by feedback on performance. This way of professional development needs to be built into 
patient care as much as possible, and should preferably take place in real time with clinical 
decision-support tools and patient-specific reminders to help doctors make the best 
decisions (21).
The P-REVIEW study is a prospective, multicentre, open intervention study, designed to 
investigate if an approach of introducing an educational programme for prescribers in 
the hospital combined with audit and feedback by the hospital pharmacist can lead to 
a clinically relevant benefit for patients at surgical wards(22). The educational program 
teaches the prescriber the pharmacological aspects of using high-risk drugs in high-risk 
patients. The hospital pharmacist suggests interventions based on a medication review of 
the patient. Guidelines are an important part of the educational program and the hospital 
pharmacist actively checks on and improves guideline adherence.
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Aim of the study
The aim of the study was to show whether this approach of education combined 
with structured audit and feedback reduced non-adherence of prescribers to key 
pharmacotherapeutic guidelines.
Ethics approval
The institutional review boards of the Isala Hospital (Zwolle, the Netherlands) and the 
Meander Medical Centre (Amersfoort, the Netherlands) stated that the study was exempt 
from ethical approval. Patients’ data were collected and stored in accordance with 
prevailing privacy regulations.
Methods
Study design and setting
The P-REVIEW study was an open intervention study with a before-after design performed 
in two large general teaching hospitals in the Netherlands (the Isala Hospital (779 beds), 
and the Meander Medical Centre (600 beds)) (22). After a six-month control period (usual 
care) the intervention was introduced during three months. This was followed by a six-
month intervention period. This sub-study on guideline adherence was performed during 
the fifth month of the usual care period and the fifth month of the intervention period.
Study population
Patients who were admitted to the surgical, urological and orthopaedic wards of the two 
hospitals during the study period were included. Guideline non-adherence was measured 
in all these patients.
Patients were followed up until discharge. Patients could be included more than once, in 
case of readmission in the study period. Day care patients were excluded.
Usual care
During the usual care period the normal procedures of medication surveillance and 
communication between hospital pharmacists and physicians were maintained. A CPOE 
and CDS system was applied in both hospitals. 
Hospital pharmacists checked medication of all patients on a daily basis with the aid 
of computer-generated alerts based on a national database (“G-standard” ) (23). They 
could warn the physician by telephone or in case the advice was less urgent send a an 
advice on paper to the ward. In both hospitals, pharmacists were supported by a same 
set of computerised “clinical rules” to screen for specific prescribing errors. These clinical 
rules are based on pharmacotherapeutic guidelines and combine clinical patient data 
(like renal function and electrolyte abnormalities) with medication specific factors: 
dose adjustments in case of renal insufficiency; hypokalemia in patients using diuretic; 
hyperkalemia in patients using potassium-saving diuretics, ACE inhibitor, trimethoprim 
or NSAID; hyponatremia in patients using SSRI, thiazide or carbamazepine; folic acid to be 
added to methotrexate; dosing of oral cytostatics; PPI to be added in case of NSAID(24).
Intervention
During the intervention phase, a combination of an educational program and medication 
counselling for prescribers on the wards took place.
An educational program covering pain management, antithrombotics, fluid and 
electrolyte management, prescribing in the case of renal insufficiency, application of 
radiographic contrast agents and surgical antibiotic prophylaxis was developed. National 
and local hospital guidelines related to these subjects were also included (25-32). 
The program consisted of two parts of approximately two hours each. All prescribers, 
who provided medical care on the participating wards during the intervention period, 
attended the course.
In addition, hospital pharmacists were trained to perform medication safety consultations 
(MSC), combining medication reviews and a visit to audit and give feedback to prescribers 
on the ward by an internist clinical pharmacologist and a hospital pharmacist with specific 
expertise in this area. Medication reviews were performed in high-risk patients, who were 
identified with a computerised screening method. The screening method was based 
on recent literature on prescription errors and targeted patients at risk for potentially 
preventable, drug-related problems. This screening method and a checklist for performing 
medication review on surgical wards is described before by Bos et al. (22). In the weekly 
visits of the hospital pharmacist to the physician on the surgical ward, there was special 
attention for adherence to important pharmacotherapeutic guidelines that were 
addressed in the educational program. Feedback was given based on the medication 
reviews to the prescriber. The attended issues and advices were discussed in a broader 
context and hospital pharmacists clarified the pharmacological background and related 
prevailing hospital guidelines.
Guidelines
In order to be able to score guideline non-adherence ten recommended 
pharmacotherapeutic measures were derived from several guidelines (Table 1).
The guidelines were selected by a group of experts, including hospital pharmacists, 
clinical pharmacologists and hospital-based physicians in a consensus meeting. The 
selected guidelines had to relate to medication that has shown to frequently be involved 
in preventable, clinically relevant, drug-related problems (1-3, 6-8). All guidelines had 
to be part of a local implemented protocol in the hospital and were addressed in the 
educational program. 
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Table 1. Pharmacotherapeutic measures based on prevailing guidelines
 
Pharmacotherapeutic 
measure
Effectuation measurement of guideline non-
adherence
Guideline
1.  Perioperative 
thrombosis prophylaxis
All patients undergoing surgery, with a high 
risk of thrombosis according to the guideline, 
were checked whether preventive therapy for 
DVT and VTE was administered.
Diagnostics, prevention 
and treatment of venous 
thromboembolism and secondary 
prevention of arterial occlusive 
disease (guideline CBO, based on 
ACCP)(25)
2.  Perioperative bridging of 
antithrombotics
All patients undergoing surgery, using 
vitamin K antagonists, were checked whether 
perioperative bridging of antithrombotics 
was indicated and antithrombotics were 
administered according to the guideline. 
Bridging was indicated in case of atrial 
fibrillation and a CHADS2 score > 3, recent 
or recurrent venous thromboembolism, 
thromboembolism due to thrombophilia or 
mechanical valve prosthesis.
Diagnostics, prevention 
and treatment of venous 
thromboembolism and secondary 
prevention of arterial occlusive 
disease (guideline CBO, based on 
ACCP)(25)
3.  PPI added in case of use 
of NSAID
All patients with an ulcer in history and/or an 
age older than 70 years, were checked whether 
a proton pump inhibitor was added.
NSAID use and prevention of 
gastric damage (guideline CBO)
(26)
4.  Laxative added in case 
of use of opioid
All patients treated with an opioid, were 
checked whether a laxative was added. Patients 
with a stoma or with diagnosed diarrhoea were 
excluded.
Pain (guideline NHG) (27), 
Diagnostics and treatment of pain 
(guideline Oncoline) (28)
5.  NSAID contraindicated 
in impaired renal 
function
All patients with an impaired renal function 
(MDRD <30 ml/min/1.73m2), were checked for 
NSAID use.
Dutch national G-standard (23)
SmPC NSAID(29)
6.  Discontinuation of 
diuretics in case of 
radiocontrast 
All patients who received iodinated radio-
contrast and who used diuretics, were checked 
whether the diuretic was discontinued on the 
day of the test.
Precautions for use of iodinated 
radio-contrast (guideline NVR) (30)
7.  Discontinuation of 
NSAID in case of radio-
contrast
All patients who received iodinated radio-
contrast and who used an NSAID, were checked 
whether the NSAID was discontinued on the 
day of the test.
Precautions for use of iodinated 
radio-contrast (guideline NVR)(30)
8.  Discontinuation of 
metformin in case of 
radio-contrast and 
impaired renal function
All patients who received iodinated radio-
contrast and had impaired renal function 
(MDRD <60 ml/min/1.73m2 ) and used 
metformin, were checked whether metformin 
was discontinued on the day of the test.
Precautions for use of iodinated 
radio-contrast (guideline NVR)(30)
9.  Perioperative antibiotics 
prophylaxis
All patients undergoing surgery, with an 
indication for perioperative antibiotics 
prophylaxis, were checked whether preventive 
therapy for infection was administered.
Perioperative antibiotic 
prophylaxis (guideline SWAB)(31)
10.  Perioperative 
endocarditis 
prophylaxis
All patients undergoing surgery, with a high 
risk of endocarditis, were checked whether 
preventive therapy for endocarditis was 
administered. 
Endocarditis prophylaxis 
(guideline by the Netherland 
Heart Foundation) (32)
ACCP, American College of Chest Physicians; CBO, Dutch Institute for Health Care Improvement; DVT, deep 
vein thrombosis; MDRD, modification of diet in renal disease; NHG, Dutch Society of General Practitioners; 
NSAID, non-steroidal anti-inflammatory drug; NVR, Dutch Association of Radiology; PPI, proton pump inhibitor; 
SmPC, Summary of Product Characteristics; SWAB, The Dutch Working Party on Antibiotic Policy; VTE, venous 
thromboembolism
Study endpoints
The primary outcome measure of guideline non-adherence was the proportion of the 
admissions of patients in which the physician did not adhere to one or more of the 
guidelines. The secondary outcome measures were the proportions of admissions of 
patients in which the physician did not adhere to each of ten guidelines.
Data collection
Collected data included patient characteristics, laboratory and medication data, as 
well as transfers to other wards, medical correspondence and medical interventions. 
Data regarding radiology, microbiology, blood transfusion and information about 
medical incidents were also collected. Part of the requisite data could not be collected 
automatically. Therefore, a trained research assistant collected data manually from the 
medical records of the patients using a predefined protocol. These data included whether 
the patient had had surgery, type of surgery and whether the patient had an indication for 
thrombosis prophylaxis, antibiotics prophylaxis or endocarditis prophylaxis.
A validated multisource Microsoft Access database (Microsoft version 2003) was used.
Sample size and data analysis
The PREVIEW-study has been powered on the outcome measure of reduction of clinically 
relevant, potentially preventable drug-related problems. For the power of this sub-study 
on guideline adherence, we studied earlier research on this subject showing that non-
compliance to several guidelines by prescribers varies between 33 % and 70%(14-16). 
Earlier studies that describe interventions that aim to improve guideline adherence 
showed results on improvement of adherence varying form 50-60% to 65-80% (19, 20). To 
detect a reduction from 30 % non-adherence to 20% non-adherence, 313 patients had to 
be included in each group. Because the primary outcome measure of the P-REVIEW study 
(adverse drug events) needed a very large patient cohort to detect a significant difference, 
we assumed that measuring during one month in both periods would generate enough 
power for this sub-study on guideline adherence. 
Baseline characteristics were presented as means and standard deviation or percentages 
for continuous or dichotomous outcomes, respectively. 
Differences between groups were expressed in odds ratios with 95% confidence intervals 
and were tested for statistical significance using independent t-test or chi-square tests, as 
appropriate. P < 0.05 was considered to be statistically significant.
In order to correct for possible confounding, multivariable logistic regression analysis was 
performed. The following possible confounders were initially entered into the model: age, 
gender, department of admission, number of medicines on the first day after admission 
and pharmacotherapeutic group of these medicines, length of stay and renal function. 
Those that showed no clear relation with the outcome (P>0.10) were removed, but only 
in case their removal did not alter the relation under study (OR on non-adherence in usual 
care period vs intervention period) by more than 10%.
Statistical analyses were performed using SPSS Statistics version 22 (IBM Software, New 
York). 
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Results
In the usual care period of the study 1435 admissions (1378 patients) and in the 
intervention period 1195 admissions (1090 patients) were included. 
Table 2 details the characteristics of these patients. There was no difference between the 
two groups in age, gender, department of admission or in the number of medications on 
the first day after admission. Also, there was no difference in use of medication, length of 
hospital stay and the proportion of patients with renal insufficiency. 
Table 2. Characteristics of admitted patients
Usual care period Intervention period p-value
No. of admissions 1435 1195
No. of patients 1378 1090
Mean age of patients in years ± SD 63.8 ± 17.2 63.3 ± 17.1 0.406
Gender of patients, n (%) female 720 (50.2 %) 599 (50.1%) 0.980
Department of admission 0.605
- General surgery, n (%) 852 (59.4%) 682 (57.1%)
- Orthopaedic surgery, n (%) 328 (22.9%) 294 (24.6%)
- Urology, n (%) 255 (17.8%) 219 (18.3%)
Mean no. of medications the first day after 
admission, ± SD
6.9 ± 5.5 7.2 ± 5.8 0.233
Medication the first day after admission, n 
(%)
- Hypoglycemics 178 (12.4%) 156 (13.1%) 0.618
- Vitamin K antagonists 149 (10.4%) 117 (9.8%) 0.616
- Heparin/LMWH 951 (66.3%) 773 (64.7%) 0.394
- Thrombocyte aggregation inhibitors 284 (19.8%) 238 (19.9%) 0.936
- Diuretics 337 (23.5%) 287 (24.0%) 0.749
- Beta blockers 391 (27.2%) 305 (25.5%) 0.318
- Calcium channel blockers 146 (10.2%) 142 (11.9%) 0.162
- RAS inhibitors 375 (26.1%) 317 (26.5%) 0.819
- NSAIDs 485 (33.8%) 424 (35.5%) 0.366
- Opioids 601 (41.9%) 491 (41.1%) 0.681
- Antipsychotics 90 (6.3%) 79 (6.6%) 0.724
Mean length of stay, days ± SD
- General surgery 7.7 ± 9.7 7.0 ± 8.3 0.154
- Orthopaedic surgery 7.6 ± 8.6 6.7 ± 6.5 0.107
- Urology 4.3 ± 4.8 4.4 ± 4.1 0.798
MDRD eGFR of patients (ml/min/1,73 m2), 
n (%)
(n = 1016*) (n = 836*) 0.476
- <10 4 (0.4%) 1 (0.1%)
- 10-30 43 (4.2%) 39 (4.7%)
- 30-60 227 (22.3%) 203 (24.3%)
- >60 742 (73.0%) 593 (70.9%)
LMWH = Low molecular weight heparin; RAS = Renin angiotensin system; NSAIDs = Non-steroidal anti-
inflammatory drugs
Table 3 shows the proportions of admissions of patients in which the physician did 
not adhere to the guidelines in the usual care period and in the intervention period, 
respectively. In 1089 admissions of 1069 patients in the usual care period and in 886 
admissions of 864 patients in the intervention period, one or more included guidelines 
were applicable.
Table 3. Non-adherence of prescribers to pharmacotherapeutic measures based on prevailing guidelines
Usual care period
(n = 1435)
Intervention period
(n = 1195)
Odds ratios and 
confidence intervals
Non-adherence Non-adherence OR 95% CI
1.  Perioperative thrombosis 
prophylaxis if indicated?
22/590 (3.7%) 10/490 (2.0%) 0.54 0.25-1.15
2.  Perioperative bridging of 
antithrombotics if indicated?
2/48 (4.2%) 2/46 (4.3%) 1.05 0.14-7.75
3.  In case of NSAID use, ppi added 
if indicated?
5/101 (5.0%) 3/83 (3.6%) 0.72 0.17-3.11
4.  In case of opioid use, laxative 
added if indicated?
154/296 (52%) 62/190 (32.6%) 0.45b 0.31-0.65
5.  In case of impaired renal 
function (MDRD <30),  
no use of NSAID?
8/50 (16.0%) 4/40 (10.0%) 0.54 0.15-1.94
6.  In case of radiocontrast, 
diuretics discontinued?
16/23 (69.6%) 20/29 (69.0%) 0.97 0.30-3.18
7.  In case of radiocontrast,  
NSAID discontinued?
17/25 (68.0%) 15/20 (75.0%) 1.41 0.38-5.26
8.  In case of radiocontrast 
and MDRD < 60, metformin 
discontinued?
2/3 (66.7%) 2/2 (100.0%) 0.33 0.01-12.79
9.  Perioperative antibiotics 
prophylaxis, if indicated?
136/832 (16.3%) 93/661 (14.1%) 0.84 0.63-1.12
10.  Perioperative endocarditis 
prophylaxis, if indicated?
6/8 (75%) 0/3 (0%) 0.05 0.00-1.50
Overall non-adherence 332/1089 (30.5%) 193/886 (21.8%) 0.64b 0.52-0.78
0.61a,b 0.49-0.76
a OR, adjusted for confounders, b statistical significant
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Figure 1. shows a forest plot in which the odds ratios for non-adherence are presented.
Figure 1. Forest plot of non-adherence of prescribers to pharmacotherapeutic measures based on 
prevailing guidelines
A significantly lower proportion of admissions of patients in which the physician did not 
adhere to the prevailing guidelines occurred in the intervention period (21.8% (193/886) 
compared to the usual care period (30.5% (332/1089)) (p<0.05). The odds ratio (OR) was 
0.64 (95% CI 0.52-0.78).
After correction for possible confounders, the adjusted OR was 0.61 (95% CI 0.49-0.76).
When the analysis was conducted with protocol non-adherence as denominator 
(total number of times that a guideline had to be followed by a prescriber) instead of 
admissions, results were comparable. (13.5 % (211/1564) in the intervention period 
compared to 18.6% (368/1976) in the usual care period (p=<0.05)). The odds ratio (OR) 
was 0.68 (95% CI 0.57-0.82). 
Discussion
Our study shows that education and support of the prescribing physician with respect 
to high-risk patients in surgical departments can lead to reduced pharmacotherapeutic 
guideline non-adherence among prescribing physicians. Achieved effects were obtained 
on top of the effect of other measures as CPOE/CDS system and clinical rules, which were 
part of usual care. 
Earlier studies describe interventions that aim to improve guideline adherence in the 
hospital. Hogli et al. describe an intervention study, reporting distribution of a recently 
published pocket version of the national guideline. This led to a substantial increase 
in prescribing of appropriate empirical antibiotics from 61.7 to 83.8%(20). Schouten et 
al. implemented a multifaceted guideline-implementation strategy, considering the 
barriers of implementation of guidelines. They found an increase of the rate of guideline 
adherence of antibiotic prescription from 50.3% to 64.3% (19). 
In the two hospitals that participated in this study, the guidelines targeted in our study 
had already been implemented. Nevertheless, we found that in nearly one third of cases 
physicians were non-adherent to the local hospital guidelines. This is in line with earlier 
research on this subject. Van den Bemt et al. found that the proportion of admissions not 
compliant with guidelines on gastric protection in case of use of NSAID in hospitalized 
surgical patients was 46.6% (16). Drenth et al. found an adherence of 53.9% with a dosing 
guideline in patients with impaired renal function at hospital discharge(15). Schilp et al. 
studied adherence to the guideline concerning identification and hydration of high-risk 
patients for contrast-induced nephropathy in different hospitals and found that only 
two third of the high-risk patients were hydrated before contrast administration (33). 
Huijts et al. reported proportions of patients receiving guideline-adherent antibiotics for 
community acquired pneumonia from 30.5% to 62.9% (34).
Educating prescribers is a measure that can be taken on top of other measures to improve 
guideline adherence. Educating prescribers is only effective if it is a part of a multifaceted 
intervention (35). Novel of the P-REVIEW education program is the combination with a 
weekly visit by the hospital pharmacist, who audited and improved guideline adherence. 
We aimed to boost the effect of the education program by the weekly visits of the 
hospital pharmacist. We previously showed that these weekly visits were feasible and also 
efficient. We hypothesized that the support by education of the prescriber by the hospital 
pharmacist in a more pro-active role is more efficient and effective than the traditional 
retrospective role of the hospital pharmacist in medication surveillance (22). In this study 
we show that this intervention can lead to a significant decrease in non-adherence of 
guidelines, although there may be still room for improvement.
The study has several strengths. 
The study was performed in two representative general teaching hospitals. The 
intervention was easily implemented, since both education and weekly visits were 
performed by health care providers already active in the hospital and the intervention did 
not lead to additional costs. 
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The intervention combines different strategies. These strategies address different factors 
that have been described to impair quality of care and can influence guideline adherence 
(17).
By educating the prescriber in the hospital and teaching the prescriber during medication 
safety consultation, the knowledge and skills needed to adhere to guidelines will improve. 
Also the attitude towards guidelines in general and motivation to adhere may improve. 
This study however, didn’t collect qualitative data from the prescribers to support this 
hypothesis, and this would be useful to integrate in future research. 
These weekly visits of the hospital pharmacist can be considered as a continuous 
form of workplace-based education. This addresses the problem that a short-term 
education programme has been found to have only a transient effect on the frequency of 
prescribing errors(36).
There are some limitations as well. We selected ten relevant pharmacotherapeutic 
measures derived from several guidelines. This selection was not complete, and our 
results may not be generalisable to other or all guidelines. Also, the study was performed 
in two hospitals, which might limit the external validity of the study.
This study was not a randomised controlled study, but was performed in a before after 
design, introducing the possibility of confounding. Therefore, to adjust for confounding, 
we performed a multivariable logistic regression analysis. Yet, we may not have identified 
all potential confounders.
We defined the outcome measure as the proportion of the admissions of patients in 
which the physician did not adhere to one or more of the guidelines. We assumed that 
in every single admission a physician has to follow all guidelines. When a patient is 
readmitted, the treating physician is often different and guidelines can be different from 
an early admission of the patient. On the other hand adherence on guidelines in an early 
admission can lead to (not intended) adherence in a readmission.
For each guideline we only included these cases in which there was no possible discussion 
on adherence (table 1). By specifying the cases, we minimized the possibility of intended 
non-adherence by the physician.
The P-REVIEW study describes 106 admissions with one or more clinically relevant, 
potentially preventable, drug-related events in the usual care period and 73 in the 
intervention period (22). These drug-related events are divided into different types of 
events, such as haemorrhage, thrombosis, renal failure related events, central nervous 
systems events, faecal impaction, hypoventilation and a group of unclassifiable 
events(22). We noted that 25 of the 106 events in the usual care period and 15 of the 73 
events in the intervention period relate to the studied guidelines and could possibly have 
been prevented in case of better guideline adherence. That means that only a modest part 
of the positive effect on these events can be related to an improvement in adherence of 
the studied guidelines.
This suggests that improving guideline adherence will have only limited effect and it may 
not be necessary to pursue 100% adherence. It may be better not to focus on guideline 
adherence or implementation of clinical rules alone, but on a comprehensive medication 
review of high risk patients, in which a check on adherence of guidelines and clinical rules 
is integrated.
Given the limited resources in healthcare, we think this could be an important question 
for future research. 
Conclusions
In summary, this study shows that education and support of the prescribing physician 
with respect to high-risk patients in surgical departments leads to an improvement of 
guideline adherence among prescribing physicians. 
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Abstract
Background
Risk stratification of hospital patients for adverse drug events (ADE) would enable 
targeting patients who may benefit from interventions aimed at reducing drug-related 
morbidity. It would support clinicians and hospital pharmacists in selecting patients 
to deliver a more efficient health care service. This study aimed to develop and test a 
prediction model that helps to identify patients on the day of hospital admission who 
are at increased risk of developing a clinically relevant, preventable adverse drug event 
during their stay on a surgical ward.
Methods
Data of the pre-intervention measurement period of the P-REVIEW study were used. 
This study was designed to assess the impact of a multifaceted educational intervention 
on clinically relevant, preventable adverse drug events in surgical patients. Thirty-nine 
variables were evaluated in a univariate and multivariate logistic regression analysis, 
respectively. Model performance was expressed in the Area Under the Receiver Operating 
Characteristics (AUROC). Bootstrapping was used for model validation. 
Results 
6780 admissions of patients at surgical wards were included during the pre-intervention 
period of the PREVIEW trial. 102 Patients experienced a clinically relevant, adverse drug 
event during their hospital stay that was deemed potentially preventable. The prediction 
model comprised five variables, each ascertained at the time of hospital admission: age, 
number of biochemical tests ordered, heparin/LMWH in therapeutic dose, use of opioids 
and use of cardiovascular drugs. The AUROC was 0.86 (95% CI 0.83-0.88). At a cut-off 
point for an increased risk of developing an ADE of 1.6%, the model had a sensitivity of 
80.4% and a specificity of 73.4%. The positive and negative predictive value were 4.5% 
and 99.6%, respectively. The bootstrap procedure did not significantly affect model 
parameters. 
Conclusion
The combined use of a limited set of easily ascertainable patient characteristics can help 
physicians and pharmacists to identify, at the time of admission, surgical patients who are 
at increased risk of developing ADEs during their hospital stay. This may serve as a basis to 
take extra precautions to safeguard medication safety in those patients. 
Introduction
Pharmacotherapy is one of the most commonly applied interventions in hospital 
healthcare. In addition to the beneficial effects, prescribing of medication also introduces 
risks of medication errors and adverse drug events, that lead to potentially preventable 
morbidity, mortality and costs(1-3). Especially patients on surgical wards are at risk, due 
to need for pain medication and antibiotics, frequent adjustments of antithrombotic 
regimens and blood and fluid loss. In the case of elderly surgical patients, multiple co-
morbidities requiring multiple drugs add even more to potential drug-related problems 
(4).
Risk prediction is a routine component in daily care practice in both specific areas (e.g. 
approaches used to determine stroke risk in patients with atrial fibrillation) as well as more 
generally, for example to identify patients at risk of hospital admission. Risk stratification 
of hospital patients for adverse drug events (ADE) can target a population that can benefit 
from interventions aimed to reduce drug-related morbidity, as a form of personalized 
medicine. It can support clinicians and hospital pharmacists in patient prioritization to 
deliver a more efficient health care service (5). Yourman et al. emphasized in a systematic 
review that failure to consider risk prediction in a clinical setting can result in poor patient 
outcome (6).
A recent review identified four studies that developed and validated ADE risk-prediction 
tools for use in adults over 65 years of age (4, 5, 7-9). These prediction models had poor 
to modest performance and did not address clinical impact, thereby limiting clinical 
usefulness. Because a large number of variables contribute to ADE occurrence in patients, 
it is impossible to precisely predict every ADE in every patient. Therefore, Stevenson et al. 
suggested that these risk prediction strategies should focus either on one specific harmful 
ADE (e.g. gastrointestinal or intracranial bleeding) or ADEs in patients with a particular 
illness or clinical characteristic, for instance surgical patients (5). In addition, since the aim 
is to prevent patient harm, it seems more rational to predict clinically relevant, potentially 
preventable adverse events, instead of adverse reactions in general.
The P-REVIEW study (Pharmacist-led Risk patients medication EValuation to Initiate 
Event reduction on surgical Wards) was designed to determine whether a multifaceted 
intervention of educating the prescriber combined with medication review and 
pharmaceutical visits to the ward by the hospital pharmacist could lead to a reduction of 
drug-related complications among surgical patients (10). In this study, experts assessed 
clinically relevant, potentially preventable ADE (leading to death, temporary or sustained 
disability, increased length of hospital stay or readmission within 30 days) in a cohort of 
13,264 admissions of surgical patients . The study showed a significant benefit for patients 
in the intervention period. To improve the cost effectiveness of medication review and 
other measures to prevent avoidable harm, it would be useful to identify the patients at 
risk of clinically relevant ADEs at the surgical ward. For this purpose, we used the P-REVIEW 
data to develop a risk-prediction model that could identify patients at risk of a clinically 
relevant, potentially preventable adverse drug event during admission at the surgical 
ward, on the day of hospital admission.
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Methods
Study setting and population
The P-REVIEW study is a prospective open intervention study designed to investigate 
whether a multifaceted educational intervention could lead to a reduction of clinically 
relevant, potentially preventable adverse drug events among patients at surgical wards. 
The study was performed in two large general teaching hospitals in the Netherlands and 
has been described in detail elsewhere (10). Patients who were admitted to the surgical, 
urological or orthopaedic ward of one of the two hospitals during a period of six months 
were included. In case of readmission , patients could be included more than once. Day 
care patients were excluded. For the development of the prediction model, data were 
used from patients during the pre-intervention period.
P-REVIEW data set and clinically relevant potentially preventable adverse drug events
Data available in the P-REVIEW dataset were collected for each admission, including 
patient characteristics, drug history and biochemical, haematological and microbiological 
markers. The major part of the data collection was performed automatically from the 
CPOE system (computerized physician order entry). In addition, some of the data were 
collected manually by a review of the medical records. 
Data from the day of admission of each patient was extracted. If more (laboratory) values 
were available of the same variable, the last one, being the most recent value available, 
was extracted.
Assessment of clinically relevant, potentially preventable adverse drug events that led to 
death, temporary or permanent disability, increased length of hospital stay or readmission 
within 30 days was performed in the P-REVIEW study by teams of experts consisting of a 
hospital pharmacist and a hospital-based physician, not related to the study hospitals(10). 
Predicting variables
From the data that were collected in the P-REVIEW study, candidate model parameters 
were selected on the basis of reports in the literature of their association with ADEs 
(1-4, 11-18). Thirty-nine risk factors were identified, including patient characteristics 
(age, gender), department of admission (general surgery versus orthopaedic surgery 
and urology), type of admission (emergency versus elective)); medication (number of 
medications, use of gastrointestinal drugs, hypoglycemic drugs, vitamin K antagonists, 
heparin or low molecular weight heparin (LMWH) in therapeutic dose, thrombocyte 
aggregation inhibitors, cardiovascular drugs in general, cardiac drugs, diuretics, 
betablockers, renin angiotensin system (RAS) inhibitors, antilipaemica, corticosteroids, 
antimicrobials, chemotherapy, non-steroidal anti-inflammatory drugs (NSAIDs), 
opioids, antiepileptics, central nervous system (CNS) agents in general, antipsychotics, 
anxiolytics, antidepressants and serious drug-drug interactions); laboratory test results 
(albumin, glucose, hemoglobin, international normalized ratio (INR), potassium, sodium, 
leucocytes, chronic kidney disease epidemiology (CKD-EPI), oxygen saturation, positive 
microbiological blood culture, number of biochemical tests ordered (<20 versus ≥20)) 
(1-4, 11-18). Drugs were coded according to the Anatomical Therapeutic and Chemical 
codes (19). The glomerular filtration rate was computed by the Chronic Kidney Disease 
Epidemiology Collaboration formula (CKD-EPI)(20). Missing data where imputed using the 
‘multiple imputation’ procedure from SPSS version 22. SPSS uses a Markov Chain Monte 
Carlo (MCMC) algorithm known as Fully Conditional Specification (FCS). This method 
can be used when the pattern of missing data is arbitrary. For each iteration and for each 
variable in the order specified in the variable list, the FCS method fits a univariate (single 
dependent variable) model using all other available variables in the model as predictors. 
Linear regression was used to predict a scale variable and logistic regression to predict 
categorical variables. Variables of which more than 60% of data were missing were left out 
of the analysis.
Model development
Model development consisted of two stages (21). In the first stage, possible predictors 
were tested using a univariate binary logistic regression model. Variables that were found 
to be statistically significant (P<0.05) were taken forward to the next stage of multivariate 
analysis. 
In case of (laboratory) variables that in clinical practice can be either too high or too 
low and confer a risk in both situations, categorization of variables was performed (for 
instance, low potassium values < 3.5 mmol/l, normal values between 3.5 and 5.0 mmol/l 
and high values > 5.0 mmol/l). 
In the second stage, backward and forward elimination procedures were used in 
multivariate logistic regression analysis in order to detect the best predictors. The removal 
criterion was set at p=0.10. 
Results from the univariate and multivariate logistic regression models were expressed in 
terms of the odds ratio with 95% confidence intervals and p-values. 
Standardized odd ratios were computed to allow for comparison of the strength of the 
association between the various continuous variables and the probability of an ADE. 
Standardization was achieved through Z-transformation.
Model performance
Model performance of the logistic regression model was expressed in the Area Under the 
Curve (AUC) as computed by a Receiver Operating Characteristics curve analysis (ROC 
analysis) using the probability as predicted by the regression model and the real outcome 
(ADE). 
Model validation
Bootstrapping was used to assess the internal validity of the model. Two hundred 
bootstrap samples were drawn to assess the reliability of the model expressed in over-
optimism and the uniform shrinkage factor. 
Statistical analyses were performed using SPSS Statistics version 22 (IBM Software, New 
York). Bootstrapping was performed in SAS version 9.4.
Ethics
For all stages of this research, patient records were anonymized prior to analysis in 
accordance with prevailing privacy regulations.
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Results
The pre-intervention period of the P-REVIEW dataset study population comprised 6780 
admissions of 5940 patients at surgical wards. A clinically relevant, potentially preventable 
adverse drug event during hospital stay, that had led to death, temporary or permanent 
disability, increased length of hospital stay or readmission within 30 days was determined 
in 102 patients. The most frequent types of events were haemorrhage, arterial or venous 
thrombosis, renal insufficiency, dehydration or electrolyte related events, central nervous 
system events and faecal impaction. Characteristics of patients who did, and who did not 
experience an ADE during hospital stay are shown in Table 1.
Table 1. Patient characteristics 
Admissions with a clinically 
relevant ADE
(n=102)
Admissions without a clinically 
relevant ADE
(n= 6678)
Mean age of patients in years ± SD 78.7 ± 8.7 63.1 ± 17.6
Gender of patients, n (%) female 50(49.0%) 3331 (49.9%)
Department of admission, n (%)
- General surgery
- Urology
- Orthopedic surgery
67 (65.7%)
4 (3.9%)
31 (30.4%)
3824 (57.3%)
1244 (18.6%)
1610 (24.1%)
Admission, n (%) elective 39 (38.2%) 4194 (62.8%)
No. of medications (mean ± SD) 11.1 ± 4.8 6.6 ± 5.5
Univariate analysis
The candidate predictive variables of a clinically relevant ADE during hospital stay and 
results of the univariate analysis are reported in Table 2. 
Table 2. Candidate predictive variables
Univariate analysis Standardized
OR
Predictive variables
(references)
N missing (%) OR CI P-value
Patient characteristics
Age (years) 0 (0) 1.09 1.07- 1.09 <0.0001 4.33 
(3.11 – 6.03)
Gender (m/f ) 0 (0) 0.97 0.65 - 1.43 0.862
Department of admission
General Surgery vs Urology
Orthopedic S vs Urology
204 (3.1)
4.95
5.89
1.79-13.65
2.07-16.28
0.004
0.002
0.001
Admission (emergency vs 
elective)
235 (3.5) 2.91 1.94-4.37 <0.0001
Medication use  
(ATC-code)
No. of medications 0 (0) 1.13 1.10 - 1.16 <0.0001 1.94 
(1.65 – 2.29)
Serious drug-drug 
interactions
0 (0) 3.99 2.20-7.24 <0.0001
Gastrointestinal drugs 
(A02)
0 (0) 1.60 1.08-2.37 0.019
Hypoglycemics (A10) 0 (0) 3.17 2.04-4.93 <0.0001
Vitamin K antagonists 
(B01AA)
0 (0) 2.03 1.04-3.90 0.038
Heparin/LMWH in 
therapeutic dose (B01AB)
0 (0) 4.23 2.37-7.55 <0.0001
Thrombocyte aggregation 
inhibitors (B01AC)
0 (0) 3.21 2.14-4.82 <0.0001
Cardiovascular drugs (C) 0 (0) 9.31 5.29-16.38 <0.0001
Cardiac drugs (C01) 0 (0) 3.55 2.23-5.65 <0.0001
Diuretics (C03) 0 (0) 3.70 2.50-5.49 <0.0001
Betablockers (C07) 0 (0) 3.35 2.26-4.76 <0.0001
RAS inhibitors (C09) 0 (0) 3.15 2.12-4.66 <0.0001
Antilipaemicae (C10) 0 (0) 2.36 1.58-3.55 <0.0001
Corticosteroids (H02) 0 (0) 2.01 0.92-4.38 0.078
Antimicrobials (J01,J02) 0 (0) 1.73 1.17-2.56 0.006
Chemotherapy (L01) 0 (0) NA
NSAIDs (M01A) 0 (0) 0.71 0.45-1.13 0.149
Opioids (N02A) 0 (0) 4.39 2.90-6.65 <0.0001
Antiepileptics (N03) 0 (0) 1.59 0.69-3.67 0.273
CNS agents (N05/N06) 0 (0) 4.91 2.70-8.94 <0.0001
Antipsychotics (N05A) 0 (0) 1.65 1.10-2.48 0.015
Anxiolytics (N05B) 0 (0) 1.59 0.84-2.99 0.153
Antidepressants (N06A) 0 (0) 1.71 0.93-3.14 0.086
Laboratory data
Albumin (g/L) 5839 (86.1) 0.96 0.92 – 1.00 0.055 0.74
(0.54 – 1.01)
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Univariate analysis Standardized
OR
Predictive variables
(references)
N missing (%) OR CI P-value
Glucose (mmol/L) 5097 (75.2) 1.14 1.04 – 1.24 0.004 1.40
(1.11 – 1.77)
Hemoglobin (mmol/L)
(low vs normal and high)a
3901 (57.5) 2.83 1.48 - 5.43 0.002
INR (ratio) 5775 (85.2) 1.07 0.84 – 1.36 0.582 1.08
(0.83 – 1.39)
Potassium (mmol/L)
(low vs. normal/
high vs. normal)a
3085 (45.5)
0.95
1.74
0.43 - 2.07
0.54 - 5.65
0.640
0.888
0.355
Sodium (mmol/L)
(low vs. normal/
high vs. normal)a
3184 (47.0)
2.06
1.11
1.17 – 3.65
0.15 – 8.21
0.046
0.013
0.916
Leucocytes (109/L) 3784 (55.8) 0.98 0.92 – 1.04 0.475 0.91
(0.69 – 1.19)
CKD-EPI (ml/min/1.73 
m2) (severely impaired vs. 
normal/
moderately impaired vs. 
normal))a
3062 (45.1)
2.70
2.25
1.26 - 5.80
1.40 - 3.64
0.001
0.010
0.001
Oxygen saturation (%) 6322 (93.2) NA
Positive microbiological 
blood culture
0 (0) NA
Number of biochemical 
tests (≥20 versus <20)
0 (0) 3.63 2.45 – 5.37 <0.0001 1.36
(1.24 – 1.48)
Abbreviations: OR, Odds Ratio; CI, confidence interval; GS, general surgery; OS, orthopedic surgery; U, urology; 
LMWH, low molecular weight heparin; CNS, central nervous system; INR, international normalized ratio; NA, not 
applicable/computable; 
Values for normal ranges were defined as follows: hemoglobin normal values: male 8,5 - 11,0 mmol/l, female 
7,5 - 10,0 mmol/l; potassium normal values: 3.5-5.0 mmol/l; sodium normal values: 135-145 mmol/l; CKD-EPI: 
normal values >60, moderately impaired renal failure 30-60, severely impaired renal failure <30 ml/min/1.73 m2. 
Multivariate analysis
The significant variables (p<0.05) were identified from the univariate analysis and taken 
forward to the next stage. 
In all 20 imputed datasets, both backward and forward elimination procedure in 
multivariate analysis identified the same 5 variables that were significantly associated 
with the risk of developing a clinically relevant adverse drug event. It appeared that these 
5 predictor variables did not have missing values. Therefore, the final analysis could be 
performed with the original, complete dataset.
The coefficients (ß), standard errors (SE) and odds ratios (OR) with 95% confidence 
intervals of the variables are shown in Table 3. The final model comprised age, number of 
biochemical tests ordered, heparin/LMWH in therapeutic dose, use of opioids and use of 
cardiovascular drugs at the time of hospital admission.
Table 3. Coefficients, standard errors and Odds Ratios (OR) with 95% confidence intervals (CI) of the five 
variables of the final model. Also presented the OR as found after applying the shrinkage factor.
Logistic regression
ß SE OR (95% CI) OR after 
applying the 
shrinkage factor
Age 0.060 .10 1.062  
(1.039-1.083)
1.059
Number of biochemical tests. 
 (≥20 tests versus <20 tests)
0.770 .208 2.159  
(1.181-2.841)
2.094
Heparin/LMWH in therapeutic dose 
(Y/N)
0.604 .307 1.830  
(1.786-3.819)
1.786
Cardiovascular drugs
(Y/N)
1.261 .220 3.529  
(1.786-5.902)
3.355
Opioids (Y/N) 0.785 .300 2.192  
(1.272-3.278)
2.125
Abbreviations: ß, coefficient; CI, confidence interval; LMWH, low molecular weight heparin; OR,Odds Ratio; 
SE, standard error; 
The AUC of the model was 0.858 (95% CI 0.831-0.884). The ROC curve is shown in Figure 1. 
The validation of the model using bootstrap samples showed an over-optimism of 0.008 
and a shrinkage factor of 0.960, leading to a corrected performance of the model of 0.85 
(Table 3). 
Figure 1. The ROC curve of the model
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When the cut-off point for a high risk of developing an ADE was set at 1.6%, the model 
showed a sensitivity of 80.4% and a specificity of 73.4%. At this cut-off level, positive and 
negative predictive value were 4.5% and 99.6%, respectively. 
The formula of the logistic regression model that allows for calculating the individual risk 
of a clinically relevant adverse drug event to a surgical patient is shown below.
Formula individual risk = 1/(1 + exp(-1*LP))
Where LP is the so called Linear Predictor which for our model is defined as:
Linear Predictor =  10.082 + 
0.060 * age (in years) + 
0.770 (in case number of biochemical tests ordered ≥ 20) + 
0.604 (in case the patient uses heparin/LMWH in therapeutic dose)+ 
1.261 (in case the patient uses cardiovascular drugs) + 
0.785 (in case the patient uses opioids) 
Discussion
The risk prediction model resulting from this study helps to identify surgical patients that 
are at increased risk of sustaining a clinically relevant potentially preventable adverse drug 
event. This model uses five clinical variables that can be obtained routinely on hospital 
admission, and that can be incorporated into clinical practice as a tool to target patients 
that can benefit from interventions aimed at reducing potentially preventable clinically 
relevant drug related problems during hospital stay at surgical wards. 
The model was developed using data from the pre-intervention phase of the P-REVIEW 
study, that assessed clinically relevant, potentially preventable ADE among patients at 
surgical wards (10). This is the first study that developed a risk prediction model focusing 
on clinically relevant potentially preventable ADE instead of adverse drug reactions 
in general. This study only targeted surgical patients, which leads to a better model 
performance. We only included variables that are available on the first day after hospital 
admission to be able to operationalize a model to predict risk during hospital stay, 
immediately after hospital admission. Therefore, variables such as length of hospital stay, 
interdisciplinary consultation or admission to the intensive care during hospital stay, were 
not included in our analysis. 
Our final model contains five variables; age of the patient, number of biochemical tests 
ordered, treatment with heparin/LMWH in therapeutic dose, treatment with opioids 
and treatment with cardiovascular drugs. Our model shows acceptable goodness of fit 
and discrimination performance. We can use the model not only to label patients at risk 
to experience a drug-related event but also to label patients that are very unlikely to 
experience an event. The negative predictive value of our model is very high. Therefore, 
one could use this model also to identify patients for whom automated computerized 
clinical decision support without surveillance by the hospital pharmacist is sufficient.
An overview of studies of development and validation of risk prediction models for ADR 
or ADE is shown in Table 4. Other studies showed different predicting variables and found 
an area under the receiver operator characteristic curve (AUROC), varying between 0.70-
0.74, with relatively low sensitivity and specificity scores. We hypothesized that focusing 
on patient cohorts with restricted clinical characteristics (surgical patients) and focusing 
on clinically relevant, potentially preventable adverse drug events, instead of adverse 
drug reactions in general would lead to a better performing prediction model.
In our study, the strongest independent risk factor was the age of the patients. Well 
known from many other studies, advancing age is associated with an increased number of 
comorbidities in association with polypharmacy resulting in an increased risk of ADEs (2, 
3, 13).
This is the first study that explores the number of biochemical tests ordered as a predictive 
factor for drug related events. We hypothesized that besides the use of specific laboratory 
values as electronic triggers, the number of biochemical tests might also be useful to 
identify a risk of ADE during hospital admission. Before diagnosing the patient’s condition, 
the physician may have an uneasy feeling which makes him concerned about a possible 
adverse outcome. This suspicion alerts the physician and leads to increased laboratory 
orders to clarify the patient’s condition and to prevent serious problems. Moreover, 
deviant laboratory values will lead to further monitoring (22). Consequently, the number 
of biochemical tests might be a useful electronic trigger to identify a patient at risk for 
ADE (16, 23). In our study this factor has shown to be a strong predictor for drug related 
problems at surgical wards. 
Surgery in patients who use anticoagulation therapy, is a challenge. Guidelines on 
perioperative management of anticoagulation are complicated and people are at risk of 
either bleeding or thrombosis because of the surgical procedures. For patients with a high 
risk of thromboembolism, measured with a CHA2DS2-VASC score, needing certain surgical 
procedures, it is necessary to perform bridging with LMWH at therapeutic dose during 
the perioperative period. If this procedure is not correctly performed, these patients are 
at high risk of serious ADEs. Pardo Carbello et al. already described that the most frequent 
cause of fatal ADE is haemorrhage (24).
We found that use of cardiovascular drugs and use of opioids are important risk factors 
in surgical patients. Cardiovascular drugs are generally used by a vulnerable older 
population with multiple co-morbidities. Use of opioids often points out (temporary) 
severe morbidity. It is already known from literature that patients that use these drugs 
have an increased risk of experiencing ADEs (15, 25).
This study has several strengths. The P-REVIEW database contains information on clinically 
relevant potentially preventable drug related events (leading to death, temporary or 
permanent disability, increases hospital stay or readmission) in a very large cohort. Aiming 
at prevention of patient harm, it seems more rational to focus on clinically relevant, 
potentially preventable adverse events, instead of adverse reactions in general. We 
focused on patients on surgical wards. By studying patient cohorts with restricted clinical 
characteristics the performance of risk prediction models will improve. Furthermore, we 
used variables that can be obtained routinely on hospital admission, so implementation 
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. can easily be operationalized. 
There are some limitations to our study. In our analysis, we used potentially predictive 
variables that were available in the P-REVIEW database. Mostly, these data were 
automatically obtained from hospital databases (10). The lack of automated coded 
information for some variables limited the use of these variables, e.g. information on co-
morbidities using the International Classification of Diseases (ICD-10), frailty or cognitive 
impairment, reason for hospital admission or type of performed surgery. We internally 
validated our model by bootstrapping but we have not yet been able to externally 
validate this model in clinical practice.
The development of our risk prediction model has potentially important implications for 
clinical practice and research. By using this model, lower-risk patients could be managed 
less extensively (for instance, only automatically using CPOE/CDSS), whereas higher risk 
patients could receive more intensive interventions, such as medication review, aimed at 
reducing drug-related adverse outcomes. Such selective use of ancillary precautions could 
also help to improve the cost-effectiveness of medication safety interventions. In that 
way, this risk model, that combines clinical and medication-related variables can guide 
clinical intervention, delivered as part of an integrated system built around the principles 
of medication safety (5).
Our risk model can be incorporated into a CPOE system and thereby generate automatic 
risk-evaluation based on patients’ medical records upon hospital admission. Above a pre-
specified cut off point, the score can assist hospital pharmacists or prescribing physicians 
in their decisions to review the patient’s medication or to perform other relevant 
interventions. Under the cut-off point (not necessarily the same cut off point), it may be 
possible for the hospital pharmacist to downgrade interventions and rely on automatic 
medication safety system.
Conclusions
A risk prediction model was developed to identify surgical patients at risk of experiencing 
a clinically relevant, potentially preventable adverse drug event during hospital 
admission. The resulting model contains five variables; age of the patient, number of 
biochemical tests ordered, treatment with heparin/LMWH in therapeutic dose, treatment 
with opioids and treatment with cardiovascular drugs. This model can be used to guide 
the hospital pharmacist and the physician to effectively and efficiently implement clinical 
interventions to improve medication safety.
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Abstract
Aim
This study determined the effect of substitution of inpatient care from medical doctors 
(MDs) to physician assistants (PAs) on non-adherence to guidelines on medication 
prescribing.
Methods
A multicenter matched-controlled study was performed comparing wards on which 
PAs provide medical care in collaboration with MDs (PA/MD model), with wards on 
which only MDs provide medical care (MD model). A set of 17 quality indicators to 
measure non-adherence to guidelines on medication prescribing by PAs and MDs was 
composed by 14 experts in a modified Delphi procedure. The indicators covered different 
pharmacotherapeutic subjects, such as gastric protection in case of use of NSAID or 
prevention of obstipation in case of use of opioids. These indicators were expressed in 
proportions by dividing the number of patients in which the prescriber did not adhere 
to a guideline, by all patients that were applicable. Multivariable regression analysis was 
performed in order to adjust for potential confounders.
Results
1021 patients from 17 hospital wards in the ‘PA/MD model’ group and 1286 patients 
from 17 hospital wards in the ‘MD model’ group were included. Two of the 17 quality 
indicators showed significantly less non-adherence to guidelines for the PA/MD model; 
the indicators concerning prescribing gastric protection in case of use of NSAID in 
combination with corticosteroids (OR 0.42, 95% CI 0.19-0.90) and in case of use of NSAID 
in patients older than 70 years (OR 0.47, 95% 0.23-0.95). For none of the other quality 
indicators for prescribing of medication a difference between the MD model and the PA/
MD model was found. 
Conclusion
This study suggests that the non-adherence to guidelines on medication prescribing on 
wards with the PA/MD model does not differ from wards with traditional house staffing 
by MDs only. Further research is needed to determine quality, efficiency and safety of 
prescribing behavior of PAs.
Introduction
Hospital care, nowadays, is characterized by a rising prevalence of chronic diseases, 
ongoing specialization in medical disciplines and increasing dependence on new 
technologies(1). To cope with these challenges, many hospitals in different countries 
have introduced dedicated ward physicians, who are responsible for the delivery and 
coordination of the daily medical care of hospitalized patients. Their work includes daily 
ward rounds, performing physical examinations, making decisions regarding necessary 
tests, treatments and procedures, rendering medical diagnoses and generating and 
reviewing clinical data(2). The role of this ward physician has mainly been fulfilled by 
medical residents or medical specialists(2, 3). The turnover of these ward physicians 
is traditionally high due to use of recent medical graduates who continue on to do 
fellowships and the mandatory rotational cycles. In recent years, however, there is an 
increasing pressure to deliver health care efficiently. Medical procedures are more and 
more standardized and there are concerns about the continuity, quality and safety of 
clinical processes. Therefore, these tasks are now increasingly allocated to physician 
assistants (PAs) in several countries, among which are the USA, Canada, the UK and 
the Netherlands. PAs generally do not rotate and constitute a factor of stability in the 
continually changing medical workforce(4-6). 
A PA is a non-physician health care professional licensed to practice medicine in defined 
domains, in collaboration with MDs but with a substantial degree of professional 
autonomy(7). PAs who are employed for medical care for admitted patients usually work 
in a team comprising both PAs and MDs (i.e. residents, staff physicians or hospitalists). The 
level of professional autonomy of PAs differs between countries. The scope of practice 
is determined by law as well as by the competencies of the PAs, the comfort level of 
the MD with the PA, and the perceived needs in health care delivery. Although there is 
a worldwide trend of an increase of PAs in the management of hospitalized patients, 
scientific evidence on the impact of PAs on health care outcomes, quality and safety of 
care, and costs is limited. Although evidence is scarce, some studies suggest that quality 
and efficiency of care provided by PAs is similar to that of MDs (8-14). 
Prescribing medication is considered a fundamental part of medical ward care practice. 
Up to 20-50% of admitted patients experience one or more adverse drug events (ADEs) 
during their hospital stay. Approximately 50% of these ADEs is potentially preventable. 
They mainly derive from prescribing errors that lead to potentially preventable morbidity, 
mortality and costs (15-18). Research on prescribing errors is mainly focused on 
prescription of medication by physicians (15-18). 
Since January 2012, legislation in Dutch healthcare authorizes PAs to prescribe medication 
without supervision of a MD (19, 20). Evaluation of this newly acquired authority in 2015 
showed that the measure had led to legalization of reserved medical procedures, already 
performed by PAs. It has created a perspective for PAs to further develop their profession 
in daily practice (20). However, scientific evidence on the quality of drug prescribing or 
adherence to clinical practice guidelines by PAs is hardly available. Published research 
about quality of drug prescribing by nurses and nurse practitioners (NPs) suggests that 
this is overall safe. This conclusion should however be interpreted cautiously given the 
methodological weaknesses in the body of research (19). Furthermore, the scope of 
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drug prescription by NPs (daily activities in care and cure, generally for a specific group 
of patients) differs from that of PAs (activities only in cure, for a broad population of 
patients). Generally, PAs prescribe more types of drugs to a higher diversity of patients 
compared to nurses and NPs (21).
In this study, we determined the effect of substitution of inpatient care from MDs to PAs 
on the non-adherence to guidelines on medication prescribing. 
Study aim
The aim of this study was to compare the non-adherence to guidelines on medication 
prescribing on hospital wards where PAs fulfill the role of ward physician, in collaboration 
with MDs, to the wards where the role of ward physician is solely fulfilled by MDs.
Methods
Study design and setting
This study was conducted as part of a multicenter matched-controlled study comparing 
wards utilizing a mixed ‘PA/MD model’, on which PAs provide medical care in collaboration 
with MDs, with wards utilizing a ‘MD model’, on which only MDs provide medical care. This 
study has been described in detail previously (22). 
In short, the study aimed to measure the effects of substitution of inpatient care from MDs 
to PAs on length of hospital stay, several indicators for quality and safety of inpatient care 
and patient experiences. 17 wards of the MD model were matched with 17 wards of the 
PA/MD model based on medical specialty and hospital type (i.e. academic versus non-
academic). 
Hospital wards were assigned to the PA/MD group if PAs were employed at the wards 
as substitutes for residents or medical specialists, taking care of inpatient management 
and daily clinical care. The PAs had to cover at least 51% of the available ward care hours 
per week during dayshifts (8 a.m. till 18 p.m.) on weekdays and had to have completed a 
master’s PA degree. The PAs as well as the residents were supervised by attending medical 
specialists. 
Wards were assigned to the control group if medical care was exclusively provided by 
MDs. Most of the MDs were residents. The resident is physically present at the department 
for at least a few hours each weekday, and is the first point of access to medical care. They 
are supervised by attending medical specialists. In some smaller hospitals, the medical 
specialists provide all medical care for the admitted patients.
In all hospitals in the Netherlands a computerized physician order entry (CPOE) system 
is implemented to support prescribing. Hospital pharmacists check medication of all 
patients on a daily basis with the aid of computer-generated alerts based on a national 
database (‘G-standard; www.z-index.nl) and with clinical decision support (CDS) systems 
combining clinical patient data (like renal function and electrolyte levels) with the 
medication to assess. If necessary, hospital pharmacists warn the prescriber for specific 
prescribing errors.
Study population
Patients admitted to 34 different hospital wards across 23 hospitals were included. 
Terminally ill patients, patients younger than 18 years and patients in daycare (hospital 
admission of 24 hours or less) were excluded. 
Outcome measures
A set of quality indicators based on pharmacotherapeutic guidelines was composed to 
measure the quality of prescribing by PAs and MDs. 
A set of 17 indicators was composed by means of a consensus procedure. First, provisional 
indicators were selected from scientific literature by a hospital pharmacist (JB) and 
an internist-clinical pharmacologist (CK). The selected quality indicators had to relate 
to medication that has shown to frequently be involved in potentially preventable, 
clinically relevant, drug-related problems (15-17, 23, 24). The indicators should be 
clearly referenced in a national clinical practice guideline or in the SmPC (Summary of 
Product Characteristics) of the concerned drug. The indicators were assumed to be part 
of general knowledge of the prescriber, and the prescriber should be able to perform 
on these indicators aided by implemented hospital guidelines. Selection was also based 
on potential relevance for a diversity of medical specialties and available data from the 
matched-controlled study. 
Second, an expert panel of five hospital pharmacists and nine medical specialists 
(two internist-clinical pharmacologists, one geriatrician-clinical pharmacologist, one 
nephrologist-clinical pharmacologist, one surgeon and four internists) were approached 
to participate in a modified Delphi procedure (25). We asked the expert panel to score 
the list of provisional indicators on their relevance to determine the quality of drug 
prescription by physicians on the ward. Scoring was done independently by e-mail. A 
nine-point Likert scale ranging from 1 (hardly relevant) to 9 (extremely relevant) was used 
to rate the indicators and also a category ‘could not assess’ was available. In addition, we 
asked for suggestions for new indicators. In case the suggestions for new indicators were 
measurable, we included the indicator in a second consensus round. We used a rating 
scale based on the RAND appropriateness method (26). Indicators with a median score of 
at least seven were considered as face valid and relevant and were selected for the final 
set of indicators. However, in case of too much diversity in scores for one indicator (i.e. at 
least 30% of the scores as well in the lowest tertile as in the highest tertile), the indicator 
was not selected(27). In table 1 we present the final set of 17 included quality indicators 
for prescribing. The indicators covered different pharmacotherapeutic subjects, such as 
gastric protection in case of use of NSAID or salicylates, prevention of obstipation in case 
of use of opioids, adequate prescribing in case of impaired renal function, adjustment 
of medication in case of use of iodinated radiocontrast agents, prevention of toxicity 
of methotrexate and avoidance of certain medication in combination with vitamin K 
antagonists. 
The outcome measure of this study is the non-adherence to guidelines on medication 
prescribing measured by 17 quality indicators. These indicators are expressed in proportions 
by dividing the number of patients in which the prescriber did not adhere to a guideline, by 
all patients that were applicable. The MD model served as the reference category. 
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Table 1. Indicators to measure adherence to guidelines on medication prescribing
Quality indicator Reference indicator Median score 
by expertsa
Gastric protection 
1.  Check whether a proton pump inhibitor was 
added in all patients with an ulcer in history 
and use of an NSAID.
NSAID use and prevention of gastric damage 
(guideline 2003 CBO)(28)
9
2.  Check whether a proton pump inhibitor was 
added in all patients with an age of older 
than 70 years and use of an NSAID.
NSAID use and prevention of gastric damage 
(guideline 2003 CBO)(28)
8
3.  Check whether a proton pump inhibitor was 
added in all patients with use of coumarines 
in combination with an NSAID.
NSAID use and prevention of gastric damage 
(guideline 2003 CBO)(28)
9
4.  Check whether a proton pump inhibitor 
was added in all patients with use of 
corticosteroids in combination with an 
NSAID.
NSAID use and prevention of gastric damage 
(guideline 2003 CBO)(28)
7,5
5.  Check whether a proton pump inhibitor was 
added in all patients with an age of older 
than 80 years and use of salicylates.
Recommendations of the Dutch HARM-
Wrestling Task Force (29)
8
Prevention of obstipation
6.  All patients with use of an opioid were 
checked whether a laxative was added. 
Patients with intestinal stoma were excluded.
Pain (guideline NHG)(30)
Diagnostics and treatment of pain (31)
8
Impaired renal function
Drugs with a contraindication
7.  All patients with impaired renal function 
(MDRD<30 ml/min/1.73m2) were checked 
whether an NSAID was avoided.
Dutch national G-standard; SmPC NSAID  
(32, 33)
9
8.  All patients with impaired renal function 
(MDRD<30 ml/min/1.73m2) were checked 
whether nitrofurantoin was avoided.
Dutch national G-standard; SmPC 
nitrofurantoin (32, 33)
7,5
9.  All patients with impaired renal function 
(MDRD<30 ml/min/1.73m2) were checked 
whether dabigatran was avoided.
Dutch national G-standard; SmPC dabigatran 
(32, 33)
8
10.  All patients with impaired renal function 
(MDRD<30 ml/min/1.73m2) were checked 
whether metformin was avoided.
Dutch national G-standard; SmPC 
metformin(32, 33)
8
Dose adjustment
11.  All patients with impaired renal function 
and use of a therapeutic dose of LMWH 
were checked whether the therapeutic dose 
of LMWH was adjusted.
Dutch national G-standard; SmPC LMWH 
(32, 33)
8
Use of iodinated radiocontrast
12.  All patients, that received iodinated 
radiocontrast because of imaging 
diagnostic examination and use of diuretics, 
were checked whether the diuretic was 
discontinued on the day of the test.
Precautions for use of iodinated radiocontrast 
(guideline 2007 NVR)(34)
7
13.  All patients, that received iodinated 
radiocontrast because of imaging 
diagnostic examination and use of an 
NSAID, were checked whether the NSAID 
was discontinued on the day of the test.
Precautions for use of iodinated radiocontrast 
(guideline 2007 NVR)(34)
8
Quality indicator Reference indicator Median score 
by expertsa
14.  All patients, that received iodinated 
radiocontrast because of imaging 
diagnostic examination and a MDRD<60 
ml/min/1.73m2, were checked whether the 
metformin was discontinued on the day of 
the test.
Precautions for use of iodinated radiocontrast 
(guideline 2007 NVR)(34)
7,5
Prevention of toxicity
15.  All patients, that use methotrexate, were 
checked on concurrent use of folic acid.
Diagnostics and treatment of rheumatoid 
arthritis (guideline 2009 CBO)(35)
7
Dosing of vitamin K antagonists
16.  All patients with use of vitamin K antagonist 
were checked whether miconazole was 
avoided.
The art of dosing of vitamin K antagonists 
(guideline FNT 2016)(36)
8
17.  All patients with use of vitamin K antagonist 
were checked whether cotrimoxazol was 
avoided. Only for patients with PJP this 
combination was allowed.
The art of dosing of vitamin K antagonists 
(guideline FNT 2016)(36)
8
a: median score of an expert panel on a nine-point scale (rated 1 to 9), performed to assess the relevance of the 
indicator in determining the adherence to guidelines on medication prescribing.
Abbrevations: FNT= Federation of Dutch Anticoagulant Services, NSAID = Non steroidal anti-inflammatory drug, 
MDRD = modification of diet in renal disease, LMWH =Low molecular weight heparin, NHG= Dutch Society of 
General Practitioners, NVR=Dutch Association of Radiology, PCP=pneumocystis jiroveci pneumonia
Data collection
All required data for the quality indicators were retrospectively derived from patient 
medical records by trained medical students and researchers. To ensure validity, a random 
sample of 10% of the patient records per ward was analyzed by a second researcher, who 
was blinded for the outcome of the initial researcher. In case of an inter-rater agreement 
of less than 95%, the records of the total sample were reassessed.
Sample size and data analysis
The sample size was calculated to detect a relative difference of 20% in length of stay 
(LOS), which is the primary outcome measure of the multicenter study. 34 Wards (17 in 
each arm) with 100 patients each were calculated to be required (22, 37). For the present 
study, no sample size calculation was performed.
Baseline characteristics of the study population are presented as mean and standard 
deviations (mean ± SD) for continuous variables, and proportion (%) for categorical 
variables. Quality indicators were expressed as proportions by dividing the number of 
patients in whom the prescriber did not adhere to a guideline, by the number of patients 
to which the guideline applied. To compare differences on the selected indicators between 
the PA/MD model and the MD model, logistic regression analyses were performed. 
Multivariable models were constructed to correct for relevant differences between the 
groups at baseline. Associations were expressed as odds ratios with 95% confidence 
interval. In all analyses, two-tailed p-values of 0.05 or lower were considered statistically 
significant. Analyses were performed with SPSS statistics version 24 (IBM Software, USA).
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Ethical considerations
Ethical approval was sought from the Research Ethics Committee of the Radboud 
University Nijmegen Medical Centre (registration number: 2012/306); the committee 
judged that ethical approval was not required under Dutch National Law. All data were 
handled strictly confidential and written informed consent was obtained from all patients.
Results
1021 Patients from 17 hospital wards were included in the ‘PA/MD model’ and 1286 
patients from 17 hospital wards were included in the ‘MD model’. The main characteristics 
of the patients are summarized in table 2. Most characteristics were well balanced 
between the groups. Less patients in the PA/MD model group were admitted electively in 
comparison with the MD model (41% versus 56%). 
Table 2. Baseline characteristics of patients
Baseline characteristic PA/MD model (n=1021) MD model (n=1286)
Medical specialty n(%)
- Surgery 601 (59%) 696 (54%)
- Gastroenterology 102 (10%) 181 (14%)
- Pulmonology 91 (9%) 107 (8%)
- Cardiology 101 (10%) 124 (10%)
- Orthopaedics 103 (10%) 100 (8%)
- ENT, head and neck oncology surgery 23 (2%) 78 (6%)
Hospital type n(%)
- Teaching 552 (54%) 709 (55%)
- Academic 23 (2%) 78 (6%)
- Non-academic 529 (52%) 631 (49%)
- Non-teaching 469( 46%) 577 (45%)
Gender, male n(%) 524 (53%) 682 (54%)
Age, years mean ± SD 64 ± 16 63 ± 15
Primary diagnoses n(%)
- Digestive system 204 (20%) 247 (19%)
- Circulatory system 158 (16%) 274 (22%)
- Neoplasms 108 (11%) 195 (15%)
- Musculoskeletal system and connective tissue 120 (12%) 119 (9%)
- Injury and poisoning 135 (13%) 80 (6%)
- Infectious diseases 59 (6%) 81 (6%)
- Respiratory system 51 (5%) 75 (6%)
Charlson index for co-morbidity score mean ± SD (% with score 
≥1)
1.1 ± 1.8 (43%) 1.1 ± 1.8 (44%)
Type of admission n(%)
- Elective 402 (41%) 687 (56%)
- Acute 588 (59%) 547 (44%)
Note: Numbers may not add up to the total because of missing values
Table 3 shows the results of the quality indicators expressed as the proportion of patients 
in which the prescriber in the ‘PA/MD model’ group and in the ‘MD model’ group did 
not adhere to a pharmacotherapeutic guideline and the matching odds ratios with 95% 
confidence interval. 
Two of the 17 quality indicators showed significantly less non-adherence for the PA/MD 
model. These were the indicators concerning prescribing gastric protection in case of use 
of NSAID in combination with corticosteroids (OR 0.42, 95% CI 0.19-0.90) and in case of 
use of NSAID in patients older than 70 years.
In none of the other quality indicators for non-adherence to guidelines on medication 
prescribing a difference between the MD model and the PA/MD mixed model was found.
Table 3. Non-adherence to pharmacotherapeutic guidelines, based on the selected quality indicators
Quality indicator PA/MD 
model **
MD model** Adjusted 
Odds ratio *
OR 95% CI
Gastric protection 
1.  All patients with an ulcer in history and use 
of an NSAID were checked whether a proton 
pump inhibitor was added. 
0/6 (0%) 1/11 (9.1%) NA
2.  All patients with an age of older than 70 
years and use of an NSAID were checked 
whether a proton pump inhibitor was added.
18/113 
(15.9%)
25/100 (25%) 0.47 0.23-0.95 
(p=0.037)
3.  All patients with use of coumarines in 
combination with an NSAID were checked 
whether a proton pump inhibitor was added.
6/27 (22.2%) 6/21 (28.6%) 0.66 0.18-2.48
4.  All patients with use of corticosteroids in 
combination with an NSAID were checked 
whether a proton pump inhibitor was added.
9/58 (15.5%) 81/248 
(32.7%)
0.42 0.19-0.90
(p=0.012)
5.  All patients with an age of older than 70 
years and use of salicylates were checked 
whether a proton pump inhibitor was added.
13/51 (25.5%) 11/50 (22%) 1.41 0.53-3.74
Prevention of obstipation
6.  All patients with use of an opioid were 
checked whether a laxative was added. 
Patients with intestinal stoma were excluded.
463/606 
(76.4%)
590/785 
(75.2%)
1.13 0.87-1.46
Impaired renal function
Drugs with a contraindication
7.  All patients with impaired renal function 
(MDRD<30 ml/min/1.73m2) were checked 
whether an NSAID was avoided.
3/24 (12.5%) 0/22 (0%) NA
8.  All patients with impaired renal function 
(MDRD<30 ml/min/1.73m2) were checked 
whether nitrofurantoin was avoided.
1/24 (4.2%) 2/22 (9.1%) 0.41 0.03-4.96
9.  All patients with impaired renal function 
(MDRD<30 ml/min/1.73m2) were checked 
whether dabigatran was avoided.
0/24 (0%) 1/22 (4.5%) NA
10.  All patients with impaired renal function 
(MDRD<30 ml/min/1.73m2) whether 
checked if metformin was avoided.
7/24 (29.2%) 3/22 (13.6%) 2.58 0.57-11.62
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Quality indicator PA/MD 
model **
MD model** Adjusted 
Odds ratio *
Dose adjustment
11.  All patients with impaired renal function 
and use of a therapeutic dose of LMWH 
were checked whether the therapeutic dose 
of LMWH was adjusted.
0/2 (0%) 0/5 (0%) NA
Use of iodinated radiocontrast
12.  All patients, that received iodinated 
radiocontrast because of imaging 
diagnostic examination and use of diuretics, 
were checked whether the diuretic was 
discontinued on the day of the test.
48/67 (71.6%) 51/68 (75%) 0.80 0.36-1.78
13.  All patients, that received iodinated 
radiocontrast because of imaging 
diagnostic examination and use of NSAID, 
were checked whether the NSAID was 
discontinued on the day of the test.
44/70 (62.9%) 37/60 (61.7%) 1.02 0.49-2.12
14.  All patients, that received iodinated 
radiocontrast because of imaging 
diagnostic examination and a MDRD<60 
ml/min/1.73m2, were checked whether the 
metformin was discontinued on the day of 
the test.
2/2 (100%) 4/9 (44.4%) NA
Prevention of toxicity
15.  All patients, that used methotrexate, were 
checked on concurrent use of folic acid.
0/8 (0%) 0/12 (0%) NA
Dosing of vitamin K antagonists
16.  All patients with use of vitamin K antagonist 
were checked whether miconazole was 
avoided.
1/124 (0.8%) 1/153 (0.7%) 1.28 0.08-20.71
17.  All patients with use of vitamin K antagonist 
were checked whether cotrimoxazol was 
avoided. Only for patients with PJP this 
combination was allowed.
4/124 (3.2%) 0/153 (0%) NA
NA=not applicable because of limited number of cases
* Adjusted for type of admission (elective or acute)
** Quality indicators are expressed in proportions by dividing the number of patients in which the prescriber did 
not adhere to a guideline, by all patients that were applicable. The MD model served as the reference category.
Discussion
In this study we aimed to determine the effect of substitution of inpatient care from MDs 
to PAs on non-adherence to guidelines on medication prescribing on the ward. Indicators 
of prescribing gastric protection in case of use of NSAID by patients with an age over 70 
years or in combination with use of corticosteroids showed less non-adherence in the ‘PA/
MD model’ group than in ‘MD model’ group. None of the other quality indicators showed 
a significant association between the involvement of PAs and the quality of prescribing. 
Adherence to recommendations varied across indicators, but tended to be low overall. 
Although we have to interpret the results cautiously because of the relatively small 
sample size for several quality indicators, this study suggests that the non-adherence to 
guidelines on medication prescribing on wards on which PAs provide medical care in 
collaboration with MDs (PA/MD model), does not differ from wards on which only MDs 
provide medical care (MD model).
In recent years the PA has been increasingly introduced in the hospital. A PA is a non-
physician health care professional licensed to practice medicine in defined domains 
and trained to do tasks that were formerly performed by physicians only. The primary 
motive for employing a PA in Dutch health care is to increase continuity and quality of 
care (38). The level of professional autonomy of PAs differs between countries. From the 
introduction of the PA there has been debate about prescribing by PAs(20). It has been 
suggested that only physicians have the capability to prescribe medication and that only 
physicians should be allowed to do so. Prescribing is viewed as a very complex, risky 
clinical task. Many studies have shown that prescription errors made by physicians lead to 
preventable adverse events in hospitals (15-18). Nowadays, although with different levels 
of autonomy, in most countries PAs have been authorized to prescribe a limited list of 
medication, based on the specific training of the PA. Until now, there have been no studies 
to evaluate prescribing of PAs compared to MDs.
It has been shown that continuity of care is higher on wards with PAs, and that 
PAs often have more years of experience on the ward than residents do. As a 
consequence, PAs might be more familiar with prevailing clinical practice protocols and 
pharmacotherapeutic guidelines (39). This could implicate that PAs are more capable, 
dedicated and motivated to follow guidelines. On the other hand, because of a lower 
degree of autonomy of the PA, it may also be more difficult for a PA to deviate from 
guidelines, when this is needed in certain circumstances. 
We found that the PA/MD model performed better on the quality indicators concerning 
gastric protection in case of NSAID use in combination with another risk factor. Van den 
Bemt et al. found that the proportion of admissions in which MDs were not compliant 
with guidelines on gastric protection in case of use of NSAID in hospitalized surgical 
patients was 46.6%(40). In our study we found a better performance in both models, but a 
significant better result in case of the PA/MD model. For this specific guideline, this could 
confirm the hypothesis that PAs are more dedicated to follow the guideline. 
For the indicator that measures prevention of obstipation in case of use of opioids 
we found no difference and also a poor adherence to the guideline (non-adherence 
76.4% for the PA/MD model and 75.2% for the MD model). We excluded patients with 
intestinal stoma, but for this guideline there are more situations in daily practice in which 
a prescriber could deviate intentionally from this guideline. It is possible that better 
compliance by PAs is masked by a higher percentage of just deviation from guidelines by 
MDs because of certain patient circumstances. Detailed clinical data necessary to assess 
justified deviation of the guideline was not available in this study.
We found that a diuretic, NSAID, or metformin in case of renal failure, was often not 
discontinued when patients received iodinated radiocontrast because of imaging 
diagnostic examination (68.3% for the PA/MD model and 70.5% for the MD model). Schilp 
et al. studied adherence to the guideline concerning identification and hydration of high-
risk patients for radiocontrast-induced nephropathy in different hospitals and also found 
that only two third of the high-risk patients were hydrated before contrast administration, 
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but they did not measure discontinuation of drugs according to the guideline (41). 
Overall, adherence to guidelines varied across the indicators we measured, but tended to 
be low. This is in line with earlier research on pharmacotherapeutic guideline adherence 
(40-42). Different variables, such as organizational, guideline or patient factors but also 
health professional factors, that are associated with poor guideline adherence, have been 
described (43). Our study suggests that a poor guideline adherence cannot be explained 
by a difference in prescribing by PAs and MDs. 
This study has some methodological strengths and limitations. A major strength of this 
study is the multicenter design. 15 wards in teaching hospitals and 19 wards in non-
teaching hospitals were included. This is approximately in proportion with the general 
situation in the Netherlands (36 teaching hospitals and 60 nonteaching hospitals). Most of 
the wards were of a surgical (sub)specialty. We know that, in the Netherlands, most of the 
PAs are employed at a surgical department.
Another strength of the study is the broad set of indicators that measures non-adherence 
to guidelines and covers different pharmacotherapeutic subjects. Moreover, this set 
was composed by a consensus procedure in which 14 medical experts participated in 
a modified Delphi procedure to select a final set of representative indicators, that are 
considered clinically relevant for inpatient care. 
One of the limitations is the non-randomized design of the study, which implies an 
increased risk of confounding. We took this into account by performing a multivariable 
analysis. However, we cannot exclude that there are small local differences like the 
organization of ward care (care by resident or specialist, arrangement of supervision), 
policies on the medication process, implementation of CPOE based clinical decision 
support, and patient case-mix, that are not accounted for in the multivariable analysis. 
Another limitation of this study is the relatively small sample size for several quality 
indicators we measured. The primary study was not powered to detect effects on 
prescribing indicators. Results of the statistical analyses should therefore be interpreted 
with caution.
The study compared wards with a PA/MD model to wards with traditional house staffing 
by MDs only. This implicates that prescribing of medication on the wards with the PA/
MD model was not only performed by PAs. It is more likely that we measured a team 
performance than the performance of the PA alone. However, PAs covered most of the 
available ward care hours per week during dayshifts (68% (IQR 48-77%))(39). Moreover, 
measurement on the ward with several medical residents and medical specialists can also 
be interpreted as team performance. 
It is important to obtain more evidence on quality, safety or efficiency of prescribing by 
PAs to be sure that the complex task of prescribing can be performed by these medically 
trained professionals. Dedicated research should be designed and performed with 
measures as guideline adherence, adverse drug events and prescribing errors, linked to 
relevant clinical patient outcome measures.
Conclusions
This study suggests that the non-adherence to guidelines on medication prescribing on 
wards with the PA/MD model does not differ from wards with traditional house staffing 
by MDs only. Further research is needed to determine quality, efficiency and safety of 
prescribing behavior of PAs.
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Chapter 7
Summarizing discussion
2. ADRs (not from errors)
3. ADRs (from
 medication
 errors)
4. Medication errors
 that cause harms
 that are not ADRs
5. Medication errors
 that don’t cause
 adverse events
3 + 4 + 5 = all medication errors
1. Adverse events that are not
 reactions to the medicines
1 + 2 + 3 + 4 = all adverse events
in people taking medicines
2 + 3 = all ADRs
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Introduction
Pharmacotherapy is the most frequently used therapeutic tool for the physician to treat 
patients. In addition to the beneficial effects, use of drugs also introduces risks of adverse 
drug events (ADE) or medication errors (ME). Drug treatment is a complex process and 
failures can occur in different steps of the drug therapy process (reconciling, prescribing, 
transcribing, dispensing, administering and monitoring), but especially prescribing is a 
frequent cause of ADE (1). This leads to potentially preventable morbidity, mortality and 
costs (2-4). 
In recent years, medication use has increased and contributed to an improvement 
in quality of life and increase of life expectancy (5). To get an impression of the vast 
number of drugs used in the Netherlands, data provided by the Dutch Foundation for 
Pharmaceutical Statistics (SFK) and the National Healthcare Institute can be used (6, 7). In 
2015 the Dutch population of 17 million used a total of 8,737 million Defined Daily Doses 
(DDDs) (6, 7). The DDD is the assumed average maintenance dose per day for a drug used 
for its main indication in adults (8). 3,244 million of these DDDs concern medicines within 
the cardiovascular risk management (7).
Many of the patients who are prescribed medication are elderly and vulnerable. They 
have comorbidities, suffer from cognitive and social problems and use multiple high risk 
drugs. According to the definition in the multidisciplinary guideline (MDR) “Polypharmacy 
in Elderly” from the Dutch Association of General Practitioners (NHG), a polypharmacy 
patient takes five or more drugs for chronic conditions (9). The number of drugs is 
counted on ATC3 code level. In the Anatomical Therapeutic Chemical (ATC) classification 
system, the active substances are divided into different groups according to the organ or 
system on which they act and their therapeutic and chemical properties (8).
In 2015 there were 1.57 million polypharmacy patients, which was 9.3% of the total 
number of insured persons in the Netherlands. In 2011 they counted 1.35 million 
patients (6).
Nearly 65%  of all polypharmacy patients are 65 years of age and older. Of the patients of 
75 years and older, half of the patients take five or more drugs. 65% of the polypharmacy 
patients use antithrombotics and a large group of polypharmacy patients receive 
medicines for heart failure and hypertension (6, 7).
This increase in drug consumption by more complex patients has inevitably led to an 
increase of side effects (ADR), medication errors and adverse drug events (fig. 1.)(10).
For this reason, medication safety has become an important theme in hospitals and 
several interventions have been introduced to cope with these drug-related problems. 
The risk of accidental injury during hospitalization has remained unchanged in recent 
years (8% of hospital admissions in 2008 and 7.1% of hospital admissions in 2012) and 
potentially preventable harm decreased (2.9 % versus 1.3%). However, despite all efforts 
put in medication safety interventions, promoting adherence to professional standards 
and decreasing shortcomings in organization of care, the potentially preventable harm 
caused by medication in hospitals remained unchanged (11, 12).
Figure 1. Venn diagram showing the relation between adverse events, adverse drug reactions, and 
medication errors (10).
Patient harm caused by medication has contributed to a negative image of drugs. In the 
Western world the expectations of therapeutic possibilities, both pharmacological and 
technological, are very high. Several publications of reports that address the increase 
in hospital costs and patient harm due to the use of drugs have attracted a lot of media 
attention (3, 13). Although the title of the report “To err is human” sounds mild, there is 
little place for forgiveness of errors in the complex process of patient treatment. 
It appears that introducing recommendations, implementing clinical practice guidelines 
and introducing changes in the process of healthcare delivery progress slowly and require 
a lot of attention and energy from different healthcare providers. Working on medication 
safety remains a continuous process of measuring, audit and feedback followed 
by improving and adapting the system and care processes. This thesis describes a 
multifaceted approach in large teaching hospitals in the Netherlands, combining different 
medication safety interventions, to address the problem of prescribing errors leading to 
adverse drug events.
In this final chapter our main results are reviewed in a wider perspective in relation to the 
main objectives of this thesis. First the challenges of the methodology of intervention 
studies on medication safety will be addressed. After that the different components of 
the multifaceted intervention we studied will be discussed. This intervention includes 
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education of the prescriber, implementation of guidelines, medication review and 
the use of information technology. This multifaceted approach must be applied in 
hospitals by using risk stratification in daily practice, embedded in a transparent and 
efficient organization of healthcare and medication safety programs. This chapter will be 
concluded by providing recommendations for clinical practice and future research. 
Methodology of intervention studies on medication safety
To design studies that assess the effect of different interventions to improve medication 
safety is challenging. Earlier medication safety intervention studies were generally 
insufficiently powered to detect actual patient harm. They mostly focused on surrogate 
endpoints such as increase of knowledge or skills, or a decrease of prescriptions errors 
or medication discrepancies. In some cases, they estimated potential harm instead of 
measuring clinically relevant outcomes. A randomized controlled design is almost never 
deemed possible and many studies used non-blinded designs and lacked robust data 
collection methods. 
We describe a systematic review (Chapter 2) that gives an overview of original research 
papers on the effect of education of prescribers that report outcomes on (potential) 
patient harm (14).
We assessed the methodological quality of these studies using the Methodological Index 
for Non-Randomized studies (MINORS) checklist and the suggested risk of bias criteria 
for Effective Practice and Organization of Care (EPOC) reviews. We found important 
methodological limitations of the studies such as short follow-ups (less than 3 months), 
lack of appropriate (equivalent, contemporary) control groups and absence of blinded 
evaluation of the outcome. It was generally unclear whether the educational intervention 
was independent of other changes over time and whether the outcome measurement 
was influenced by other confounders during the study period (performance bias). Also, 
the risk of reporting bias through selective outcome reporting was high. The majority 
(if not all) of studies lack robust data collection methods. In their report “Supervision on 
investigator initiated clinical research 2014-2016” the Dutch Inspectorate of Healthcare 
expressed concerns on methods of data management, often caused by a shortage of 
financial resources (15). The validity of conclusions drawn in this kind of research critically 
depends on the validity of the data used. Adequate measures must be taken to prevent 
the data from being incorrect, missing, or misinterpreted. The automatic extraction from 
hospital databases and use of these data for medical research involves additional data 
processing steps. These steps, that may be made ad hoc, codified into procedures or 
automated with special-purpose scripting, should be validated. 
In the design of the P-REVIEW study (Chapter 3) we tried to overcome such limitations 
in study design (16). We collected data on a very large patient cohort. With this large 
cohort it was possible to study clinically relevant outcome measures (death, temporary or 
permanent disability, increased hospital stay or readmission) as the primary outcome. We 
blinded all case record forms with respect to the study period before assessment by the 
experts. 
The major part of the data collection was performed automatically, using a validated 
multisource Microsoft Access database. Also the identification of possible cases with 
a clinically relevant, drug-related problem based on a trigger list was performed semi-
automatically. The Laboratory for Quality Software (LaQuSo) connected to the University 
of Technology in Eindhoven validated three steps of data generation of the P-REVIEW 
database; automated collection of data, general data clean up, conversion and filtering 
steps and specific queries as additional filtering and aggregation steps (17).
Detecting clinically relevant adverse drug events requires an intensive outcome-based 
approach, such as chart review by experts. Even when an automatic trigger instrument 
based on electronic patient records is used to select possible drug related problems, chart 
review of large patient cohorts remains time-consuming. 
The assessment of the causal association between drug treatment and patient harm and 
the preventability of the event is also challenging, since a high inter-rater variability has 
been described among experts. Using a standardized causality algorithm can help to 
achieve a reproducible assessment, but a clinical and inevitably subjective judgement will 
be required for an evaluation of other contributing factors such as disease and patient 
related factors. In the P-REVIEW study we used three expert teams consisting of a hospital 
pharmacist and a hospital-based physician, assessing adverse drug events from their own 
perspective given their profession. To minimize bias due to subjectivity of the assessment 
process it is important to use standardized methods and intensive sessions to agree 
upon adverse drug events included. Even when experts completely agree on the causal 
association between drug treatment and patient harm, the degree in which the causal 
drug contributes to the adverse event often remains unclear.
In addition to the design of the study, the design of the intervention itself needs attention. 
In the P-REVIEW study we chose a multifaceted approach by combining different 
interventions. We hypothesized that the combination of interventions would address 
different factors that may influence the quality of prescribing. Conscious combination 
of interventions leads to more efficient and effective strategies. For instance, the effect 
of educational programs could be boosted by frequent consultation and audit of the 
prescriber on the wards. Medication review would become more feasible by introducing 
methods of risk-stratification of patients. De Smet et al. promoted a combination of 
implicit and explicit screening criteria in medication review as it may offer a more 
thorough approach (18). We also hypothesized that the support of education of the 
prescriber by the hospital pharmacist in a more pro-active role is more efficient and 
effective than the traditional reactive role of the hospital pharmacist in medication 
surveillance. It is better to prevent prescribing errors than to solve them. 
Components of the multifaceted intervention
Education of healthcare providers
In the review (Chapter 2) we searched for studies that evaluated the effects of educational 
programs for hospital physicians and reported outcomes on (potential) patient harm. 
These studies showed a large variation in study settings and in the percentages found 
on intermediate outcome markers such as prescription errors and potential ADEs. Four 
out of seven studies in which the intervention was education alone, showed efficacy. 
All studies in which education was the main part of a multifaceted intervention showed 
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positive results. Education alone may not have a large effect, but education embedded in 
a broader array of measures aimed at appropriate prescribing may be more effective.
The P-REVIEW study (Chapter 3) was designed to determine whether a multifaceted 
intervention of educating the prescriber combined with medication review and 
pharmaceutical visits to the ward by the hospital pharmacist could lead to a reduction in 
drug-related complications among surgical patients. A total of 6780 admissions of 5940 
patients to surgical patients to surgical, urological and orthopaedic wards during the 
usual care period and 6484 admissions of 5711 patients during the intervention period 
were included. A significantly lower proportion of admissions with one or more clinically 
relevant, potentially preventable, drug-related problems (including death, temporary 
or sustained disability, increased length of hospital stay or readmission within 30 days ) 
occurred in the intervention period (1.1% (73/6484) compared to the usual care period 
(1.6% (106/6780)) (p=0.029). The relative risk (RR) was 0.72 (95% CI 0.53-0.97). Several 
types of drug-related problems occurred less frequently. 
The P-REVIEW study shows that education and support of the prescribing physician 
with respect to high-risk patients in surgical departments leads to a significant, clinically 
relevant benefit for patients. However, further work is needed to develop effective 
educational interventions. The knowledge of how to teach effectively should be 
combined with optimizing the content of the education. Clearly, educational programs 
need a follow-up to enhance learning retention. We recently developed E-learning 
modules of the P-REVIEW educational programs. When these E-learning modules are 
followed by classroom sessions, efficiency and efficacy for students and teachers may be 
higher as the result of regular education sessions. The content of pharmacology education 
should be related to known risk factors for medication errors in hospital patients, and 
should focus on the use of high-risk drugs in high-risk patients or high-risk situations. 
Therefore, these programs need to be adjusted in time. For Dutch pre-graduate medical 
students a mandatory “License to prescribe” has been introduced (19). It would be useful 
to investigate if a mandatory test for physicians in hospitals can be introduced. If this 
exam has been passed, physicians will be allowed to prescribe. 
We suggest that educational sessions should be combined with other measures to 
improve medication safety. Workplace-based pharmacotherapy education, using 
complementary knowledge of different specialties, is effective. The P-REVIEW study 
showed that continuous audit and feedback on the main pharmacological issues and 
prevailing guidelines in the workplace of healthcare professionals, will lead to a sustained 
effect of the education. 
Implementation of guidelines
We describe the results of a study (Chapter 4) designed to determine whether the 
P-REVIEW approach of introducing an educational program for prescribers in the hospital 
combined with audit and feedback by the hospital pharmacist reduces non-adherence of 
prescribing physicians to key pharmacotherapeutic guidelines (20).
Clinical practice guidelines with evidence-based recommendations for physicians are 
being developed in hospitals to assist doctors and improve care. In routine daily practice, 
it appears to be difficult to implement key recommendations and guidelines seem to 
have limited impact on physician prescribing behaviour. Most clinicians can barely keep 
pace with the rapid advances in pharmacotherapy. And even if doctors are aware of the 
guidelines and are willing to change, to alter well established patterns of prescribing is 
difficult. Adherence to guidelines by prescribers is inconsistent(21-23).
In our study we used implementation of guidelines as a medication safety intervention in 
order to reduce potentially preventable adverse drug events. We also measured guideline 
adherence as a process-based outcome, because of its potential to improve the quality of 
healthcare and patient outcomes.
We hypothesized that, by educating the prescriber, the guidelines in the hospital and 
reinforcing this knowledge during medication safety consultation, the knowledge and 
skills needed to adhere to guidelines should improve. Also, we expected that the attitude 
towards guidelines in general and motivation to adhere would improve.
1435 admissions of 1378 patients who were admitted to surgical, urological or 
orthopaedic wards during the usual care period and 1195 admissions of 1090 patients 
during the intervention period were included. Ten guidelines were selected, such as 
perioperative thrombosis prophylaxis, NSAID contraindication in impaired renal function 
and discontinuation of drugs in case of radiocontrast. The literature has shown that these 
subjects are frequently involved in potentially preventable, clinically relevant, drug-related 
problems. Non-adherence was observed significantly less often during the intervention 
period as compared to the usual care period.
Not only the development, but more importantly the implementation and evaluation of 
guidelines needs attention in coming years. Known determinants of practices that prevent 
or enable guideline adherence or, more generally, adherence to healthcare process 
agreements should be taken into account in clear implementation projects in hospitals. 
These are for instance guideline factors, such as quality of evidence and accessibility 
of the guideline, organizational factors and resources, such as the information system, 
frequent rotations of physicians on the ward, workload, the presence of a continuous 
education system, patient factors such as increasingly complex multi-morbidity and 
also individual health professional factors, such as knowledge and skills, awareness and 
professional behaviour. By a continuous process of audit and feedback, implementation 
methods and adherence to guidelines of prescribers should be followed. However, it is 
often not necessary to pursue 100% adherence. In individual cases the physician may 
correctly decide to deviate from the guideline.
Medication review
Medication review by clinical pharmacists and clinical pharmacologists has been used 
as a tool to improve prescribing quality in hospital patients. However, the application 
of medication review is rather time-consuming in practice. A combination with risk 
stratification tools to identify patients at risk to experience drug-related problems during 
hospital stay and who would benefit from medication review is therefore indispensable. 
Also further automatization of some of the used criteria during medication review, by 
developing more intelligent clinical decision support, could make the efforts of the 
hospital pharmacist more efficient.
On the other hand, when medication review is integrated in an educational program 
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and considering the purpose of the medication review is not only to detect adverse drug 
risks but also to educate the prescriber in good prescribing and to enhance guideline 
adherence, it may not be needed to address all possible drug related problems. Low-
risk patients (without medication reviews) may also benefit from the effect of such an 
intervention.
In the P-REVIEW study (Chapter 3) hospital pharmacists performed medication reviews as 
part of the multifaceted intervention. This systematic assessment of the medication of the 
patient in combination with assessment of the clinical data of the patient was performed 
using a standardized checklist (Appendix 2) and targeted patients at risk for potentially 
preventable, drug-related problems (16). We developed this checklist based on expert 
experience and recent literature on prescribing errors and drug-related problems (3). We 
also used different screening tools described in literature as input for a comprehensive 
assessment of the medication of the patient, such as the STOPP and START criteria (24). 
Hamilton et al. showed that STOPP criteria are significantly associated with potentially 
preventable ADEs in older people that cause or contribute to urgent hospitalization (25). 
Verdoorn et al. however showed recently that the majority of drug-related problems 
identified during medication review was not associated with STOPP/START criteria (26), 
and (solely) these explicit criteria may not very useful in the clinical practice of hospital 
care.
Hospital pharmacists were trained to perform medication safety consultations, combining 
a medication review and a visit to the ward to discuss potential drug related problems 
and associated recommendations. The development of the method of medication review 
and the training and experience of hospital pharmacists and clinical pharmacologist to 
perform reviews of good quality need great attention and it would be useful to share 
experiences in hospitals at a national level.
Risk prediction tools in clinical practice
Risk prediction is a routine component in daily care practice in many specific areas 
(e.g. approaches used to determine stroke risk in patients with atrial fibrillation). Risk 
stratification of potentially preventable, clinically relevant adverse drug events should be 
able to assist in patient prioritization, supporting clinicians and hospital pharmacists to 
make decisions about treatment, and can deliver more efficient healthcare service. If we 
are able to identify patients at risk for drug adverse events in the different wards of the 
hospital, we can implement all possible interventions more efficient. Risk models need an 
acceptable goodness of fit and good discriminative performance. A low specificity means 
that the model may incorrectly label patients at risk who will not develop a drug-related 
event. This may lead to inefficient use of resources due to interventions or increased 
monitoring.
We describe the results of a study in which the P-REVIEW dataset was analyzed to develop 
a risk-prediction model (Chapter 5) that could identify the patients at risk for potentially 
preventable clinically relevant drug related problems during admission at the surgical 
ward, at time of hospital admission (27). 6780 admissions of patients at surgical wards 
were included. In 102 patients a clinically relevant, potentially preventable adverse drug 
event during hospital stay was detected. The resulting model contained five variables 
including age, number of biochemical tests, heparine/LMWH in therapeutic dose, opioids 
and cardiovascular drugs. The AUC was 0.86 (95% CI 0.83-0.88). When the cut-off point 
for a high risk of developing an ADE was set to a model-predicted probability of 1.6%, 
the model shows a sensitivity of 80.4%, and a specificity of 73.4%. The positive predictive 
value is 4.5% and the negative predictive value is 99.6%. These results implicate that this 
model should not only be used to label hospitalized patients at risk to experience a drug-
related event but especially to label patients that are unlikely to experience a drug related 
event. We can downgrade interventions for this group of patients and use the resources 
for patients with a higher risk.
A recent review identified four studies that developed adverse drug reaction (ADR) risk-
prediction tools (28). These tools had poor to modest performance and did not address 
clinical impact or implementation, thereby limiting universal applicability. Because a large 
number of variables contribute to ADR occurrence in patients, it is impossible to correctly 
predict every ADR in every patient. To improve ADR or ADE risk prediction strategies, 
they should focus either on one specific harmful ADR (e.g. gastrointestinal or intracranial 
bleeding) or ADRs in patients with a particular illness or clinical characteristic, for instance 
patients with a delirium, studied by de Wit et al. (29), or surgical patients, as performed in 
our study. Also we believe it is more efficient to focus on clinically relevant, preventable 
adverse drug events instead of adverse drug reactions to develop a risk prediction tool, 
of which implementation actually leads to more efficient healthcare. Our study aimed 
to predict the risk of a surgical patient at time of hospital admission. Therefore, variables 
such as length of hospital stay, interdisciplinary consultation or admission to the intensive 
care during hospital stay, were not included in our analysis. These variables must be 
considered in further research to develop models that follow a possible increasing risk 
during hospital stay. 
The performance of risk-prediction models will increase when we will be able to study 
more potentially predictive factors. Therefore we need more structured automated 
documentation of patient related factors such as comorbidities, diagnoses, reason for 
hospital admission, type of surgery, cognitive impairment and frailty, organizational 
factors or drug-related factors.
Implementation of these risk models in daily practice and integration of these models 
in Computerised Physician Order Entry/Clinical Decision Support (CPOE/CDS) systems is 
the next step. This creates the possibility to alert the healthcare worker when a patient’s 
individual risk is high and above a defined cut-off point. 
The role of information technology
Patient risk stratification is needed to make the efforts of the hospital pharmacist more 
efficient. One important condition to be able to focus on high-risk patients with high-risk 
medication is a further development of more advanced clinical decision support systems 
to build a safe and efficient medication check for all patients in the hospital. 
The CPOE/CDS systems currently used in Dutch hospitals generates a vast number of 
alerts of drug-drug interactions, duplicate medication and dosing advices. These alerts 
are only relevant in a minority of cases and often the physician is unnecessarily warned. 
It is necessary to discuss the relevance of these alerts, the right time that alerts should be 
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presented and also to which caregiver the alert should be presented (prescriber, hospital 
pharmacist, pharmacy assistant or nurse). This can improve specificity of the alerts and 
efficiency of the medication safety process (30). This multidisciplinary discussion should 
preferably be brought to a national level, so this information can be added to a national 
standard (G-standard). 
More advanced clinical decision support systems combine clinical data of the patient (like 
laboratory results) with the medication to assess whether for instance dose adjustments 
should be made in case of renal insufficiency. When these clinical data are included in 
algorithms, this will lead to more clinically relevant alerts. It is necessary to document 
these relevant clinical data in electronic health records so they can be made available for 
this purpose.
In the P-REVIEW study (Chapter 3) we already used a computerized screening method to 
identify high risk patients, for whom hospital pharmacists performed a medication review. 
This algorithm was built by combining medication data and clinical data based on recent 
literature on prescribing errors (3, 31). 
Another algorithm, the trigger instrument, was developed to identify possible drug-
related problems in the large patient cohort, consisting of a comprehensive set of 
phenomena such as (change in) laboratory results, medication use, clinical interventions, 
radiology examinations, consultations of other specialists, transfer to the intensive care 
unit, readmission within 30 days and death. The major part of the data collection for 
this trigger instrument was performed automatically, but some of these data were not 
available in the electronic health records and had to be collected manually. For further 
development of these kinds of algorithms structured documentation of relevant clinical 
data of patients in a CPOE-CDSS system is essential. Only then these algorithms can 
be made applicable for medication surveillance and for extraction of quality indicators 
related to patient outcomes.
Organization of healthcare
A well organized and transparent process of healthcare delivery and a multidisciplinary 
collaborative care model are important preconditions for safe prescribing of drugs. 
Hospital care, nowadays, is characterized by ongoing specialization in medical disciplines 
and development of new technologies. Elderly, vulnerable patients with multiple 
co-morbidities requiring multiple drugs intensively consult many different medical 
specialists and medical residents, who are often rotating in shifts. This fragmentation of 
healthcare is a challenge for medication safety. The recent report ‘Safe Prescribing must 
improve’ of the Dutch Inspectorate of Healthcare stated that the “Recommendation on 
Dividing Responsibilities for Cooperation in Healthcare”, composed by the KNMG in 2010, 
is insufficiently implemented in daily care practice (32, 33). It is often not clear which 
physician or pharmacist is responsible for the complete overview of drugs, used by the 
patient (34). The results of the SURPASS study (Surgical Patient Safety System) have shown 
the effect of a transparent organization on patient safety in the surgical pathway (35).
In the increasing demand for efficiency in healthcare and continuity of clinical processes, 
but also because of a shortage of medical residents (MDs), many hospitals have adopted 
the hospitalist model as a method to cope with this challenges in medical ward care. 
Hospitalists are responsible for the delivery and coordination of the daily medical care 
of hospitalized patients. Their work includes daily ward rounds, performing physical 
examinations, making decisions regarding necessary tests, treatments and procedures, 
rendering medical diagnoses and generating and reviewing clinical data. Besides, this 
ward care is also increasingly reallocated to physician assistants (PAs) (36). A PA is a non-
physician healthcare professional licensed to practice medicine in defined domains with 
a substantial degree of professional autonomy. PAs who are employed for medical care 
for admitted patients usually work in a team comprising both PAs and MDs (i.e. residents, 
staff physicians or hospitalists). PAs generally do not rotate and constitute a factor of 
stability in the continually changing medical workforce. Since January 2013, legislation in 
Dutch Healthcare authorizes PAs to prescribe medication without supervision. However, 
data on quality of drug prescribing or adherence to clinical practice guidelines by PAs 
is not available. We describe the results of a study which aimed to determine the effect 
of substitution of inpatient care from MDs to PAs on the non-adherence to guidelines 
on medication prescribing (Chapter 6) (37). This study was conducted as part of a 
multicenter matched-controlled study comparing wards utilizing a mixed ‘PA/MD model’, 
on which PAs provided medical care in collaboration with MDs, with wards utilizing a ‘MD 
model’, on which only MDs provided medical care (38). A set of 17 quality indicators to 
measure non-adherence to guidelines on medication prescribing by PAs and MDs was 
composed by 14 experts in a modified Delphi procedure. The indicators covered different 
pharmacotherapeutic subjects, such as gastric protection in case of use of NSAID or 
prevention of obstipation in case of use of opioids. In this study 1021 patients from 17 
hospital wards in the ‘PA/MD model’ group and 1286 patients from 17 hospital wards in 
the ‘MD model’ group were included. Two of the 17 quality indicators showed significantly 
less non-adherence to guidelines for the PA/MD model; the indicators concerning 
prescribing gastric protection in case of use of NSAID in combination with corticosteroids 
(OR 0.42, 95% CI 0.19-0.90) and in case of use of NSAID in patients older than 70 years (OR 
0.47, 95% 0.23-0.95). For none of the other quality indicators for prescribing of medication 
a difference between the MD model and the PA/MD model was found. This study suggests 
that non-adherence to guidelines on medication prescribing on wards with the PA/MD 
model generally does not differ from wards with traditional house staffing by MDs only. 
In the next years a further reallocation of tasks concerning prescribing of medication from 
medical residents and medical specialists to physician assistants, hospitalists and hospital 
pharmacists can be expected. Giving ongoing specialization of medical disciplines it 
remains an important task for the hospital pharmacist to support doctors, physician 
assistants and hospitalists in the prescribing process in multifaceted ways and to monitor 
quality and safety of prescribing behavior by audit and further research.
Economic analysis of medication safety interventions
In the field of medication safety research there is also a growing need for economic 
analysis of interventions in the hospital organization. More and more, we have to critically 
monitor costs that are incurred by the hospital as a result of running mediation safety 
programs in relation to clinical outcome. 
In the P-REVIEW study (Chapter 3) we registered the time, spent by pharmacy assistants 
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and hospital pharmacists on activities such as checking prescribed medication and 
interventions performed (16). In the intervention period they also registered time spent 
on activities such as medication review of high-risk patients and medication safety 
consultation (MSCs) on the ward. An estimate of the time spent by the prescribing 
physician to follow up the advice was made. Time spent on the educational program by 
hospital pharmacists and prescribing physicians of the participating wards during the 
intervention was also registered. 
Costs were calculated by multiplying the time spent on the study-related activities by 
salary expenditures of healthcare providers, obtained from the collective labor agreement 
of Dutch hospitals (www.nvz-ziekenhuizen.nl). Not surprisingly, we found that during 
the intervention, the costs per admission were higher for hospital pharmacists because 
they performed MSC and ward visits. The costs of pharmacy assistants, however, were 
lower. We suggested that the educational intervention of the P-REVIEW study proactively 
intervenes in an earlier stage of the prescribing process, which results in a lesser need of 
reactive interventions of pharmacy assistants. Taken together, the difference between 
mean total costs per admission in the usual care period and the intervention period was 
not statistically significant.
Besides the effectiveness of interventions in clinical practice, the economic impact of the 
interventions is also very relevant. In our future designs of medication safety research 
economic evaluation in relation to patient outcome should be taken into account more 
systematically.
Medication safety programs in Dutch hospitals
This thesis described different studies that assess the effect of interventions or the 
development of tools to improve medication safety. This kind of research should be 
structurally integrated in medication safety programs in Dutch hospitals. To further 
improve medication safety in the hospital we must use a multifaceted approach and 
combine and integrate a range of interventions, such as the interventions described 
above.
Such interventions should be combined with the development of validated risk prediction 
tools, enabling risk stratification to make the efforts of these interventions more 
worthwhile. Knowledge of the high risks, but equally important, acceptance of low risks in 
the prescribing process can help us to focus safety interventions on high-risk patients and 
achieve best results in decreasing drug related problems.
A multifaceted and multidisciplinary strategy allows us to design tailored interventions 
for different patient categories or patients treated by different medical specialties. 
Participatory action research (PAR) can assist in implementing the right interventions 
in the right place. PAR is a research approach to empower healthcare providers to take 
action to improve their daily clinical care and investigate complex problems in healthcare 
systems. It is characterized by the involvement of local stakeholders (physicians, hospital 
pharmacists, nurses) in the identification of opportunities for improved practice, the 
subsequent development and implementation of tailored interventions directed at these 
opportunities and the evaluation of the implemented interventions (39).
In case of medication safety research patients are also important participants. The role 
and responsibility of the patient in medication safety has not been subject of the research 
described in this thesis. However, it is obvious that (in)patient empowerment deserves our 
attention as well to improve efficiency and safety of the prescribing process. 
Our quality system can support the integration of these interventions and with structural 
audits and adequate quality indicators, related to patient outcomes, we can introduce 
a well-functioning PDCA (Plan, Do, Control, Act) cycle. We will be able to monitor the 
prescribing process and adapt the process if necessary.
Taking into account the huge numbers of medications prescribed and the risks that 
are associated with the complex process of pharmacological treatment, it will never be 
possible to completely prevent all drug-related problems. However, by studying the 
causes of potentially preventable drug-related calamities in our clinical practice, and 
translating these findings to the care process, we can use these incidents to optimize the 
system.
The hospital pharmacist has a leading role in the medication safety program in the 
hospital and in this Participatory Action Research because of the combination of 
knowledge on pharmacological treatment, science of quality improvement and risk 
stratification and knowledge of health informatics and process management. 
To confirm this role in the future, the training of hospital pharmacists must emphasize 
(besides obtaining pharmacological expertise) CanMEDs roles such as medical leadership, 
collaborator and health advocate (40). By leading the improvement of medication 
safety in organizations and systems, the hospital pharmacist facilitates changes in 
the prescribing process to enhance clinically relevant patient outcomes. This requires 
accountability to society and trust and respectful relationships with patients, physicians 
and other healthcare professionals, community partners and health system stakeholders 
to establish shared decision making.
Recommendations for clinical practice
•  To further improve medication safety in the hospital, a multifaceted approach should be 
used.
•  The multifaceted intervention for surgical patients described in the P-REVIEW study 
is an example of such an approach. It contributes to medication safety and could be 
implemented in all hospitals. 
•  Validated risk prediction tools should be introduced, for example the P-REVIEW tool 
for surgical patients, in our daily clinical practice. Risk stratification in the prescribing 
process can help us to focus safety interventions on high-risk patients and achieve best 
results in decreasing drug related problems.
•  We should also label patients who are most unlikely to experience a drug related 
adverse event. Acceptance of low risks in prescribing gives us the possibility to 
downgrade interventions or monitoring for this group of patients.
•  Multifaceted tailored interventions must be developed for different wards by 
involvement of local stakeholders. One size does not fit all.
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•  Implementation of interventions should be routinely evaluated consisting of a 
continuous process of measuring, audit and feedback on prescribing followed by 
improving and adopting the interventions and the system.
•  We need to optimize and update the content of education to the prescriber related to 
the risk factors for clinically relevant, potentially preventable drug related problems. 
Introduction of effective educational methods as workplace-based pharmacotherapy 
education with continuous audit and feedback on the main pharmacological issues 
and prevailing guidelines will lead to a sustained effect. It may be useful to introduce a 
“licence to prescribe” for physicians in hospitals.
•  Not only the development of clinical practice guidelines, but more importantly the 
implementation and evaluation of these guidelines deserves attention in coming years.
•  We have to critically monitor costs that are incurred by the hospital as a result of 
running medication safety programs in relation to clinical outcomes.
•  For further development of these interventions and evaluation in medication safety 
programs structured documentation of relevant clinical data of patients in a CPOE-CDSS 
system is essential.
Recommendations for future research
•  Participatory action research (PAR) can be used in the identification of suitable 
interventions, the subsequent development and implementation of tailored 
interventions and the evaluation of the implemented interventions.
•  The design of future medication safety studies need robust automated data collection 
methods and the development of uniform assessments of causal relationships between 
drug prescribing and patient harm.
•  Further development of risk-prediction tools that focuses on specific harmful adverse 
drug events or on patients with a particular illness of clinical characteristic, has to be 
performed. Time of risk stratification (in general practice, at hospital admission or during 
hospital stay) acquires different variables and different models.
•  In our future designs of medication safety research economic evaluation in relation to 
patient outcome should be taken into account more systematically.
References
1.  Passarelli MC, Jacob-Filho W, Figueras A. Adverse drug reactions in an elderly hospitalised population: 
inappropriate prescription is a leading cause. Drugs Aging. 2005;22(9):767-77.
2.  Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in 
hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One. 2009;4(2):e4439.
3.  Hoonhout LH, de Bruijne MC, Wagner C, Asscheman H, van der Wal G, van Tulder MW. Nature, 
occurrence and consequences of medication-related adverse events during hospitalization: a 
retrospective chart review in the Netherlands. Drug Saf. 2010;33(10):853-64.
4.  Krahenbuhl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krahenbuhl S. Drug-related 
problems in hospitals: a review of the recent literature. Drug Saf. 2007;30(5):379-407.
5.  Centraal bureau voor de statistiek (CBS). Levensverwachting nederlandse bevolking. www.cbs.nl.
6.  Stichting Farmaceutische kengetallen. Data en feiten 2016. Het jaar 2015 in cijfers. www.sfk.nl.
7.  Zorginstituut Nederland. GIPeilingen 2015. Ontwikkelingen in genees-en hulpmiddelengebruik. 
December 2016. www.gipdatabank.nl.
8.  WHO Collaborating Centre for Drug Statistics Methodology. Definition and general considerations. 
www.whocc.no.
9.  Multidisciplinaire richtlijn Polyfarmacie bij ouderen. NHG, NVKG, OMS. 2012. www.nhg.org/themas/
publicaties/multidisciplinaire-richtlijn-polyfarmacie-bij-ouderen.
10.  Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf. 2005;28(10):851-70.
11.  Langelaan M dBM, Baines RJ, et al. Monitor Zorggerelateerde Schade 2011/2012 Dossieronderzoek in 
Nederlandse Ziekenhuizen. www.nivel.nl.
12.  VWS Mv. Eindrapport: vervolgonderzoek medicatieveiligheid. Januari 2017. www.rijksoverheid.nl/
documenten/rapporten/2017/01/31/eindrapport-vervolgonderzoek-medicatieveiligheid.
13.  Medicine Io. To Err is Human: Building a Safer Health System. Washington DC. 2000.
14.  Bos JM, van den Bemt P, De Smet P, Kramers C. The effect of prescriber education on medication-
related patient harm in the hospital: a systematic review. Br J Clin Pharmacol. 2017;83(5):953-61.
15.  Inspectie voor de Gezondheidszorg. Toezicht op onderzoeker geininitieerd klinisch onderzoek 2014-
2016. www.igz.nl.
16.  Bos JM, van den Bemt PM, Kievit W, Pot JL, Nagtegaal JE, Wieringa A, et al. A multifaceted intervention 
to reduce drug-related complications in surgical patients. Br J Clin Pharmacol. 2017;83(3):664-77.
17.  Laboratory for Quality Software. Softwarevalidaterapport multisource Microsoft Access database 
P-REVIEW study. 27 maart 2013. Available on request.
18.  De Smet PA, Dautzenberg M. Repeat prescribing: scale, problems and quality management in 
ambulatory care patients. Drugs. 2004;64(16):1779-800.
19.  Kramers C, Janssen BJ, Knol W, Hessel MH, Mulder WM, Dumont G, et al. A Licence to Prescribe. Br J 
Clin Pharmacol. 2017.
20.  Bos JM, Natsch, S., van den Bemt, P.M.L.A., Pot, J.L.W., Nagtegaal, E., Wieringa, A., van der Wilt, G.J., De 
Smet, P.A.G.M., Kramers, C. A multifaceted intervention to reduce guideline non-adherence among 
prescribing physicians at surgical wards. Submitted to Int J Clin Pharm 2017.
21.  Chen Y, Sloan FA, Yashkin AP. Adherence to diabetes guidelines for screening, physical activity and 
medication and onset of complications and death. J Diabetes Complications. 2015;29(8):1228-33.
22.  Drenth-van Maanen AC, van Marum RJ, Jansen PA, Zwart JE, van Solinge WW, Egberts TC. Adherence 
with Dosing Guideline in Patients with Impaired Renal Function at Hospital Discharge. PLoS One. 
2015;10(6):e0128237.
7
127
7
126
Summarizing discussion
23.  van den Bemt PM, Chaaouit N, van Lieshout EM, Verhofstad MH. Noncompliance with guidelines on 
proton pump inhibitor prescription as gastroprotection in hospitalized surgical patients who are 
prescribed NSAIDs. Eur J Gastroenterol Hepatol. 2016;28(8):857-62.
24.  O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for 
potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213-8.
25.  Hamilton H, Gallagher P, Ryan C, Byrne S, O’Mahony D. Potentially inappropriate medications defined 
by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med. 
2011;171(11):1013-9.
26.  Verdoorn S, Kwint HF, Faber A, Gussekloo J, Bouvy ML. Majority of drug-related problems identified 
during medication review are not associated with STOPP/START criteria. Eur J Clin Pharmacol. 
2015;71(10):1255-62.
27.  Bos JM, Kalkman, G.A., Groenewoud, H., van den Bemt, P.M.L.A., De Smet, P.A.G.M., Nagtegaal, E., 
Wieringa, A., van der Wilt, G.J., Kramers, C. Prediction of clinically relevant adverse drug events in 
surgical patients Submitted to PloS One 2017.
28.  Stevenson JM, Williams JL, Burnham TG, Prevost AT, Schiff R, Erskine SD, et al. Predicting adverse 
drug reactions in older adults; a systematic review of the risk prediction models. Clin Interv Aging. 
2014;9:1581-93.
29.  de Wit HA, Winkens B, Mestres Gonzalvo C, Hurkens KP, Mulder WJ, Janknegt R, et al. The development 
of an automated ward independent delirium risk prediction model. Int J Clin Pharm. 2016;38(4):915-
23.
30.  Heringa M, Siderius H, Floor-Schreudering A, De Smet PA, Bouvy ML. Lower alert rates by clustering of 
related drug interaction alerts. J Am Med Inform Assoc. 2017;24(1):54-9.
31.  Warle-van Herwaarden MF, Kramers C, Sturkenboom MC, van den Bemt PM, De Smet PA, Dutch 
H-WTF. Targeting outpatient drug safety: recommendations of the Dutch HARM-Wrestling Task Force. 
Drug Saf. 2012;35(3):245-59.
32.  Recommendation on Dividing Responsibilities for Cooperation in Health Care. KNMG, 2010.  
www.knmg.nl/advies-richtlijnen/dossiers/verantwoordelijkheidsverdeling.htm.
33.  Report Safe Prescribing must improve. The Dutch Inspectorate of Health Care 2017.  
www.igz.nl/Images/20170106_IGZ%20Veilig%20voorschrijven%20moet%20beter_tcm294-
381020pdf.
34.  Wachter R. Personal accountability in healthcare: searching for the right balance. Thought paper. 
www.health.org.uk.
35.  de Vries EN, Prins HA, Crolla RM, den Outer AJ, van Andel G, van Helden SH, et al. Effect of a 
comprehensive surgical safety system on patient outcomes. N Engl J Med. 2010;363(20):1928-37.
36.  Recommendation on Implementation of Reallocation of Care. KNMG, V&VN and NAPA, 2012.  
www.knmg.nl/advies-richtlijnen/dossiers/verantwoordelijkheidsverdeling.htm.
37.  Bos JM, Timmermans, M.J.C.., Kalkman, G.A., van den Bemt, P.M.L.A., De Smet, P.A.G.M., Wensing, M. 
Kramers, C, Laurant, M.G.H. The effect of subsitution of hospital ward care from medical doctors to 
physician assistants on non-adherence to guidelines on medication prescribing. Submitted to PloS 
One 2017.
38.  Timmermans MJ, van Vught AJ, Wensing M, Laurant MG. The effectiveness of substitution of hospital 
ward care from medical doctors to physician assistants: a study protocol. BMC Health Serv Res. 
2014;14:43.
39.  van Buul LW, Sikkens JJ, van Agtmael MA, Kramer MH, van der Steen JT, Hertogh CM. Participatory 
action research in antimicrobial stewardship: a novel approach to improving antimicrobial 
prescribing in hospitals and long-term care facilities. J Antimicrob Chemother. 2014;69(7):1734-41.
40.  CanMEDS Framework. Royal College of Physicians and Surgeons of Canada. 2015.  
www.royalcollege.ca/rcsite/canmeds-e.
8
129
Chapter 8
Appendices
English summary
Nederlandse samenvatting
Dankwoord
List of publications
List of co-authors
About the author
8
131
8
130
health care. Implementation of strategies to prevent adverse drug events, that lead 
to death, disability, increased length of hospital stay or readmission has shown to be 
worth the effort of clinical pharmacists and prescribing physicians. It is important that 
interventions, that are designed to prevent prescribing errors are cost-effective. Time 
spent by the hospital pharmacist and the physician on education, implementation of 
guidelines, optimal use of CPOE-CDSS or performing medication reviews will also incur 
cost. Through a change of focus to high-risk patients and less focus on low-risk patients, 
these interventions could be more efficient. 
In the Canisius Wilhelmina Hospital we started a multifaceted approach, combining 
different safety interventions, to address the problem of prescribing errors leading to 
adverse drug events. Hospital pharmacists and physicians from the surgical wards of the 
Isala Hospital and the Meander Medical Centre were willing to adopt this multifaceted 
approach and to cooperate in the P-REVIEW study (Pharmacist-led Risk patients 
medication Evaluation to Initiate Event reduction on surgical Wards). The main objective 
of this thesis is to assess the effect of education and support of prescribing physicians at 
surgical wards on clinically relevant drug-related complications in hospitalized patients, 
on guideline adherence and costs.
Chapter 2
The effect of prescriber education on medication related patient harm in the 
hospital: a systematic review
Prescribing errors defined as “irrational, inappropriate, and ineffective prescribing, 
underprescribing and overprescribing” caused by a lack of pharmacological knowledge, 
might be in particular amenable to a clinical pharmacological educational intervention. 
Therefore, a logical strategy to reduce prescription errors in hospitals is education of 
prescribers. It is however unclear if education programs actually reduce patient harm. 
We performed a systematic review that gives an overview of original research papers on 
education of prescribers, reporting outcomes on (potential) patient harm. A search of the 
databases Embase and Medline using the Ovid interface was performed. Research on 
the effect of education of physicians in order to prevent medication related problems of 
inpatients, reporting original data and outcomes on prescribing errors and/or (potential) 
patient harm, was included. Assessment of methodological quality and risk of bias was 
performed using the MINORS checklist and the suggested risk of bias criteria for EPOC 
reviews. This review shows that only a relatively small number of studies have evaluated 
the effects of educational programs for hospital physicians, reporting outcomes on 
(potential) patient harm. Eight studies investigated an intervention on education alone 
and in 7 studies education was the main part of a multifaceted intervention. All studies 
were small and had short follow up periods. The educational programs varied and were 
given to physicians of different specialties and level of experience. Most studies reported 
intermediate process parameters as outcome. The risk of performance and reporting bias 
was high. All included studies suffer from poor methodology. The majority, especially 
studies in which education is part of a multifaceted intervention, report effectiveness on 
intermediate outcome markers as prescription errors and potential adverse drug events. 
English summary
Chapter 1
General introduction
Although drugs can cure, they can also cause harm. An adverse drug event may result 
from either appropriate care (non-preventable adverse drug event (ADE)) or from 
suboptimal care (preventable ADE). Inappropriate prescribing is the most frequent 
cause of ADEs in the hospital. Prescribing errors can have serious consequences and 
can lead to potentially preventable death, disability, increased length of hospital stay 
and readmission. Studies show that up to 20-50% of admitted patients experience one 
or more adverse drug events during their hospital stay. Approximately 50% of ADEs 
are potentially preventable. In the last years, older and more vulnerable patients are 
admitted to the hospital because of transient disease, and they frequently need surgical 
procedures. Surgical patients have comorbidities, are often treated with multiple high 
risk drugs and suffer from cognitive and social problems. In case of a surgical procedure, 
patients are treated with analgesics and antibiotics. Anticoagulant therapy must be 
temporarily changed because of the surgical procedure. Diuretics and cardiovascular 
drugs must be adapted on a day to day basis because of rapid alterations of hydration 
status due to gastro-intestinal disturbances, fever, sweating and lack of intake of fluid and 
food. These patients are often given radiocontrast for diagnostic procedures. It is known 
that the complexity of care for these patients contributes to the problem of potentially 
preventable adverse drug events in the hospital.
The development of a targeted educational programme that covers pharmacotherapy 
associated with adverse drug events caused by prescribing errors and addresses national 
and local pharmacotherapeutic guidelines seems useful. This programme should be 
followed by continuous audit and feedback of the prescriber to boost the effect of 
education and assures sustainability of knowledge and prescribing behaviour over time. 
Computerized physician order entry (CPOE) with an integrated clinical decision support 
system (CDSS) can support both the physician and the hospital pharmacist in clinical 
decision making. It has been shown to reduce medication errors and even ADEs. However, 
the specificity of the alerts need to be improved with more advanced CDSS. 
Also, medication review by clinical pharmacists or clinical pharmacologists is deployed to 
improve prescribing quality in hospital patients. Hereby a systematic assessment of the 
medication of the patient is performed in combination with assessment of the clinical 
data of the patient with feedback to their physician or to the patient. The impact of this 
approach on clinical outcomes is unknown and performing medication reviews is time 
consuming. 
Clinical practice guidelines with evidence-based recommendations for physicians have 
been developed to assist doctors and to improve clinician prescribing in hospitalized 
patients. In routine daily practice however, it appears to be difficult to implement key 
recommendations and guidelines seem to have a limited ability to change physician 
prescribing behaviour. 
In recent years, hospital care is characterized by increasing demands for efficiency in 
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There is no firm evidence that educating prescribers in the hospital leads to a decrease 
of patient harm. However, there is also no sound research showing that education has 
no effect, and many studies, especially studies with the multifaceted interventions, show 
benefit on intermediate outcome parameters. Future research should be targeted at 
development and implementation of educational programs which should be evaluated 
by high-quality research with outcomes on improvement of patient care. These programs 
should be a part of a multi-faceted approach in which education is supported by other 
measures.
Chapter 3
A multifaceted intervention to reduce drug-related complications in surgical 
patients
The P-REVIEW study was a prospective, multicenter, open intervention study, designed 
to determine whether a multifaceted intervention of educating the prescriber combined 
with medication review and pharmaceutical visits to the ward by the hospital pharmacist 
could lead to a reduction of drug-related complications among surgical patients. After 
a six-month control period (usual care) the intervention was introduced during three 
months. This was followed by a six-month intervention period. During the intervention, 
a combination of an educational programme and medication counselling for prescribers 
dealing with high-risk patients on the wards took place, in addition to usual care. 
An educational programme covering pain management, antithrombotics, fluid and 
electrolyte management, prescription in case of renal insufficiency and antibiotics was 
developed. National and local hospital guidelines were included. All prescribers on the 
participating wards attended the course. Hospital pharmacists performed medication 
safety consultations, combining medication review of patients who are at risk of drug 
adverse events and a visit to the physician on the ward. The goal of the visits by the 
hospital pharmacist was to boost the effects of education and to suggest interventions 
based on the medication review. To improve feasibility of the intervention, patients, who 
are at risk of drug-related problems, were selected based on medication use and clinical 
features. Clinically relevant patient outcome measures were studied in a very large patient 
cohort. Prescription errors, leading to these clinically relevant drug-related problems, 
were identified in a broad perspective, including possible adverse drug reactions, drug 
interactions, guideline non-adherence and omission of medication. By blinding all case 
record forms with respect to the study period before assessment by the experts and by 
correcting for confounders, the probability of bias was minimised. 
6780 admissions of 5940 patients who were admitted to surgical, urological and 
orthopaedic wards of two large general teaching hospitals in the Netherlands (the Isala 
Hospital in Zwolle and the Meander Medical Centre in Amersfoort) during the usual 
care period and 6484 admissions of 5711 patients during the intervention period were 
included. We found a significantly lower proportion of admissions with one or more 
clinically relevant, potentially preventable, drug-related problems (including death, 
temporary or sustained disability, increased length of hospital stay or readmission within 
30 days ) in the intervention period (1.1% (73/6484) compared to the usual care period 
(1.6% (106/6780)) (p=0.029). The relative risk (RR) was 0.72 (95% CI 0.53-0.97). Several 
types of drug-related problems occurred less frequently during the intervention period, 
especially haemorrhage, thrombosis and central nervous system events (mainly delirium). 
Costs incurred as result of time spent on study-related activities by hospital pharmacists, 
pharmacy assistants and prescribers were not different before and after the intervention.
The P-REVIEW study showed that education and support of the prescribing physician with 
respect to patients who are at risk of drug adverse events in surgical departments leads to 
a significant clinically relevant benefit for patients without generating additional costs.
Chapter 4
A multifaceted intervention to reduce guideline non-adherence among 
prescribing physicians in Dutch hospitals
Clinical practice guidelines with evidence-based recommendations for physicians have 
been developed to assist doctors and to improve patient outcomes. In routine daily 
practice however, it appears to be difficult to implement key recommendations and 
guidelines seem to have limited impact on physician prescribing behaviour. Adherence to 
guidelines by prescribers is inconsistent, despite their potential to improve the quality of 
health care. Several determinants of practice that prevent or enable guideline adherence, 
have been described. Interactive and continuous education is one of the possible 
strategies to tackle several of these determinants for non-adherence. 
In the P-REVIEW study we determined whether an approach of introducing an educational 
programme for prescribers in the hospital combined with audit and feedback by 
the hospital pharmacist reduces non-adherence of prescribing physicians to key 
pharmacotherapeutic guidelines. The educational program teaches the prescriber the 
pharmacological aspects of using high-risk drugs in high-risk patients. The hospital 
pharmacist performed medication reviews in high-risk patients, who were identified 
with a computerised screening method. In the visits of the hospital pharmacist to the 
physician on the surgical ward, there was special attention for adherence to important 
pharmacotherapeutic guidelines that were addressed in the educational program. 
Feedback was given based on the medication reviews to the prescriber. The attended 
issues and advices were discussed in a broader context and hospital pharmacists clarified 
the pharmacological background and related prevailing hospital guidelines. Patients who 
were admitted to the surgical, urological and orthopeadic wards of the two hospitals 
during the fifth month of the usual care period and the fifth month of the intervention 
period were included. 
The outcome measure was the proportion of the admissions of patients in which the 
physician did not adhere to one or more of the included guidelines. The guidelines were 
selected by a group of experts and were related to medication that has shown to frequently 
be involved in preventable, clinically relevant, drug-related problems. 1435 Admissions of 
1378 patients during the usual care period and 1195 admissions of 1090 patients during 
the intervention period were included. Non-adherence was observed significantly less 
often during the intervention period (21.8% (193/886)) as compared to the usual care 
period (30.5% (332/1089)). The adjusted odds ratio (OR) was 0.61 (95% CI 0.49-0.76). 
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This study showed that education and support of the prescribing physician with respect 
to high-risk patients in surgical departments can lead to reduced pharmacotherapeutic 
guideline non-adherence among prescribing physicians. Achieved effects were obtained 
on top of the effect of other measures as CPOE/CDS system and clinical rules, which 
were part of usual care. However, it may not be necessary to pursue 100% adherence. We 
suggested it may be better not to focus on guideline adherence or implementation of 
clinical rules alone, but on a comprehensive medication review of high risk patients, in 
which a check on adherence of guidelines and clinical rules is integrated.
Chapter 5
Prediction of clinically relevant adverse drug events in surgical patients
Risk stratification of hospital patients for adverse drug events (ADE) would enable 
targeting patients who may benefit from interventions aimed at reducing drug-related 
morbidity. It can support clinicians and hospital pharmacists in selecting patients to 
deliver a more efficient health care service. We performed a study that aimed to develop 
and test a prediction model that helps to identify patients on the day of hospital 
admission, who are at increased risk of developing a clinically relevant, preventable 
adverse drug event during their stay on a surgical ward.
Data of the pre-intervention measurement period of the P-REVIEW study were used. 
Thirty-nine variables, including patient characteristics, type of admission, medication and 
laboratory test results, were evaluated in a univariate and multivariate logistic regression 
analysis, respectively. Model performance was expressed in the Area Under the Receiver 
Operating Characteristics (AUROC). Bootstrapping was used for model validation. 6780 
admissions of 5940 patients at surgical wards were included during the pre-intervention 
period of the PREVIEW trial. 102 Patients experienced a clinically relevant, adverse drug 
event during their hospital stay that was deemed potentially preventable. The most 
frequent type of events were haemorrhage, arterial and venous thrombosis, renal 
insufficiency, hydration or electrolyte related events, central nervous system events and 
faecal impaction. The prediction model comprised five variables, each ascertained at the 
time of hospital admission: age, number of biochemical tests ordered, heparin/LMWH in 
therapeutic dose, use of opioids and use of cardiovascular drugs. The AUROC was 0.86 
(95% CI 0.83-0.88). At a cut-off point for an increased risk of developing an ADE of 1.6%, 
the model had a sensitivity of 80.4% and a specificity of 73.4%. The positive and negative 
predictive value were 4.5% and 99.6%, respectively. The bootstrap procedure did not 
significantly affect model parameters. 
The combined use of a limited set of easily ascertainable patient characteristics can help 
physicians and pharmacists to identify, at the time of admission, surgical patients who are 
at increased risk of developing ADEs during their hospital stay. By using this model, lower-
risk patients could be managed less extensively (for instance, only automatically using 
CPOE/CDSS), whereas higher risk patients could receive more intensive interventions, 
such as medication review, aimed at reducing drug-related adverse outcomes. Such 
selective use of ancillary precautions could also help to improve the cost-effectiveness 
of medication safety interventions. In that way, this risk model, that combines clinical 
and medication-related variables can guide clinical intervention, delivered as part of an 
integrated system built around the principles of medication safety. This risk model can 
be incorporated into a CPOE system and thereby generate automatic risk-evaluation 
based on patients’ medical records upon hospital admission. Above a pre-specified cut 
off point, the score can advise the hospital pharmacist or the prescriber to review the 
patient’s medication or to perform other relevant interventions. Under the cut-off point 
(not necessarily the same cut off point), it may be possible for the hospital pharmacist to 
downgrade interventions and rely on the automatic medication safety system.
Chapter 6
The effects of substitution of hospital ward care from medical doctors 
to physician assistants on non-adherence to guidelines on medication 
prescribing
In recent years, there is an increasing pressure to deliver healthcare efficiently. Medical 
procedures are more and more standardized and there is more attention for continuity, 
quality and safety of clinical processes. Therefore, medical tasks are increasingly allocated 
to physician assistants (PAs). A PA is a non-physician healthcare professional licensed 
to practice medicine in defined domains, in collaboration with medical doctors (MDs) 
but with a substantial degree of professional autonomy. PAs who are employed for 
medical care for admitted patients usually work in a team comprising both PAs and MDs 
(i.e. residents, staff physicians or hospitalists). Since January 2012, legislation in Dutch 
healthcare authorizes PAs to prescribe medication without supervision of a MD. However, 
scientific evidence on the quality of drug prescribing or adherence to clinical practice 
guidelines by PAs is hardly available. Until now, there have been no studies to evaluate 
prescribing of PAs compared to MDs.
In this study the effect of substitution of inpatient care from medical doctors (MDs) to 
physician assistants (PAs) on non-adherence to guidelines on medication prescribing 
was determined. This study was conducted as part of a multicenter matched-controlled 
study comparing wards utilizing a mixed ‘PA/MD model’, on which PAs provide medical 
care in collaboration with MDs, with wards utilizing a ‘MD model’, on which only MDs 
provide medical care. The study aimed to measure the effects of substitution of inpatient 
care from MDs to PAs on length of hospital stay, several indicators for quality and safety 
of inpatient care and patient experiences. 17 wards of the MD model were matched 
with 17 wards of the PA/MD model based on medical specialty and hospital type (i.e. 
academic versus non-academic). A set of 17 quality indicators to measure non-adherence 
to guidelines on medication prescribing by PAs and MDs was composed by 14 experts 
in a modified Delphi procedure. The indicators covered different pharmacotherapeutic 
subjects, such as gastric protection in case of use of NSAID, adequate prescribing in case 
of impaired renal function, avoidance of certain medication in combination with vitamin 
K antagonists or prevention of obstipation in case of use of opioids. The outcome measure 
of this study was the non-adherence to guidelines on medication prescribing measured 
by 17 quality indicators. The indicators were expressed in proportions by dividing the 
number of patients in which the prescriber did not adhere to a guideline, by all patients 
8
137
8
136
that were applicable. Multivariable regression analysis was performed in order to adjust 
for potential confounders.
1021 patients from 17 hospital wards in the ‘PA/MD model’ group and 1286 patients 
from 17 hospital wards in the ‘MD model’ group were included. Two of the 17 quality 
indicators showed significantly less non-adherence to guidelines for the PA/MD model; 
the indicators concerning prescribing gastric protection in case of use of NSAID in 
combination with corticosteroids (OR 0.42, 95% CI 0.19-0.90) and in case of use of NSAID 
in patients older than 70 years (OR 0.47, 95% 0.23-0.95). For none of the other quality 
indicators for prescribing of medication a difference between the MD model and the PA/
MD model was found. 
From the introduction of the PA there has been debate about prescribing by PAs. It has 
been suggested that only physicians have the capability to prescribe medication and that 
only physicians should be allowed to do so. Prescribing is viewed as a very complex, risky 
clinical task. Many studies have shown that prescription errors made by physicians lead 
to potentially preventable adverse events in hospitals. Overall, adherence to guidelines 
varied across the indicators we measured, but tended to be low. This is in line with earlier 
research on pharmacotherapeutic guideline adherence. Although we have to interpret the 
results cautiously because of the relatively small sample size for several quality indicators, 
this study suggested that the non-adherence to guidelines on medication prescribing on 
wards on which PAs provide medical care in collaboration with MDs (PA/MD model), does 
not differ from wards on which only MDs provide medical care (MD model).
Chapter 7
Summarizing discussion 
The increase in drug consumption by more complex patients has inevitably led to an 
increase of adverse drug events. Therefore, medication safety has become an important 
theme in hospitals and several interventions have been introduced to cope with drug-
related problems. However, despite all efforts put in medication safety interventions, 
promoting adherence of professional standards and decreasing shortcomings in 
organization of care, the potentially preventable harm caused by medication in hospitals 
did not change. It appears that introducing recommendations, implementing clinical 
practice guidelines and introducing changes in the healthcare process progress slowly 
and require a lot of attention and energy of different healthcare providers. Working 
on medication safety remains a continuous process of measuring, audit and feedback 
followed by improving and adapting the system and care processes. This thesis describes 
a multifaceted approach in large teaching hospitals in the Netherlands, combining 
different medication safety interventions, to address the problem of prescribing errors 
leading to adverse drug events. In this final chapter the main results are reviewed in a 
wider perspective in relation to the main objectives of this thesis. First the challenges of 
the methodology of intervention studies on medication safety are addressed. After that 
the different components of the multifaceted intervention we studied are discussed. 
This intervention included education of the prescriber, implementation of guidelines, 
medication review and the use of information technology. This multifaceted approach 
must gain focus and be applied in hospitals by using risk stratification in daily practice, 
imbedded in a good, transparent and efficient organization of healthcare and medication 
safety programs. These themes are discussed. At the end recommendations for clinical 
practice and future research are given.
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Hoofdstuk 1
Inleiding
Geneesmiddelen kunnen ziekten genezen en symptomen bestrijden, maar ze kunnen 
ook schade aanrichten. Een bijwerking van een geneesmiddel kan optreden als gevolg 
van doelmatige zorg (niet-vermijdbare bijwerking of adverse drug event (ADE)) of kan het 
resultaat zijn van suboptimale zorg (vermijdbare ADE). Het inadequaat voorschrijven van 
medicatie is de meest voorkomende oorzaak van vermijdbare ADE’s in het ziekenhuis. 
Voorschrijffouten kunnen ernstige gevolgen hebben en kunnen leiden tot overlijden, 
invaliditeit, langere ziekenhuisopnames en heropnames. Onderzoek laat zien dat 20 tot 
50% van de patiënten één of meer onbedoelde effecten van geneesmiddelen ervaart 
tijdens de opname in het ziekenhuis. Ongeveer 50 % van deze ADE’s zijn vermijdbaar.
De afgelopen jaren worden steeds oudere en meer kwetsbare patiënten opgenomen 
in ziekenhuizen. Chirurgische patiënten hebben vaak meerdere aandoeningen, 
worden veelal behandeld met meerdere medicijnen en lijden aan cognitieve en 
sociale problemen. Wanneer patiënten geopereerd worden, worden zij behandeld met 
pijnstillers, antistolling en antibiotica. Diuretica en cardiovasculaire medicatie moeten 
dagelijks worden aangepast vanwege snelle veranderingen van de hydratietoestand door 
gastro-intestinale problematiek, koorts, zweten en een verminderde inname van vocht en 
voedsel. Ook krijgen patiënten vaak contrast toegediend voor diagnostische procedures. 
De complexe farmacotherapie bij deze kwetsbare patiënten draagt bij aan vermijdbare 
ADE’s in het ziekenhuis.
Verschillende maatregelen zijn denkbaar om ADE’s in ziekenhuizen te verminderen. 
Een mogelijkheid is de ontwikkeling van een onderwijsprogramma voor voorschrijvers, 
waarin deze complexe farmacotherapie wordt behandeld en nationale en lokale 
farmacotherapeutische richtlijnen worden besproken. 
Digitale ondersteuning met Computerized physician order entry (CPOE) met een 
ingebouwd klinisch, beleidsondersteunend beslissingssysteem, kan zowel de arts als de 
ziekenhuisapotheker helpen bij het nemen van klinische beslissingen. 
Ook worden medicatiereviews door ziekenhuisapothekers of klinisch farmacologen 
ingezet om de voorschrijfkwaliteit bij ziekenhuispatiënten te verbeteren. Hierbij wordt de 
medicatie van een patiënt systematisch beoordeeld in relatie tot de klinische gegevens 
van de patiënt, waarna er feedback naar de arts of patiënt volgt. Het effect van deze 
maatregel is echter niet duidelijk en het uitvoeren van deze medicatiebeoordeling is 
tijdrovend. 
Ter ondersteuning van de dokter worden er praktische, wetenschappelijk onderbouwde, 
klinische richtlijnen ontwikkeld met als doel de zorg aan ziekenhuispatiënten te 
verbeteren. In de dagelijkse praktijk blijkt het echter lastig om deze aanbevelingen 
te implementeren en blijken richtlijnen maar een beperkte invloed te hebben op het 
voorschrijfgedrag van de arts.
In de afgelopen jaren zien we in de gezondheidszorg een toenemende vraag naar 
efficiëntie. Het is belangrijk dat de interventies die worden ontwikkeld ter voorkoming 
van voorschrijffouten ook kosteneffectief zijn. Door patiënten te identificeren die een 
hoger risico lopen op een ADE, zouden we ons meer op deze hoog-risico patiënten 
kunnen focussen en minder op de laag-risico patiënten, en kunnen we onze interventies 
efficiënter inzetten.
In het Canisius Wilhelmina Ziekenhuis zijn we van start gegaan met een combinatie van 
verschillende interventies om de kwaliteit van voorschrijven te verbeteren en het aantal 
vermijdbare ADE’s te verminderen. Ziekenhuisapothekers, chirurgen, orthopeden en 
urologen en zaalartsen van de afdeling chirurgie van het Isala ziekenhuis in Zwolle en het 
MeanderMC in Amersfoort zijn bereid geweest om deze benadering over te nemen en 
mee te werken in de P-REVIEW studie (Pharmacist-led Risk patients medication Evaluation 
to Initiate Event reduction on surgical Wards). Het doel van dit proefschrift is om het effect 
te onderzoeken van een onderwijsprogramma voor voorschrijvers gecombineerd met 
de ondersteuning van deze dokters bij hoog-risicopatiënten op de snijdende afdelingen 
door de ziekenhuisapotheker, op het optreden van vermijdbare, klinisch relevante 
geneesmiddel gerelateerde problemen, op het naleven van richtlijnen en op de kosten. 
Hoofdstuk 2
Het effect van onderwijs aan voorschrijvers op geneesmiddel gerelateerde 
problemen bij patiënten in het ziekenhuis 
Voorschrijffouten die gedefinieerd worden als ‘irrationeel, ongepast en ineffectief 
voorschrijven en het te veel en te weinig voorschrijven van geneesmiddelen’ en 
het gevolg zijn van een gebrek aan farmacologische kennis, zijn bij uitstek een 
aangrijpingspunt voor een klinische, farmacologische, educatieve interventie. Het is 
echter niet bekend of dit soort onderwijsprogramma’s ook daadwerkelijk leiden tot 
minder schade bij de patiënt. Wij hebben een systematisch review uitgevoerd waarin 
we een overzicht geven van onderzoeken die het effect hebben onderzocht van 
onderwijsprogramma’s voor voorschrijvers, waarbij (potentiële) schade bij de patiënt als 
uitkomstmaat is genomen. 
Dit review laat zien dat er maar een beperkt aantal studies het effect van onderwijs 
programma’s voor dokters in ziekenhuizen op (potentiele) schade bij de patiënt 
geëvalueerd hebben. Acht studies onderzochten een interventie uitsluitend gericht 
op onderwijs en in zeven studies was onderwijs een onderdeel van een meervoudige 
interventie. Alle studies waren klein en hadden een korte follow-up periode. De inhoud 
van de onderwijs programma’s varieerde sterk en ze werden aangeboden aan artsen 
van verschillende specialismen en opleidingsniveaus. De meeste studies rapporteerden 
intermediaire procesparameters als uitkomstmaat. Alle geïncludeerde studies hebben 
een zwakke methodologie. De meerderheid, met name de studies waarin voorlichting 
deel uit maakt van een meervoudige interventie, laat effectiviteit zien ten aanzien van 
intermediaire parameters, zoals vermindering van voorschrijffouten. Er is geen duidelijk 
bewijs dat het geven van onderwijs aan voorschrijvers in het ziekenhuis leidt tot 
minder geneesmiddel gerelateerde schade bij de patiënt. Er is echter ook geen degelijk 
onderzoek waaruit blijkt dat educatie geen effect heeft en veel studies laten een voordeel 
zien ten aanzien van de intermediaire uitkomstparameters. Toekomstig onderzoek zou 
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gericht moeten zijn op het ontwikkelen en implementeren van onderwijsprogramma’s, 
waarbij evaluatie zou moeten plaatsvinden op de verbetering van de patiëntenzorg 
als uitkomstmaat. Deze onderwijsprogramma’s zouden een onderdeel moeten zijn van 
een gecombineerde benadering, waarbij onderwijs ondersteund wordt door andere 
maatregelen. 
Hoofdstuk 3
Een gecombineerde interventie om geneesmiddel gerelateerde problemen 
bij chirurgische patiënten te voorkomen
De P-REVIEW studie is een prospectief, multicenter, open interventieonderzoek, 
dat is uitgevoerd om te bepalen of een onderwijsprogramma aan de voorschrijver 
gecombineerd met medicatiereviews bij hoog-risico patiënten gevolgd door een consult 
van de ziekenhuisapotheker op de afdeling, kunnen leiden tot een vermindering van 
geneesmiddel gerelateerde problemen bij chirurgische patiënten. Allereerst werd 
de standaardzorg gemeten in een controle periode van zes maanden. Daarna werd 
de interventie geïmplementeerd. Vervolgens werd er gedurende 6 maanden in een 
interventieperiode gemeten. 
Er is een onderwijsprogramma ontwikkeld, waarin onder andere pijnbeleid, 
antistollingsbeleid, vocht- en elektrolytenhuishouding, het voorschrijven van 
geneesmiddelen bij verminderde nierfunctie en inzet van antibiotica aan bod komen. 
De nationale en lokale richtlijnen van ziekenhuizen op deze onderwerpen zijn 
hierin opgenomen. Alle voorschrijvers van de participerende ziekenhuisafdelingen 
namen deel aan dit onderwijs. Ziekenhuisapothekers voerden medicatiereviews 
uit bij patiënten die een hoog risico lopen op een ADE en combineerden dit met 
een medicatieveiligheidsconsult aan de voorschrijver op de afdeling, waarbij het 
medicatiebeleid van deze patiënten werd besproken. Met dit consult werd beoogd 
het effect van het onderwijs te versterken en de richtlijn adherentie te vergroten. De 
belangrijkste uitkomstmaat van dit onderzoek was het percentage klinisch relevante, 
potentieel vermijdbare, geneesmiddel gerelateerde problemen bij patiënten die leiden 
tot overlijden, tijdelijke of blijvende invaliditeit, een verlengde opnameduur of een 
heropname binnen 30 dagen. 
6780 opnames van 5940 patiënten op de afdelingen chirurgie, urologie of orthopedie van 
twee grote perifere opleidingsziekenhuizen in Nederland (de Isala klinieken in Zwolle en 
het Meander Medisch Centrum in Amersfoort) in de controleperiode en 6484 opnames 
van 5711 patiënten in de interventieperiode werden onderzocht. Er werd een significant 
lager aantal opnames gezien, waarbij sprake was van een of meer klinisch relevante, 
potentieel vermijdbare, geneesmiddel gerelateerde problemen, in de interventieperiode 
(1.1% (73/6484) ten opzichte van de controleperiode (1.6% (106/6780)) (p=0.029). Met 
name bloedingen, trombose en klachten van het centrale zenuwstelsel (voornamelijk 
delier) traden minder op. De kosten die voortvloeiden uit de tijd die werd besteed aan 
medicatie gerelateerde activiteiten van ziekenhuisapothekers, apothekersassistenten en 
voorschrijvers bleven in de twee bestudeerde perioden gelijk. 
De P-REVIEW studie laat zien dat onderwijs en ondersteuning van de voorschrijvende 
arts bij hoog-risico patiënten op de snijdende afdelingen leidt tot minder vermijdbare 
geneesmiddel gerelateerde problemen bij deze patiënten zonder dat dit extra kosten met 
zich meebrengt. 
Hoofdstuk 4
Een gecombineerde interventie om de non-adherentie aan 
farmacotherapeutische richtlijnen op chirurgische afdelingen te 
verminderen
 Klinische richtlijnen met wetenschappelijk onderbouwde aanbevelingen voor artsen 
worden ontwikkeld om de patiëntenzorg te verbeteren. In de dagelijkse praktijk blijkt het 
echter lastig om deze afspraken te implementeren en blijken daardoor richtlijnen maar 
een beperkte invloed te hebben op het voorschrijfgedrag van de arts. Het naleven van 
richtlijnen door voorschrijvers is inconsistent. Er zijn verschillende factoren beschreven 
die het naleven van richtlijnen in de weg staan of juist stimuleren. Interactief en continu 
onderwijs op de werkplek is één van de mogelijke strategieën om de non-adherentie van 
richtlijnen aan te pakken.
In de P-REVIEW studie hebben we vastgesteld of introductie van een 
onderwijsprogramma voor voorschrijvers, gecombineerd met audit en feedback 
door de ziekenhuisapotheker, leidt tot een vermindering van de non-adherentie van 
de belangrijkste farmacotherapeutische richtlijnen door voorschrijvende artsen. De 
ziekenhuisapotheker voerde medicatiebeoordelingen bij hoog-risicopatiënten uit. 
Tijdens de consulten van de ziekenhuisapotheker aan de artsen op de afdelingen, werd er 
speciaal aandacht besteed aan farmacotherapeutische richtlijnen die waren behandeld in 
het onderwijsprogramma. 
Het aantal opnames van patiënten waarbij de arts zich niet hield aan een of meer van 
de geïncludeerde richtlijnen werd als uitkomstmaat genomen. De richtlijnen werden 
geselecteerd door een groep experts en hadden betrekking op geneesmiddelen 
die regelmatig betrokken waren bij vermijdbare, klinisch relevante, geneesmiddel 
gerelateerde problemen. 1435 opnamen van 1378 patiënten tijdens de controleperiode 
en 1195 opnames van 1090 patiënten tijdens de interventieperiode werden geïncludeerd. 
De non-adherentie aan richtlijnen werd significant minder vaak waargenomen gedurende 
de interventie periode (21,8% (193/886)) in vergelijking met de controleperiode (30,5% 
(332/1089)). De vastgestelde odds ratio (OR) was 0. 61 (95% CI 0.49-0.76).Dit onderzoek 
toont aan dat onderwijs en ondersteuning van de voorschrijvende arts met betrekking tot 
hoog-risicopatiënten op chirurgische afdelingen kan leiden tot een vermindering van de 
non-adherentie aan farmacotherapeutische richtlijnen door voorschrijvende artsen. Het 
lijkt verstandig de focus niet alleen te leggen op het naleven van richtlijnen alleen, maar 
op een uitgebreide medicatiebeoordeling van hoog-risicopatiënten, waarin een controle 
op het naleven van richtlijnen geïntegreerd is.
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Hoofdstuk 5
Het voorspellen van klinisch relevante geneesmiddel gerelateerde 
problemen bij chirurgische patiënten 
Risicostratificatie van ziekenhuispatiënten ten aanzien van het optreden van ADE’s, 
maakt het mogelijk om patiënten te selecteren die mogelijk profijt hebben van 
interventies met als doel geneesmiddel-gerelateerde morbiditeit te verminderen. Het 
kan dokters en ziekenhuisapothekers helpen bij het selecteren van patiënten om een 
zo efficiënt mogelijke zorg te bieden. We hebben een onderzoek verricht met als doel 
een predictiemodel te ontwikkelen, dat patiënten identificeert op de dag van opname 
die een verhoogd risico hebben op het ontwikkelen van een vermijdbaar geneesmiddel 
gerelateerd probleem tijdens hun opname op de afdeling chirurgie, orthopedie of 
urologie. 
Hiervoor hebben we de gegevens uit de controle periode van de P-REVIEW studie 
gebruikt. 39 variabelen, zoals patiënten kenmerken, soort opname, medicatiegegevens 
en laboratoriumuitslagen werden gebruikt voor de bouw van het model met behulp 
van logistische regressieanalyse. Model prestaties worden uitgedrukt in de Area Under 
the Receiver Operating Characteristics (AUROC). 6780 opnames van 5940 patiënten op 
chirurgische afdelingen werden geïncludeerd. 102 patiënten hebben tijdens hun verblijf 
in het ziekenhuis een klinisch relevant ADE gehad, die mogelijk voorkomen had kunnen 
worden. De meest voorkomende bijwerkingen waren bloedingen, arteriële en veneuze 
trombose, nierinsufficiëntie, hydratie- of elektrolytengerelateerde problemen, klachten 
van het centrale zenuwstelsel en obstipatie. Het predictiemodel bestaat uit vijf variabelen, 
vastgesteld bij het moment van ziekenhuisopname: leeftijd, aantal aangevraagde 
biochemische testen, heparine/LMWH in therapeutische dosis, gebruik van opioïden en 
het gebruik van cardiovasculaire medicijnen. De AUROC was 0.86 (95% BI 0.83-0.88). Bij 
een afkappunt van 1.6 % voor een verhoogd risico op het ontwikkelen van een bijwerking, 
had het model een sensitiviteit van 80,4% en een specificiteit van 73,4%.
De positieve en negatieve voorspellende waarde waren respectievelijk 4,5% en 99,6%. 
De combinatie van een klein aantal gemakkelijk te bepalen patiëntkenmerken helpt 
artsen en apothekers om bij opname chirurgische patiënten te identificeren, die een 
verhoogd risico hebben op het ontwikkelen van een ADE. Door dit model te gebruiken 
kunnen laag-risico patiënten minder intensief gecontroleerd worden (bijvoorbeeld alleen 
automatisch met CPOE/CDSS), terwijl we hoog-risico patiënten meer intensief kunnen 
bewaken, zoals met medicatiereview.
Dit selectieve gebruik van ondersteunende voorzorgsmaatregelen door de inzet 
van een predictiemodel vergroot de kosteneffectiviteit van interventies gericht op 
medicatieveiligheid. Dit risicomodel kan worden opgenomen in een CPOE systeem, 
om zo een automatische risico inschatting te maken aan de hand van de medische 
gegevens bij ziekenhuisopname. Een score boven een vooraf bepaalde afkapwaarde kan 
de ziekenhuisapotheker of arts adviseren om de medicatie van de patiënt te reviewen 
of andere relevante interventies uit te voeren. Bij een score onder de afkapwaarde (niet 
noodzakelijk dezelfde afkapwaarde) kan de ziekenhuisapotheker controles verminderen 
en varen op het automatische medicatieveiligheidssysteem. 
Hoofdstuk 6
Het effect van taakherschikking in de zorg van artsen naar physician 
assistants op het voorschrijven van geneesmiddelen
In de afgelopen jaren is er een toenemende roep naar efficiëntie in de gezondheidszorg. 
Medische procedures worden gestandaardiseerd en er is meer aandacht voor de 
continuïteit, kwaliteit en veiligheid van klinische processen. Medische taken worden 
steeds vaker toegewezen aan physician assistants (PAs). Een PA is geen dokter, maar 
een zorgverlener die bevoegd is om in samenwerking met artsen geneeskunde te 
beoefenen in gedefinieerde domeinen, met een aanzienlijke mate van professionele 
autonomie. Sinds januari 2012 zijn PA’s volgens de Nederlandse wetgeving geautoriseerd 
om geneesmiddelen voor te schrijven zonder supervisie van een arts. Onderzoek naar 
de kwaliteit van het voorschrijven van geneesmiddelen of het naleven van klinische 
richtlijnen door PA’s is nauwelijks beschikbaar. Er zijn tot dusver geen studies verricht, 
waarbij de kwaliteit van voorschrijven van geneesmiddelen door PA’s en artsen met elkaar 
vergeleken zijn. 
In deze studie wordt het effect van de verschuiving van de intramurale patiëntenzorg 
van artsen naar PA’s bepaald door te kijken naar het naleven van farmacotherapeutische 
richtlijnen. Deze studie maakt deel uit van een multicenter onderzoek waarbij afdelingen 
met een gemixt ‘PA/arts model’, waarbij PA’s de medische zorg verlenen in samenwerking 
met de artsen, worden vergeleken met een ‘arts model’, waarbij alleen artsen de 
medische zorg verlenen. De studie heeft als doel het effect van deze taakherschikking 
te meten aan de hand van de duur van de ziekenhuisopname, verschillende kwaliteit- 
en veiligheidsindicatoren en de ervaring van de patiënt zelf. 17 afdelingen van het 
‘arts model’ werden gematched met 17 afdelingen met het ‘PA/arts model’ op basis 
van medisch specialisme en ziekenhuistype (bijvoorbeeld academisch versus non-
academisch). Een set van 17 kwaliteitsindicatoren werd opgesteld door 14 experts om de 
non-adherentie aan farmacotherapeutische richtlijnen door PA’s en artsen te meten door 
middel van een aangepaste Delphi-procedure. De indicatoren omvatten verschillende 
farmacotherapeutische onderwerpen, zoals maagbescherming bij NSAID-gebruik, 
adequaat geneesmiddelen voorschrijven bij verminderde nierfunctie, het vermijden van 
bepaalde medicamenten in combinatie met vitamine K-antagonisten of het preventief 
voorschrijven van laxantia bij opiaat gebruik. 
1021 patiënten van 17 ziekenhuisafdelingen in de groep ‘PA/arts model’ en 1286 patiënten 
van 17 ziekenhuisafdelingen in de groep ‘arts model’ werden bestudeerd. Twee van de 17 
kwaliteitsindicatoren lieten een significante verbetering van het naleven van richtlijnen bij 
het ‘PA/arts model’ zien; de indicatoren betroffen het voorschrijven van maagbescherming 
bij NSAID-gebruik in combinatie met corticosteroïden (OR 0,42, 95% BI 0,19-0,90) en het 
gebruik van NSAID bij patiënten ouder dan 70 jaar (OF 0,47, 95% 0,23-0,95). Voor geen van 
de andere kwaliteitsindicatoren voor het voorschrijven van medicatie werd een verschil 
gevonden tussen het ‘arts model’ en het ‘PA/arts model’.
Vanaf het moment dat PA’s werkzaam werden in ziekenhuizen, is er discussie geweest over 
het voorschrijven door PA’s. Er is geopperd dat alleen artsen bekwaam zijn om medicatie 
voor te schrijven en dat alleen zij deze complexe, risicovolle, klinische taak zouden mogen 
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uitvoeren. Er zijn veel studies beschikbaar die laten zien dat door artsen gemaakte 
voorschrijffouten leiden tot vermijdbare ADE’s in ziekenhuizen. Hoewel we voorzichtig 
moeten zijn met het interpreteren van de resultaten vanwege de relatief kleine 
steekproefomvang voor de verschillende kwaliteitsindicatoren, suggereert dit onderzoek 
dat de non-adherentie aan de farmacotherapeutische richtlijnen niet verschillend is op 
afdelingen met een ‘PA/arts model’ in vergelijking met afdelingen met een ‘arts model’. 
Hoofdstuk 7
Afsluitende discussie 
De toename van geneesmiddelengebruik bij complexere patiënten heeft onvermijdelijk 
geleid tot een toename van ADE’s. Hierdoor is medicatieveiligheid een belangrijk 
thema geworden in ziekenhuizen en zijn er verschillende strategieën geïntroduceerd 
in een poging geneesmiddel-gerelateerde problemen te verminderen. Ondanks alle 
inspanningen die zijn geleverd om de medicatieveiligheid in ziekenhuizen te vergroten, 
zoals het aansturen op het naleven van professionele richtlijnen en het verminderen 
van tekortkomingen in zorgorganisaties, is de door geneesmiddelen veroorzaakte 
vermijdbare schade in ziekenhuizen onveranderd gebleven. Het introduceren van 
veranderingen in het zorgproces verloopt traag en vraagt veel aandacht en energie 
van verschillende zorgverleners. Het werken aan medicatieveiligheid blijft een continu 
proces van meten, audit en feedback, gevolgd door het verbeteren en aanpassen van 
zorgprocessen.
Dit proefschrift beschrijft een meervoudige aanpak in perifere opleidingsziekenhuizen 
in Nederland, waarbij verschillende interventies gericht op medicatieveiligheid 
gecombineerd worden, om het probleem van voorschrijffouten die leiden tot ADE’s aan 
te pakken. In dit afsluitende hoofdstuk worden de belangrijkste resultaten in een breder 
perspectief bekeken, in relatie tot de belangrijkste doelstellingen van dit proefschrift. 
Allereerst worden de uitdagingen van de methodologie van interventiestudies naar 
medicatieveiligheid behandeld. Daarna worden de verschillende componenten van 
de meervoudige interventie die we onderzocht hebben besproken. Deze bestond uit 
onderwijs aan de voorschrijver, het implementeren van richtlijnen, medicatiereview 
en het gebruik van informatietechnologie. Deze meervoudige aanpak kan worden 
toegepast in ziekenhuizen door risicostratificatie in de dagelijkse praktijk te gebruiken, 
ingebed in een werkzame, transparante en efficiënte gezondheidszorgorganisatie en in 
programma’s voor medicatieveiligheid. Deze thema’s worden besproken. Tot slot worden 
aanbevelingen gedaan voor de klinische praktijk en toekomstig onderzoek. 
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Dankwoord
Mijn proefschrift is klaar. Het was geen vooropgezet plan, eigenlijk is het allemaal een 
beetje uit de hand gelopen. Het begon een aantal jaren geleden op mijn kamer in het 
CWZ met een goed idee, het vliegwiel is gaan draaien en ik ben gegrepen door het 
onderzoek. Dat ik dit proefschrift heb kunnen afronden, komt met name omdat ik me 
omgeven heb gevoeld door enthousiaste, bevlogen, aardige, deskundige en bijzondere 
mensen. Ja, ik heb het over jou.
Ik wil al mijn collegae, vrienden en familie hartelijk bedanken voor hun bijdrage en 
belangstelling in welke vorm dan ook. Zonder iemand tekort te willen doen, zal ik een 
aantal personen met naam noemen.
Als eerste wil ik mijn promotieteam prof. dr. G.J. van der Wilt, prof. dr. P.A.G.M. De Smet, 
prof. dr. P.M.L.A. van den Bemt en prof. dr. C. Kramers bedanken.
Beste Gert Jan, bedankt dat je mijn promotor wilde zijn. Met enige afstand kon je de 
methodologie en de onderzoeksresultaten helder structureren. Ik heb veel geleerd van je 
analyses tijdens onze gesprekken. Je bijdrage aan mijn onderzoek was onmisbaar.  
Beste Peter, ik had aan één promotor niet genoeg. Bedankt voor de waardevolle 
brainstormsessies en discussies, maar ook voor je vertrouwen in mij als promovendus. 
Beste Patricia, bedankt dat je het P-REVIEW onderzoeksteam hebt versterkt. Je hebt 
met jouw expertise in het onderzoeksveld van medicatieveiligheid een belangrijke 
bijdrage geleverd aan dit proefschrift. Ik kon altijd rekenen op jouw positieve blik en een 
razendsnelle feedback, waarbij jij vooral de kunst van het weglaten uitstekend beheerste. 
Je begon als co-promotor en eindigt als promotor, want inmiddels bekleed je, meer dan 
verdiend, een leerstoel Medicatieveiligheid. 
Beste Kees, wat heb ik geboft dat jij, na een beklonken samenwerkingsverband 
tussen FarmTox en de KF, mijn kamergenoot werd in het CWZ. Jouw bevlogenheid en 
enthousiasme, deskundigheid en innovatieve drive, didactische vaardigheden en je visie 
op verbetering van medicatieveiligheid door de kennis van de apotheker en de dokter te 
combineren, zijn een aanvulling binnen onze vakgroep. We hebben de afgelopen jaren 
vele mooie initiatieven kunnen ontwikkelen. Het P-REVIEW onderzoek hebben we samen 
bedacht en als een geolied team tot een goed einde gebracht. Ook jij bent inmiddels 
hoogleraar Medicatieveiligheid, maar een vierde promotor staat het Reglement niet toe. 
Maar goed ook, je bent mijn enige en enigste co-promotor. Ik heb veel van je geleerd en 
hoop nog vele jaren met je samen te werken. 
Prof. dr. H. van Goor, prof. dr. M.G.M. Olde Rikkert en prof. dr. A.C.G. Egberts wil ik 
bedanken voor de bereidheid om zitting te nemen in de manuscriptcommissie en voor de 
inhoudelijke beoordeling van dit proefschrift.
Prof. dr. M.L. Bouvy, prof. dr. T. van Gelder, prof. dr. E.N. van Roon en prof. dr. P. Jeurissen 
dank ik voor hun deelname aan de oppositie.
De P-REVIEW studie is uitgevoerd in het Meander Medisch Centrum in Amersfoort en de 
Isala klinieken in Zwolle. We hebben de ziekenhuisapothekers, chirurgen, orthopeden 
en urologen bereid gevonden om deel te nemen en zonder hun omarming van en 
enthousiasme voor ons onderzoeksplan was dit proefschrift er niet gekomen. Heel veel 
dank hiervoor.
In het bijzonder wil ik mijn collega ziekenhuisapothekers in de Isala klinieken (ten tijde 
van de studie), die meegewerkt hebben aan het onderzoek, bedanken; André Wieringa, 
Judith Bosman, Wobbe Hospes, Thea van Herpen, JanCees van Niel en Gerben Veen. Veel 
dank ook aan de apothekersassistente, Barbara Draaijer, die de data heeft verzameld en 
aan de ICT-medewerkers Teun Bagerman en Marien van den Hoorn.
Beste André, jij was, samen met Judith, de trekker van de P-REVIEW studie in Zwolle. 
Je hebt als lid van het onderzoeksteam heel wat reisjes naar Nijmegen gemaakt en 
meegedacht in de uitvoering van het onderzoek en de analyse van de resultaten. Hartelijk 
dank hiervoor.
Ook wil ik de collega ziekenhuisapothekers uit het MeanderMC met naam noemen; 
Elsbeth Nagtegaal, Dorieke van Baalen, Monique van der Westerlaken, Maurice Steeghs 
en Mirte Malingré. Daarnaast gaat mijn dank uit naar de twee analisten die aan de 
dataverzameling hebben gewerkt, Hilly de Graaf en Ed van Hamersveld, en naar Lisette 
Geurtsen, die de koppeling van de ziekenhuissystemen van het MeanderMC met de 
P-REVIEW database mede mogelijk heeft gemaakt.
Beste Elsbeth, jij bent vanaf de start een groot voorstander geweest van dit onderzoek 
en was een enthousiast deelnemer van het onderzoeksteam. Tot op de dag van vandaag 
zie ik jou als de grootste fan van het P-REVIEW concept (op mij na dan). Ik wil je hartelijk 
danken voor je inzet, deskundige bijdrage en vertrouwen.
Hans Pot heeft de P-REVIEW database gebouwd. Beste Hans, in een driemanschap van 
jou, Kees en mijzelf hebben we uitgedacht op welke wijze we de data uit de deelnemende 
ziekenhuizen zouden gaan verzamelen, valideren en beheren. De combinatie van jouw 
kennis op het gebied van ICT en farmacologie was onmisbaar. Ik ben blij dat je na het 
onderzoek in opleiding bent gegaan tot ziekenhuisapotheker in het MeanderMC en ze 
inmiddels ook in het UMC in Utrecht je kwaliteiten hebben ontdekt. Ik wil je danken voor 
je inzet en ik wens je een succesvolle loopbaan toe.
Ook op Matthijs van Gijssel en Arno Kalkman heb ik een beroep kunnen doen als het ging 
om analyses van de P-REVIEW database. Beste Matthijs en Arno, dank voor jullie snelle en 
accurate assistentie.
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Voor de analyse van de primaire uitkomstmaat hebben experts met de database gewerkt. 
Naast Kees Kramers en ikzelf hebben Marieke Zeeman, Sara Rongen, Stephanie Natsch en 
Hanneke Fleuren dagen en avonden lang vele patiëntendossiers beoordeeld. In diverse 
consensus sessies hebben we interessante casus besproken. Het was een ongelofelijk 
grote, maar ook leerzame klus, die we met elkaar geklaard hebben. Beste dames, ik wil 
jullie hartelijk danken voor jullie deskundige inzet. De titel “expert” mogen jullie met recht 
voeren.
Ik wil Erik van Haaren, bibliothecaris van de medische bibliotheek van het CWZ bedanken 
voor het (razendsnel) opspeuren van moeilijk vindbare artikelen. Laura Boerboom, 
informatiespecialist bij de medische bibliotheek van het Radboudumc, heeft mij 
geassisteerd bij de literatuursearch voor mijn systematische review. Dank.
Beste Kim Wever, dank voor je deskundige suggesties bij de beoordeling van de 
methodologische kwaliteit van publicaties voor mijn review. 
Beste Wietske Kievit en Hans Groenewoud, ik wil jullie bedanken voor jullie hulp bij de 
statistische analyses van mijn onderzoek. Ook in het bouwen van een predictiemodel heb 
ik me moeten verdiepen. Ik heb veel van jullie geleerd.
Beste Bart Kramers, hoewel je vader en ik eigenlijk vinden dat de Engelse taal ons wel ligt 
(alleen de weidevogel konden we niet vertalen), lieten we jou de finale versies van mijn 
artikelen altijd nog even nalezen. Jij zette de laatste puntjes op de i, en wees me op de 
verschillen in British en American English. Het eerste commentaar van de reviewers was 
daardoor altijd dat het een “well written paper” betrof. Dank dat je hiervoor de tijd hebt 
willen nemen in je eigen drukke onderzoekersbestaan.
Vanuit IQ Healthcare wil ik Dr. Marijke Timmermans, Dr. Miranda Laurant en Prof. dr. 
Michel Wensing bedanken voor de samenwerking in het onderzoek naar de kwaliteit van 
voorschrijven door physician assistants. Het was interessant om het medicatieonderdeel 
te mogen invullen in jullie lopende onderzoek naar de effecten van taakherschikking in 
de zorg.
Verschillende subsidiegevers hebben het P-REVIEW onderzoek mogelijk gemaakt. Ik wil de 
Nederlandse organisatie voor gezondheidsonderzoek en zorginnovatie ZonMw bedanken 
voor het beschikbaar stellen van een grant in het kader van doelmatigheidsonderzoek. 
Daarnaast gaat mijn dank uit naar de zorgverzekeraar VGZ en de Koninklijke Nederlandse 
Maatschappij ter bevordering der Pharmacie (KNMP), die zijn opgetreden als co-financier.
Ook wil ik de Raad van Bestuur van het CWZ bedanken voor het in mij gestelde 
vertrouwen. Zij hebben zich achter mijn onderzoek naar medicatieveiligheid geschaard 
en mij de mogelijkheid geboden het laatste anderhalf jaar een klein deel van mijn CWZ 
tijd te besteden aan het schrijven van mijn artikelen.
Het idee voor de P-REVIEW studie is ontsproten vanuit een samenwerkingverband tussen 
de afdeling Klinische Farmacie van het CWZ en de afdeling Farmacologie en Toxicologie 
van het Radboudumc. Ik wil prof. dr. Frans Russel bedanken voor het vertrouwen en het 
beschikbaar stellen van een bijdrage aan mijn onderzoek.
Ik heb mij op de kamer van prof. dr. Gerard Rongen met regelmaat kunnen terugtrekken 
uit het CWZ. Beste Gerard, dank voor de rust en de gezelligheid. Ik heb grote stappen in 
schrijven gezet op jouw kamer.
Beste Wendy, jij hebt me als secretaresse van de afdeling vele malen ondersteund, maar 
ook van gezellige praatjes voorzien. Dank.
Om deze financiële stromen goed te kunnen verantwoorden, ben ik dank verschuldigd 
aan de afdeling SBFA van het RadboudUMC, de voormalig bedrijfsleider van de afdeling 
Farmacologie en Toxicologie van het RadboudUMC, Robert Opsteeg en de manager 
bedrijfsvoering van de afdeling Klinische Farmacie van het CWZ, Antoine Migchielsen.
Bijzondere dank gaat uit naar mijn collega ziekenhuisapothekers Hans Smit, Yuhan Kho, 
Marien Pluim, Hanneke Fleuren en Hugo de Wit. Jullie hebben mij de ruimte gegund mijn 
ambitie om te promoveren waar te maken. Het P-REVIEW onderzoek is voortgekomen 
uit onze gezamenlijke visie op maatregelen om de medicatieveiligheid in het CWZ te 
verbeteren. Door onze inmiddels lange plezierige samenwerking als vakgroep en jullie 
bijzondere collegialiteit, heb ik het op kunnen brengen dit proefschrift af te ronden. Ik 
prijs me gelukkig met jullie als mijn collegae.
Ook de overige medewerkers van de afdeling Klinische Farmacie wil ik bedanken voor 
hun collegialiteit en de getoonde belangstelling voor mijn onderzoek. 
In het bijzonder wil ik Danielle Jansen bedanken voor de administratieve ondersteuning. 
Vooral de laatste maanden rondom de versturing van de proefschriften en de 
voorbereiding van de verdediging was je hulp heel welkom.
En natuurlijk Maren Blonk, mijn bijzondere dank gaat ook uit naar jou. Jij hebt onze 
vakgroep waardevol aangevuld en een deel van mijn portefeuille ingevuld in de laatste 
fase van mijn promotietraject. Door jouw aanwezigheid kon ik me op vaste momenten 
terugtrekken uit het CWZ om te schrijven. Ik wens je alle geluk toe in de bijzondere tijd 
die voor je ligt en je verdere loopbaan als ziekenhuisapotheker.
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Mijn lieve paranimfen, Klaartje en Eveline. Ik ben heel trots en vereerd dat jullie naast me 
willen staan bij de verdediging. Zoals onze zinsspreuk “langer met dan zonder” aangeeft, 
dateert onze vriendschap al van ver in de vorige eeuw. Na onze tijd in Utrecht zitten er 
vele jaren met etentjes, feestjes, concerten, weekenden weg en vakanties op en hebben 
we vooral veel lief en ook leed gedeeld. Jullie kennen mij als je broekzak en dat is niet 
vanzelfsprekend. Ook tijdens mijn onderzoek, als ik me wel eens afvroeg waar ik mee 
bezig was, hebben jullie mij met humor, begrip voor ambitie en relativeringsvermogen 
gestimuleerd. Het is een heerlijk gevoel dat ik waar ook ter wereld en op welk moment 
dan ook bij zulke fantastische vriendinnen terecht kan. We vieren nu een feestje en ik 
hoop dat er nog vele volgen.
Lieve Maarten, je hebt, samen met Claudia, met interesse dit traject gevolgd. Ik ben trots 
op jou en wat we samen hebben.
Lieve mam, jij stak je trots niet onder stoelen of banken. Ik wil je bedanken voor je 
onvoorwaardelijke liefde voor mij, Raymond en de kinderen en je lieve hulp in ons drukke 
huishouden. Je bent voor mij een voorbeeld hoe je gezellig, gezond en gelukkig ouder 
kan worden. Het is zo ontzettend jammer dat papa er niet meer bij is. Hij zou hier enorm 
van hebben genoten. Dank zij jullie twee sta ik waar ik nu sta.
Lieve Ties, Cato en Anouk, jullie zijn mijn grote geluk! De wijze waarop jullie met me 
hebben meegeleefd en me hebben ondersteund om tot dit boekje te komen is bijzonder. 
Ik ben zo trots op jullie en vind het fantastisch dat jullie dit zo bewust en intensief mee 
kunnen maken.
De deal was om als afsluiting een groot feest te geven met z’n vijven. Niet vanwege de 
promotie, het twintig-jarige huwelijk of de vijftigste verjaardag, maar gewoon omdat we 
zo lekker gaan met de Braakhuisjes. Steek aan dat ding!
Ik sluit dit dankwoord af met jou, Raymond, de liefde van mijn leven. Jij stimuleert mij 
altijd om alles eruit te halen wat erin zit. Je geduld is op de proef gesteld, maar nu is het 
klaar. We gaan onze tijd weer samen invullen. Je hebt een kleine voorsprong genomen op 
het Wad, maar die ga ik inhalen. Mijn leven met jou is Splendid.
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